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Abstract
Malignant tumors can be detected with high sensitivity and specificity by imaging their increased metabolic
rate for glucose, amino acids and fatty acids. Positron emission tomography (PET) with glucose analog
[18F]FDG, which utilizes increased glucose metabolism, has become a routine clinical test for diagnosis,
staging and restaging a variety of cancers. Despite the tremendous success of PET-FDG, there are some well-
known limitations of [18F]FDG such as high cerebral uptake, uptake in inflammatory tissues, high excretion
through urinary tract and low or negligent uptake in certain type of tumors. Decades of nuclear medicine
research have lead to development of other PET imaging agents to overcome such limitations.
We examined two series of tracers targeting two different altered metabolic processes in the tumor cells in
order to improve on imaging properties of existing clinically utilized PET ligands. One series is 18F labeled
tyrosine and phenylalanine derivatives, which targets altered amino acid metabolism – increased amino acids
uptake and protein synthesis rate in cancer cells. We synthesized three new 18F labeled fluoroalkyl tyrosine
derivatives, in vitro studies in human glioblastoma cells of these tyrosine derivatives indicated they were not
very promising tumor-imaging agents since in comparison to clinically utilized imaging agent O-
(2-[18F]fluoroethyl)-L-tyrosine (FET), their uptake was much lower. We also synthesized and evaluated L-
and D-isomers of new phenylalanine derivatives, p-(2-[18F]fluoroethyl)-phenylalanine (FEP) and p-
(3-[18F]fluoropropyl)-phenylalanine (FPP) in comparison to clinically utilized FET and its D-isomer. In
vitro studies in 9L glioma cells as well as biodistribution and small animal PET imaging studies demonstrated
that L- isomer of FEP is comparable to FET and it is a potential useful tracer for tumor imaging with PET.
Comparison of L- and D-isomers of phenylalanine derivatives showed that D-isomers did not have improved
imaging properties than their corresponding L-isomers. Of all new aromatic amino acid derivatives, L- isomer
of FEP had the best outcome and is comparable to clinically established FET in imaging rats bearing 9L tumor
model.
The other series of tracers is 11C labeled ethanolamine amine derivatives, which targets the altered lipid
metabolism associated with increased cellular proliferation in tumors. Here, we developed 11C labeled
ethanolamine and two ethanolamine derivatives — N-methyl ethanolamine and N,N-dimethyl ethanolamine.
In vitro studies demonstrated that they could be more sensitive PET tracers than clinically utilized
[11C]choline for the imaging of phospholipids biosynthesis in tumors.
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ABSTRACT 
 
 
NOVEL AMINO ACID AND ETHANOLAMINE DERIVATIVES AS 
POTENTIAL TUMOR IMAGING AGENTS FOR POSITRON EMISSION 
TOMOGRAPHY 
 
Limin Wang 
 
Hank F. Kung, Ph.D. 
Datta E. Ponde, Ph.D. 
 
 
Malignant tumors can be detected with high sensitivity and specificity by imaging 
their increased metabolic rate for glucose, amino acids and fatty acids. Positron emission 
tomography (PET) with glucose analog [18F]FDG, which utilizes increased glucose 
metabolism, has become a routine clinical test for diagnosis, staging and restaging a 
variety of cancers. Despite the tremendous success of PET-FDG, there are some well-
known limitations of [18F]FDG such as high cerebral uptake, uptake in inflammatory 
tissues, high excretion through urinary tract and low or negligent uptake in certain type of 
tumors.  Decades of nuclear medicine research have lead to development of other PET 
imaging agents to overcome such limitations.  
 
We examined two series of tracers targeting two different altered metabolic 
processes in the tumor cells in order to improve on imaging properties of existing 
clinically utilized PET ligands. One series is 18F labeled tyrosine and phenylalanine 
derivatives, which targets altered amino acid metabolism – increased amino acids uptake 
and protein synthesis rate in cancer cells. We synthesized three new 18F labeled 
fluoroalkyl tyrosine derivatives, in vitro studies in human glioblastoma cells of these 
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tyrosine derivatives indicated they were not very promising tumor-imaging agents since 
in comparison to clinically utilized imaging agent O-(2-[18F]fluoroethyl)-L-tyrosine 
(FET), their uptake was much lower. We also synthesized and evaluated L- and D-isomers 
of new phenylalanine derivatives, p-(2-[18F]fluoroethyl)-phenylalanine (FEP) and p-(3-
[18F]fluoropropyl)-phenylalanine (FPP) in comparison to clinically utilized FET and its 
D-isomer. In vitro studies in 9L glioma cells as well as biodistribution and small animal 
PET imaging studies demonstrated that L- isomer of FEP is comparable to FET and it is a 
potential useful tracer for tumor imaging with PET. Comparison of L- and D-isomers of 
phenylalanine derivatives showed that D-isomers did not have improved imaging 
properties than their corresponding L-isomers. Of all new aromatic amino acid 
derivatives, L- isomer of FEP had the best outcome and is comparable to clinically 
established FET in imaging rats bearing 9L tumor model. 
 
The other series of tracers is 11C labeled ethanolamine amine derivatives, which 
targets the altered lipid metabolism associated with increased cellular proliferation in 
tumors. Here, we developed 11C labeled ethanolamine and two ethanolamine derivatives 
— N-methyl ethanolamine and N,N-dimethyl ethanolamine. In vitro studies demonstrated 
that they could be more sensitive PET tracers than clinically utilized [11C]choline for the 
imaging of phospholipids biosynthesis in tumors.  
 
 - vii -  
Table of Contents 
 
Acknowledgements............................................................................................................iii 
Abstract................................................................................................................................v 
Table of Contents...............................................................................................................vii 
List of Figures....................................................................................................................xii 
List of Tables....................................................................................................................xiv 
List of Schemes..................................................................................................................xv 
Abbreviations....................................................................................................................xiv 
 
Chapter 1: Introduction....................................................................................................1 
1.1 Altered metabolism of cancer cells……........................................................................2 
1.2 Imaging .........................................................................................................................3 
 1.2.1 Radionuclide imaging …………………………………...………………….4 
1.3 Tumor metabolism imaging...........................................................................................8 
1.4 Tumor glucose metabolism and its clinical applications...............................................9 
1.4.1 Tumor glucose metabolism and the development of FDG.……………...….9 
1.4.2 Clinical success and limitations of FDG-PET……………….…………….10 
1.5 Developing new PET tracers for tumor metabolism imaging…….............................12 
1.5.1 Tumor amino acid metabolism and novel amino acid based tracers……....13 
1.5.2 Tumor phospholipids metabolism and new ethanolamine tracers …...........19 
1.6 Scope of thesis research...............................................................................................22 
1.7 Clinical significance of this work................................................................................23 
1.8 References....................................................................................................................24 
 - viii -  
 
Chapter 2: Synthesis and in vitro evaluation of 18F labeled tyrosine derivatives as 
potential PET imaging agents.........................................................................................31 
2.2 Introduction..................................................................................................................32 
2.2 Results and discussion.................................................................................................34 
2.2.1 Synthesis of precursors and authentic standards for radiotracers.................34 
2.2.2 Radiolabeling of tyrosine derivatives...........................................................39 
2.2.3 In vitro cell uptake studies…………............................................................40 
2.3 Conclusion...................................................................................................................42 
2.4 Experimental Section...................................................................................................42 
 2.4.1 General information......................................................................................42 
 2.4.2 Synthesis of precursors and authentic standards for radiolabeling...............43 
 2.4.3 Radiochemistry ............................................................................................57 
2.4.4 In vitro cell uptake studies............................................................................60 
2.5 References....................................................................................................................61 
 
Chapter 3: Synthesis, uptake mechanism characterization and biological evaluation 
of 18F labeled fluoroalkyl L-phenylalanine analogs as potential tumor imaging 
agents for PET..................................................................................................................64 
3.1 Introduction..................................................................................................................65 
3.2 Results and Discussion................................................................................................68 
 3.2.1 Synthesis of precursors and authentic standards...........................................68 
 3.2.2 Radiosynthesis of phenylalanine derivatives ...............................................70 
 - ix -  
 3.2.3 Cell uptake studies........................................................................................71 
 3.2.4 Uptake mechanism studies of FEP...............................................................72 
3.2.5 Biodistribution studies of FEP......................................................................75 
3.2.6 Small animal imaging studies.......................................................................76 
3.3 Materials and methods.................................................................................................78 
 3.3.1 General........................................................... ..............................................78 
3.3.2 Synthesis of precursors and authentic standards for radiotracers….............78 
 3.3.3 Radiosynthesis..............................................................................................86 
 3.3.4 In vitro cell uptake studies and transport characterization studies..............87 
 3.3.5 Biodistribution in Fisher rats with 9L glioma tumors..................................88 
 3.3.6 Small animal imaging with a microPET.......................................................89 
3.4 Conclusion...................................................................................................................90 
3.5 References....................................................................................................................91 
 
Chapter 4: Synthesis and comparative biological evaluation of L- and D-isomers of 
18F labeled fluoroalkyl phenylalanine derivatives as tumor imaging agents..............95 
4.1 Introduction..................................................................................................................96 
4.2 Results and Discussion................................................................................................99 
 4.2.1 Synthesis of labeling precursors and standards............................................99 
4.2.2 Radiolabeling of L- and D-FET, FEP and FPP……………...……............100 
 4.2.3 Cell uptake studies......................................................................................103 
 4.2.4 Transport characterization studies..............................................................104 
 4.2.5 Small animal PET imaging studies.............................................................107 
 - x -  
4.3 Conclusions................................................................................................................109 
4.4 Materials and methods...............................................................................................100 
 4.5.1 Synthesis of precursors and standards for labeling.....................................100 
 4.5.2 Log D measurement....................................................................................117 
4.5 References..................................................................................................................118 
 
Chapter 5: Radiosynthesis and in vitro evaluation of 11C labeled ethanolamine 
derivatives as potential tumor imaging agents for PET.............................................122 
5.2 Introduction................................................................................................................123 
5.2 Results and Discussion..............................................................................................125 
 5.2.1 Comparison of 14C labeled choline and ethanolamine as probe for cancer   
                      detection.....................................................................................................125 
 5.2.2 Radiolabeling of  [11C]EA, [11C]MEA and [11C]DMEA............................127 
 5.2.3 In vitro cell uptake studies..........................................................................133 
 5.2.4 Inhibition studies.........................................................................................134 
5.3 Conclusions................................................................................................................135 
5.4 Experimental section..................................................................................................136 
 5.4.1 General........................................................................................................136 
 5.4.2 Radiochemistry...........................................................................................136 
 5.4.3 In vitro studies.............................................................................................137 
5.5 References..................................................................................................................139 
 
Chapter 6: Conclusions remarks and future directions……...……...…...…………142 
 - xi -  
6.1 Concluding remarks...................................................................................................143 
6.2 Future directions........................................................................................................144 
 
Appendix A: 1H and 13C NMR spectra of compounds...............................................145 
A.1 1H and 13C NMR spectra of key compounds in chapter 2........................................146 
A.2 1H and 13C NMR spectra of key compounds in chapter 3........................................158 
A.3 1H and 13C NMR spectra of D-isomers in chapter 4.................................................164 
 
 
 
 
 - xii -  
List of Figures 
 
Chapter 1 
Figure 1.1 The altered metabolism of cancer cells 
Figure 1.2 Principles of positron emission tomography imaging acquisition 
Figure 1.3 Principles of positron emission tomography 
Figure 1.4 Simplified overview of metabolic process targeted by PET 
Figure 1.5 The cellular metabolism of glucose and [18F]FDG 
Figure 1.6 Tumor cell amino acid metabolism 
Figure 1.7 Structures of clinically utilized amino acid based tracers 
Figure 1.8 Proposed model for the substrate binding of LAT1 
Figure 1.9 Aromatic amino acid derivatives as potential PET imaging agents 
Figure 1.10 Choline phospholipids metabolism 
Figure 1.11 Choline and its derivatives as PET imaging agents 
Figure 1.12 11C labeled ethanolamine and its derivatives  
 
 
Chapter 2 
Figure 2.1 FET([18F]1) and its new analogs 
Figure 2.2 Uptake of new ligands in reference to FET ([18F]1) 
 
 
Chapter 3 
Figure 3.1 Some clinically utilized amino acid based tracers 
Figure 3.2 Chemical structures of new phenylalanine derivatives 
Figure 3.3 Time course of uptake of FET, FEP and FPP in 9L glioma cells 
Figure 3.4 Summry of uptake characterization studies of FEP in 9L glioma  
Figure 3.5 Small animal PET images of FEP and FET in tumor bearing rats 
Figure 3.6      Time-activity curves after injection of FEP and FET in rats  
Figure 3.7      Comparison of FEP and FET tumor to muscle ratio 
 
 
 
 
Chapter 4 
Figure 4.1 Chemical structures of L- and D-18F labeled tyrosine and phenylalanine 
derivatives 
 - xiii -  
Figure 4.2 HPLC profile of fluorination intermediate [18F]10a and final products FEP 
under condition using K2.2.2/K18F at 90 oC for radiofluorination. 
Figure 4.3 HPLC profile with L- and D-isomers of FEP. 
Figure 4.4 Comparative cellular uptake of L- and D-isomers of FET, FEP and FPP in 
9L glioma cells. 
Figure 4.5 Transport characterization studies of L- and D-FEP in 9L glioma cells. 
Figure 4.6 Small animal PET images of L-FEP and D-FEP in tumor bearing rats. 
Figure 4.7 Time activity curves of L- and D-FEP in the rat bearing 9L tumors. 
Figure 4.8 Comparison of tumor to muscle ratio of L- and D-FEP and in the rat 
bearing 9L tumors. 
 
 
 
Chapter 5 
Figure 5.1 Radiolabeled choline and its derivatives 
Figure 5.2 31P MR spectrum in a NHL patient 
Figure 5.3 Radiolabeled ethanolamine and its derivatives 
Figure 5.4 Normalized uptake of [14C]EA, [14C]DMEA and [14C]MEA relative to 
[14C]CH in tumor cell lines. 
Figure 5.5 Cellular uptake studies of [14C]CH and [14C]EA in A172 cells. 
Figure 5.6 Formation of [11C]CH in radiosynthesis of [11C]DMEA at high  
                        temperature 
Figure 5.7 Schematic diagram of the automated system for the production of 
[11C]MEA and [11C]DMEA 
Figure 5.8 Cell uptake studies in PC- and LnCap prostate cancer cells 
Figure 5.9 Inhibition studies result in PC-3 and LnCap 
 
 
 
 - xiv -  
List of Tables 
 
Chapter 1 
Table 1.1 Comparison of modalities for tumor metabolic imaging  
Table 1.2 Selected clinically used tumor metabolic imaging agents for PET 
Table 1.3 Major amino acid transport system upregulated in cancer cells 
Table 1.4 Selected clinically utilized amino acid tracers and their uptake mechanism 
 
 
Chapter 2 
Table 2.1 Boc protection result of 5 under various conditions 
Table 2.2 Conditions and results of synthesis of 23 via Negishi coupling 
Table 2.3 Deprotection reaction conditions, average decay-corrected RCY and                    
specific activities at end of synthesis (EOS) 
 
 
Chapter 3 
Table 3.1 Overall synthesis time, decay-corrected yields, radiochemical purity, 
enantiomeric purity and specific activity (EOS) 
Table 3.2 Inhibitors and their specificity towards amino acid transport systems 
Table 3.3 Biodistribution of FEP ([18F]2) in Fisher rats with 9L xenograft 
 
 
Chapter 4 
Table 4.1 Synthesis time, decay-corrected yields, radiochemical purity, enantiomeric 
purity and specific activity (EOS) 
 
 
Chapter 5 
Table 5.1 Cell type and their origins 
Table 5.2 Effect of temperature on radiolabeling of [11C]MEA and [11C]DMEA 
Table 5.3 Experimented purification methods and results 
 
 
 
 - xv -  
List of Schemes 
 
Chapter 2 
Scheme 2.1 Initial synthetic route of FEMT 2 
Scheme 2.2 Improved synthesis of FEMT 2 
Scheme 2.3 Synthesis of FEAT 3 
Scheme 2.4 Attempted synthesis of 3-azatyrosine derivative 
Scheme 2.5 Synthesis of FETA 4 
Scheme 2.6 Radiolabeling reactions for tyrosine derivatives 
 
Chapter 3 
Scheme 3.1 Synthesis of radiolabeling precursors and standards 2 and 3 
Scheme 3.2 Radiolabeling of FEP and FPP 
 
 
Chapter 4 
Scheme 4.1 Synthesis of labeling precursor and standards 2 and 3 
Scheme 4.2 Synthesis of precursor and standard 1 
Scheme 4.3 Radiolabeling of D-FET, FEP and FPP 
 
Chapter 5 
Scheme 5.1 Radiolabeling of [11C]EA 
Scheme 5.2 Radiolabeling of [11C]MEA and [11C]DMEA 
 
 - xvi -  
List of Abbreviations 
 
Abbreviation Full Name Chemical Structure 
AA amino acid NA 
Ala alanine 
NH2
COOH
 
A-PET small animal positron emission 
tomography 
NA 
ASC alanine-serine-cysteine NA 
BBN (9-BBN) 9-borabicyclo[3.3.1]nonane 
HB  
BCH 2-aminobicyclo-(2,2,1)-heptane-2-
carboxylic acid COOH
NH2  
Boc t-butoxycarbobnyl 
O O  
Bq Becquerel NA 
BSA bovine serum albumin NA 
CDCl3 deuterated chloroform 
C
Cl
Cl Cl
D
 
CH choline 
N
OH
 
Ci curie NA 
d day NA 
DIAD diisopropyl azodicarboxylate 
N
N
O
O
O
O
 
DIPEA diisopropylethylamine 
N
 
DMEA N,N-Dimethyl ethanolamine 
 
 
N
OH
 
 - xvii -  
Abbreviation Full Name Chemical Structure 
DMF dimethylfomamide 
NO
H  
dppf 1,1'-
Bis(diphenylphosphino)ferrocene 
 
Fe
PPh2
Ph2P  
EA ethanolamine H2N
OH
 
EOB end-of-bombardment NA 
EOS end-of-synthesis NA 
EtOAc ethyl acetate O
O  
EtOH ethanol OH  
FC flash chromatography NA 
FDG 2-fluorodeoxyglucose 
O
OHF
HO
HO
HO
 
FEAT O-(2-fluoroethyl)-2- azatyrosine 
N
COOH
NH2O
F
 
FEMT O-(2-fluoroethyl)-α-methyl-
tyrosine COOHH2NOF  
FEP p-(2-fluoroethyl)-phenylalanine COOH
NH2F  
FET O-(2-fluoroethyl)-tyrosine COOH
NH2O
F
 
FETA O-(2-fluoroethyl)-tyrosineamide 
NH2O
F
O
NH2
 
FPP p-(3-fluoropropyl)-phenylalanine COOH
NH2
F
 
h hours NA 
HPLC high performance liquid 
chromatography 
NA 
HRMS high-resolution mass spectrometry NA 
 - xviii -  
Abbreviation Full Name Chemical Structure 
ID initial dose NA 
IACUC Institutional Animal Care and Use 
Committee 
NA 
K[2.2.2] Kryptofix 2.2.2 ( or 1,10-diaza-
4,7,13,16,21,24-
hexaoxabicyclo[8.8.8]hexacosane) 
N
O O
O O
N
O
O
 
LAH Lithium aluminum hydride LiAlH4 
LATs System L amino acid transporters NA 
LC/MSD TOF liquid chromatography/mass 
selective detector with time of 
flight 
NA 
Me Methyl CH3  
MEA N-methylethanolamine N
H
OH
 
MeAIB 2-(methylamino)-isobutyrate 
OH
HN
O
 
MET methionine 
NH2
COOHS
 
MeOH methanol CH3OH 
min minute NA 
MRS magnetic resonance spectroscopy NA 
MS mass spectrometry NA 
NaH sodium hydride NaH 
NEM N-ethyl ethylmaleimide 
N
O
O  
NMR nuclear magnetic resonance NA 
PCho phosphocholine 
N
O P
O
O-
O-  
 - xix -  
Abbreviation Full Name Chemical Structure 
PET positron emission tomography NA 
PEPPSI Pyridine-Enhanced Precatalyst 
Preparation Stabilization and 
Initiation 
Pd ClCl
N
NN
Cl
R
R
R
R
 
PEtn phosphoethanolamine 
H3N
O P
O
O-
O-  
Phe phenylalanine 
H2N
COOH
 
Py pyridine 
N  
RCP radiochemical purity NA 
RCY radiochemical yield NA 
ROI region of interest NA 
rt room temperature NA 
s second NA 
SAIF small animal imaging facility NA 
SD standard deviation NA 
SPECT single photon emission computed 
tomography 
NA 
t1/2 half-life NA 
tR rentention time NA 
TAC time activity curve NA 
TBAHCO3 tetrabutylammonium bicarbonate 
 
Bu4NHCO3 
TBAF tetrabutylammonium fluoride Bu4NF 
TBDMS t-butyldimethylsilyl 
 
Si
 
 - xx -  
Abbreviation Full Name Chemical Structure 
TFA trifluoroacetic acid O
OH
FF
F
 
THF tetrahydrofuran O
 
Tmob trimethoxylbenzyl 
OMe
OMeMeO
 
Ts p-toluenesulfonyl 
S
O
O  
Tyr tyrosine HO
H2N
COOH
 
              
  
 - 1 - 
Chapter 1 
 
 
 
 
 
 
Introduction 
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1.1 Altered metabolism of cancer cells 
Cellular metabolism within tumors is significantly different from that of 
corresponding normal cells.  Metabolism of neoplastic cells has been studied for many 
decades, with the aim of designing new strategies for cancer prevention, diagnosis and 
therapy, based upon the identification of tumor-specific enzymatic alterations. One of the 
major metabolic changes in tumors is the high rate of aerobic glycolysis, also known as 
the “Warburg effect”. Since Otto Warburg first discovered that tumor cells consume 
glucose at higher rate than normal cells over 80 years ago [1], the “Warburg effect”  has 
been observed in many cancers. This increased glucose uptake in tumors provided the 
basis for the development of glucose analog 2-[18F]fluoro-2-deoxy glucose (FDG) as a 
positron emission tomography (PET) tracer [2], which is widely used clinically for 
detection, staging and restaging of various cancers. Besides glucose, cancer cells also 
have increased metabolism of nutrient such as amino acids and fatty acids that meet or 
exceed the bioenergetic demands of cell growth and proliferation [3, 4]. Figure 1.1 
presents an overview of the possible drivers, advantage and potential liabilities of altered 
metabolism of cancer cells [5].  
In recent years, there have been great advance in our understanding of the causes, 
benefits and vulnerability of cancer cell metabolism. This advance has led to the 
identification of new drug targets and facilitated the design of tumor specific metabolic 
substrates. Research in profiling metabolites and enzymatic activities has enabled us to 
develop diagnostic test and tracers for molecular imaging of cancer. In comparison to 
other molecular imaging probes, tracers based on altered tumor metabolism could provide 
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unique information about integrated function of multiple transporters and enzymes in a 
metabolic pathway [6]. 
Figure 1.1. The altered metabolism of cancer cells. Drivers (A, low oxygen and low pH microenviroment 
and B, cancer-associated signaling pathways induce metabolic reprogramming). Advantages (C, increased 
biosynthesis, D, avoid apoptosis and E, engage in local metabolite-based paracrine and autocrine 
signaling). Potential liabilities (F, build up of toxic metabolites and G, high energetic demand). Adapted 
from [5]. 
 
1.2 Imaging  
Molecular imaging methods can non-invasively detect specific biological 
processes that are aberrant in cancer. These methods can be used in detection, staging and 
restaging of various cancers, evaluation and prediction of treatment response, and assist 
in determining the prognosis of patients. Several modalities can be used for tumor cell 
metabolic imaging, including PET, single photon emission computed tomography 
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(SPECT) and Magnetic Resonance Spectroscopy Imaging (MRS). Metabolic imaging is 
increasingly fused with Computed Tomography (CT)/MRI for precise anatomical 
localization [7, 8].  
The development of MRSI is result of combining imaging techniques with 
magnetic resonance spectroscopy (MRS). MRSI is used for detecting endogenous cellular 
metabolites and can provide information for cancer diagnosis and treatment planning, 
particularly for brain, breast and prostate cancers [9]. The application of MRSI is limited 
by its low sensitivity and spatial resolution. An emerging technique, hyperpolarizing 13C 
MRS imaging, dramatically enhances the sensitivity for detection and could further 
extend the clinical use of MRS [10]. PET and SPECT, which are based on radiotracers, 
are highly sensitive and can target a specific protein. The existing imaging modalities 
mainly differ in five aspects: detection limit, spatial and temporal resolution, depth of 
penetration, energy for imaging generation and availability of molecular probes [11]. 
Table 1.1 lists some of the general characteristics of available imaging modalities for 
altered tumor metabolism. 
Table 1.1.  Comparison of modalities for tumor metabolic imaging [11, 12] 
Imaging  
Modality 
Isotopes Radiation 
spectrum in 
image generation 
Spatial 
resolution 
Temporal 
resolution 
Detection 
limit 
Amount of 
molecular 
probe used 
MRSI 1H,19F, 
31P,13C 
Radiowave 5 to 7 mm mins to h ~10-3 to 
~10-5 M 
µg to mg 
PET 11C,18F, 
15N,15O, 
64Cu,  
124I, 68Ga,  
High energy 
γ rays 
1-2 mm 
(micro); 
~ 4-5 mm 
(clinical) 
10s to mins 10-11 to 
10-12 M 
ng to µg 
SPECT 99mTc, 
111In, 123I 
low energy 
γ rays 
1-2mm 
(micro); 
>4mm 
(clinical) 
mins 10-10 to 
10-11 M 
ng to µg 
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1.2.1. Radionuclide imaging  
Radionuclide imaging is a specialty of medical imaging that uses 
radiopharmaceuticals (radionuclides incorporated into pharmaceutically-active 
molecules) and relies on the process of radioactive decay for image generation. The 
fundamental principle in nuclear imaging is the tracer principle invented in 1912 by 
Nobel laureate George de Hevesy, who found that radioactive elements had identical 
chemical properties to the nonradioactive form and therefore could be used to trace 
chemical behavior in solutions or in the body [13]. Radioactive tracers allow the 
distribution of labeled molecules to be followed, making it possible to study the 
biochemistry within the various organs of the living body. Radionuclide imaging can 
trace biochemical pathways without perturbing native biochemistry by using 
submicromolar quantities of tracers thus having little chance of pharmacologic toxicity 
and minimal radiation burden for the patients. 
Of the available radioisotope imaging methods, PET has been gaining widespread 
use thanks to its advantages over more conventional SPECT [14, 15]. PET provides a 
superior combination of sensitivity and spatial resolution over single-photon imaging, 
and allows accurate quantification of dynamic regional tracer concentration [14]. 
Furthermore, PET offers a greater range of radiopharmaceuticals for cancer imaging and 
many PET isotopes have natural occurrence in biologically active molecules in contrast 
to heavy isotopes used in SPECT, resulting in higher possibility of synthesizing 
physiologically active tracers for PET. Now PET has become an increasingly important 
tool for clinical oncology, so in this thesis work we mainly focus on developing imaging 
agents for PET. 
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1.2.1.1 Positron Emission Tomography (PET)  
PET detects high energy γ rays generated from positron emitting radionuclides. 
The unstable radioisotopes undergo β+ decay and emit a positron (e+) and neutrino (v). 
The emitted positrons travels a short distance (~1.1 mm) before they encounter electrons 
(e+) in the surrounding medium, consequently annihilate and give off two coincident γ 
rays with 511 Kev energy in opposite direction (Figure 1.2).  These γ rays can be detected 
within nanoseconds from each other, which defines the line of events in space and thus 
the direction of flight. These events are registered and reconstructed into volumetric 
images of radiotracers in vivo (Figure 1.3) [13].  
Figure 1.2. Principles of positron emission tomography image acquisition. 
(http://www.heartandmetabolism.org/images/HM34/HM3407gr1.gif) 
 
 
A number of commonly occurring elements, such as carbon, oxygen, nitrogen, 
and fluorine have positron-emitting isotopes. The stable nuclides of these elements can be 
potentially replaced by their positron emitting counterparts in a number of compounds 
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and used as PET imaging agents. The short half-life of certain positron emitting nuclides 
(t ½ for O15, N13 and C11 are 2, 10 and 20 min respectively) poses limit on the applications 
of the radiotracers because their production requires an on-site cyclotron. Tracers with 
isotopes of longer half-life such as 18F (t ½ is 110 min) may overcome such limitation. 
Advances in radiochemistry could lead to a greater number of radiotracers for PET [16]. 
PET currently has remarkable impact in the field of oncology as a diagnostic, staging and 
restaging tool. Furthermore, PET can provide information pertaining to the drugs 
effectiveness, the potential of PET to influence cancer therapy is significant and its role 
in anti-cancer drug development and therapy is being increasingly recognized [17]. 
 
Figure 1.3. Principles of positron emission tomography. a. A cyclotron is used to produce short-lived 
positron-emitting isotopes. b. Well-established molecular probe can be prepared using automated 
synthesizers. c. The tracers (e.g. FDG) can be synthesized and intravenously injected. d. The PET scanner 
can detect the coincident gamma-rays, and images can be reconstructed showing the location(s) and 
concentration of the tracer of interest. e. Cross-sectional FDG-PET images are shown. Uptake in tumor (T), 
brain (Br), myocardium (C) and renal excretion into the urinary bladder (B) are visible. Adapted from [2]. 
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1.3 Tumor metabolism imaging
Imaging altered tumor cell metabolism has been tremendously successful in 
recent years. Numerous studies have shown that various cancers can be detected with 
high sensitivity and specificity based on their increased metabolic rates for glucose, 
amino acids or lipids [6] (Figure 1.4). A number of analogs of glucose, choline and amino 
acids have been developed as PET or SPECT imaging agents and have shown promising 
clinical results (Table 1.2). Here we will focus on discussion of altered tumor glucose, 
amino acids and phospholipids metabolism and their clinical applications. 
 
Figure 1.4 Simplified overview of metabolic processes targeted by PET. AA = amino acid; FAS = fatty 
acid synthase; G6P = glucose-6-phosphate; LDH = lactate dehydrogenase; MCT = monocarboxylate 
transporter; Ribose 5P = ribose-5-phosphate. Arrows indicates upregulation.  
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Table 1.2. Selected clinically used tumor metabolic imaging agents for PET 
Modified from Vallabhajosula [18] 
 
 
 
1.4 Tumor glucose metabolism and its clinical applications  
1.4.1 Tumor glucose metabolism and the development of FDG 
The most well known altered metabolism in tumor cells is increased aerobic 
glycolysis (the Warburg effect). In comparison to normal cells, cancerous cells mainly 
use glycolysis without entering kreb cycle in mitochondria even when oxygen is present 
[24]. It seems to be paradoxical as pointed out by Gatenby [25] since cancer cells have 
high demand for energy while glycolytic metabolism is very inefficient (producing only 2 
mol of adenosine triphosphate (ATP) per mole of glucose vs. 36 mol of ATP per mole of 
glucose for the citric acid cycle) and generates an acidic, potentially toxic environment 
[26].  It is suggested that increased glycolysis confers survival and growth advantages for 
cancer cells and it is an adaptation to intermittent hypoxia in malignant lesions [27]. 
Furthermore, increased glycolysis is result of oncogenic action. Re-programming of gene 
expression may be an important mechanism for altered tumor cell metabolism. Activation 
Radiotracers Biochemical 
Process 
Mechanism of Uptake or 
Localization 
Reported clinical 
applications 
[18F]FDG Glucose 
metabolism 
Facilitated diffusion via 
glucose transporters. Substrate 
for hexo- kinase in glucose 
metabolism 
Colorectal cancer, mel-
anoma, Non-small cell 
lung cancer, lymphoma, 
et al. [18] 
[11C]Methionine 
(MET), 
[18F]Fluoroethyl 
tyrosine (FET) 
Amino acid trans- 
port and protein 
synthesis 
Transport into the cells 
involves amino acid carrier 
protein 
Brain tumors et al. [19, 
20] 
[11C]Choline, 
[18F]Fluorocholine 
(FCH) 
Membrane 
synthesis 
Substrates for choline kinase 
in choline metabolism 
Prostate cancer, brain 
tumors et al.[21, 22] 
[11C]Acetate 
[18F]Fluoroacetate 
Lipid synthesis Acetate is activated to acetyl-
CoA in both the cytosol and 
mitochondria by acetyl-CoA 
synthetase 
Prostate cancer, brain 
tumors et al. [23] 
 
 - 10 - 
of oncogenes such as (e.g. HIF1, Akt, Myc [28-30]) or loss of tumor suppressor genes 
(e.g. p53 [31]) could be the underlying mechanism for increased glycolysis in cancer 
cells.  
 
Figure 1.5. The cellular metabolism of glucose and [18F]FDG. G6P = glucose-6-phosphate; LDH = lactate 
dehydrogenase; MCT = monocarboxylate transporter. Arrows indicates upregulation or downregulation.  
 
1.4.2 Clinical success and limitations of FDG-PET 
FDG-PET, which is based on altered tumor glucose metabolism, is the most 
widely used imaging method by far. It is a routine clinical test for diagnosing, staging, 
restaging and monitoring therapy for a variety of cancers including lung cancer, 
lymophoma, colorectal cancer et al [18]. Uptake and trapping of FDG results from 
upregulation of glucose transporters (GLUT, notably GLUT1 [32], GLUT3 [33] and 
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GLUT12 [34]) and hexokinase [35]. FDG is transported across the cell membrane by 
sodium independent, facilitative glucose transporters and is then phosporylated by 
hexokinase to FDG-6-phosphate (as in Figure 1.5). In contrast to glucose-6-phosphate, 
which can further be metabolized to fructose-1, 6-biphosphate via glycolysis pathway, 
FDG-6-phosphate cannot be further metabolized because of substitution of F atom at C2 
position. As a result of lack of transporters for FDG-6-phosphate, it is trapped and 
steadily accumulates in metabolically active tumor cells. 
The current clinical applications of FDG in cancer diagnosis and management are 
very broad [36]. Despite the tremendous success of FDG, it has several well-known 
drawbacks that limit its applications: 1) the normal brain depends exclusively on glucose 
metabolism for energy demand. As a result, normal cerebral cortex has high 
accumulation of FDG. In case of diagnosis of brain tumor, this leads to low contrast 
making differentiation of tumor from surrounding grey matter difficult; 2) inflammatory 
cells and macrophages have same level of uptake of FDG as tumor cells, this could cause 
false-positive results [37]; 3) some tumors do not have increased uptake of FDG thus 
could not be detected by FDG-PET. The reasons for lack of uptake include relatively low 
glucose metabolism, as seen in prostate cancer, high mucin content, low proliferation 
rates and necrosis [38]; 4) FDG has high urinary excretion, because pelvic malignancies 
such as prostate cancer, urinary bladder carcinoma and renal cell carcinoma, are close to 
the urinary route, thus can not be satisfactorily visualized via FDG-PET [39]. To 
overcome these limitations of FDG, various radiopharmaceuticals have been developed 
for PET studies. We will focus on the advance of amino acid and choline based ligands as 
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tumor imaging agents in the following sections. The new tracers we developed in this 
thesis work will be discussed in the meantime. 
 
1.5 Developing new PET tracers for tumor metabolism imaging 
Developing new PET tracers is a multidisciplinary process involving selecting 
desirable targets, organic synthesis, radiolabeling, and in vitro/in vivo biological 
evaluations before tracers could be used in preclinical or clinical settings [40]. A 
promising imaging agent for aberrant tumor metabolism should have but not limited to 
the following properties: 1) ease of synthesis of radioactive ligands and their 
corresponding non-radioactive precursors and standards; 2) high affinity and selectivity 
towards enzymes associated with altered tumor metabolism; 3) good in vivo stability; 4) 
desirable in vivo pharmacokinetics (e.g. fast accumulation in targets, appropriate 
clearance rate). To evaluate the potential of new tracers as PET imaging agents, in vitro 
and/or in vivo tests should be performed. In vitro tests such as uptake studies provide a 
way to test tracers’ accumulation in target tumor cells. Protein binding and competition 
studies allow assessing the affinity and/or selectivity of tracers to the target enzymes.  
Biodistribution and small animal PET imaging studies in rat or mice tumor models enable 
evaluation of in vivo pharmacokinetics of the PET tracers. Further metabolites analysis to 
study tracers’ in vivo stability and metabolic pathways could be carried out via HPLC 
analysis of plasma sample after certain time post-injection. Preclinical evaluations are 
important and provide insightful information before the new PET tracers go into 
clinically trials. But the data acquired in these biological evaluations need to be 
interpreted with caution considering the interspecies difference.  
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1.5.1 Tumor amino acid metabolism and novel amino acid based tracers  
1.5.1.1 Tumor amino acid metabolism 
 
Figure 1.6. Tumor cell amino acid metabolism. There are at least four amino acid transporters that are 
generally upregulated in tumor cells: ASCT2, LAT1/4F2hc, xCT/4F2hc, and ATB0,+. All four transporters 
participate in providing tumor cells with amino acids necessary for protein synthesis. EAA, essential amino 
acids; Glu, glutamate; αKG, α-ketoglutarate. Adapted from [41]. 
 
Amino acids (AAs) are not only essential for protein synthesis, but also function 
as an energy source and precursors for biomolecules such as nucleotides, amino sugars 
and serotonin. Tumor cells have increased transport of amino acids and/or protein 
synthesis to support their growth and survival (Figure 1.6). The essential mechanisms 
involved in uptake of amino acids are the carrier-mediated transport into cells and the 
esterification of the amino acids to form the aminoacyl-t-RNA, which forms the 
polypeptide chain in the ribosome (incorporation into protein). Of these two mechanisms, 
transport and incorporation into protein, uptake of amino acid tracers is generally 
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dominated by carrier-mediated transport [42-44]. So amino acid transporters have been 
the main focus of the development of amino acid tracers in recent years.  
Amino acid transporters are classified into distinct systems based on ion 
dependence, substrate selectivity, sensitivity to selective inhibitors, kinetics, regulatory 
properties et al [45]. A number of amino acid transport systems have been shown to be 
upregulated in a variety of cancer cell lines and play important roles for tumor growth 
and survival (Table 1.3). System L (LATs), in particular its subtype LAT1, has attracted 
special interest. It is a promising target for imaging agents and cancer therapy for a 
number of reasons: 1) elevated expression correlates well with tumor growth and poor 
prognosis [46]; 2) low expression in normal and inflammatory tissues ensuring high 
tumor specificity [47]; 3) pivotal in transport of amino acids through blood-brain barrier 
[48]; 4) plays important role in transporting certain anti-cancer drugs such as melphalan 
[49]; 5) inhibition of LAT1 suppresses cancer growth [50]; 6) substrates of LATs have 
demonstrated promising clinical imaging results (as shown in Table 1.4). 
Table 1.3. Major amino acid transport system upregulated in cancer cells 
System 
 
Protein Na+ dependence Substrate specificity 
 
Comments 
 
A 
 
 
SAT1 
SAT2 
SAT3 
Na+ dependent Short, polar, straight chain 
AAs such as Gly and Ala,  
Influx transporter, inducible by 
starvation, hormones, growth 
factors [51] 
ASC 
 
ASCT1 
ASCT2 
Na+ dependent Small polar AAs such as Ala, 
Ser,Cys, Gln et al 
Upregulation observed in 
prostate cancer and colorectal 
carcinoma [52, 53] 
B0,+ ATB0,+ Na+ dependent Neutral and cationic amino 
acids such as Gln, Lys et al,  
Broad substrate selectivity, 
accepts 18 of 20 natural amino 
acids, induced in cervical cancer 
and colorectal cancer [54, 55] 
L 
 
LAT1 
LAT2 
LAT3 
LAT4 
Na+ independent Large branched neutral AAs 
such as Phe, Tyr, Met, Trp et 
al 
Broad substrate selectivity, 
subytpe LAT1 can accept D-
isomer, upregulation has been 
observed in brain, colon, lung, 
liver and skin cancers [56] 
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1.5.1.2 Clinical applications of amino acid based tracers 
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Figure 1.7. Structures of clinically utilized amino acid based tracers. 
 
Table 1.4. Selected clinically utilized amino acid tracers and their uptake mechanism. 
Tracers 
 
Transport 
mechanism 
 
Clinical applications 
 
Comments 
 
MET 
 
A; LATs [57] Brian tumors, head and neck, 
lung, malignant lymphomas, 
and breast cancer  
Short half life, high excretion through 
bladder, complicate in vivo metabolism 
 
IMT 
 
LATs [58, 59] 
 
Brian tumor, non-small cell 
lung cancer 
May not differentiate low grade glioma 
from non-neoplasmatic lesions or high 
grade gliomas 
FPro A; PAT1 [60] Brain tumors 
 
Uptake is limited to areas of blood brain 
barrier disruption  
FDOPA LATs [61]* Parkinson’s disease Substrate for aromatic amino acid 
decarboxylase, undergoes extensive in 
vivo metabolism with multiple metabolites  
FACBC LATs [62] Brain tumor, prostate cancers 
and renal cell carcinomas 
Low urinary excretion  
FET 
 
LATs; B0,+ 
contribute to a 
lesser extent [20] 
Brain tumor, 
head and neck cancer 
 
Efficient labeling process, limited 
applications in extracranial tumors 
(negligible uptake in peripheral tumors 
such as breast cancer, lung cancer, 
lymphomas) 
 
 
Currently, the most widely used amino acid based tracer is [11C]methionine 
(MET), which has proven useful for imaging brain, head and neck, lung, malignant 
lymphomas, and breast cancer [19, 63]. However, it has high uptake in liver, pancreas, 
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and intestine and is excreted through the bladder, characteristics that interfere with tumor 
imaging in the abdominal region and in the region of the bladder or prostate. Its uptake 
also reflects non-protein metabolic pathways such as transamination and 
transmethylation, which makes imaging kinetic analysis difficult [64]. In additional, short 
half-life of 11C necessitates onsite cyclotron, limiting its clinical applications. This led to 
the development of non-natural amino acid labeled with longer half-life isotopes such as 
18F and 123I. A variety of tyrosine and phenylalanine derivatives have been developed for 
tumor imaging (Figure 1.7) such as 3-[123I]-α-methyl-L-tyrosine (IMT) [59], 3-
[18F]fluoro-α-methyl-L-tyrosine (FMT) [65], 3,4-dihydroxy-6-[18F]fluorophenylalanine 
(FDOPA) [66],  and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) [20]. Other compounds such 
as cyclic 1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (FACBC) [67] and proline 
derivatives cis-4-[18F]fluoro-L-proline (FPro) [68] have also been clinically used. As we 
can see from Table 1.4, system L represents the major underlying uptake mechanism for 
these amino acid tracers.  
 
1.5.1.3 Design of novel aromatic amino acids derivatives  
As we stated in section 1.5.1, system L, in particular its subtype LAT1, is a 
promising target for developing amino acid based tracers. For a radiotracer to be 
clinically successfully and reflect specific protein activity associated with altered tumor 
metabolism, it should have efficient radiolabeling process, high selectivity and/or affinity 
towards target protein, desirable in vivo kinetics, and stability in vitro and in vivo. From 
studying substrate recognition for LAT1 [69], it is proposed that for a ligand to be 
substrate for LAT1, it should satisfy the following requirements (as shown in Figure 1.8): 
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1) have a free carboxyl and an amino group; 2) The carbonyl oxygen in the binding site 
needs an appropriate polarity and must not participate in hydrogen bonding; 3) desirable 
hydrophobic interaction in the side change. 
 
Figure 1.8. Proposed model for the substrate-binding sites of LAT1. 3,4-dihydroxy L-phenylalanine 
(DOPA) used as the model compound.  Adapted from [68].
 
There are no extensive quantitative studies on structure-activity of LATs. In 
search of new amino acid based tracers with potential improved imaging characteristics, 
we chose one of clinically established LATs L-[18F]FET,  as our reference tracer and 
parent compound for further modification. L-[18F]FET is one of the first 18F labeled 
amino acid based tracers that could be produced in a large quantity for clinically use and 
satellite distribution similar to FDG. It has high radiochemical yield, low accumulation in 
normal brain and peripheral tissues, rapid tumor uptake, and good in vivo stability and 
has established clinically applications in imaging brain tumors and head and neck cancer 
[20, 70, 71].  However, it has negligible accumulations in many extracranial tumors and 
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high urinary excretion, which limit its applications [72]. Using the fluoroalkyl tyrosine 
core structure of L-[18F]FET as the lead, modifications (as Figure 1.9) were made to 
structure to probe the affinity and selectivity for amino acid transporters. 
L-FEP D-FEPL-FPP D-FPP
N
H2N
COOH
O
18F
FEAT
H2N
CONH2
O
18F
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H2N
COOH
O
18F
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Fluoroalkyl Tyrosine Derivatives
Fluoroalkyl Phenylalanine Derivatives
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alteration of alkyl chain
alteration  on aromatic ring
amide
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p-(2-[18F]fluoroethyl)-
L-phenylalanine
p-(3-[18F]fluoropropyl)-
L-phenylalanine
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D-phenylalanine
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Figure 1.9 Design of novel aromatic amino acid derivatives as potential PET imaging agents 
In designing this new series of amino acid tracers, we kept alkyl chain as the 
linker for 18F. In this way, 18F can be incorporated in to the target molecule through a 
direct nucleophilic reaction to form fluroalkyl side chain, which generally has high 
radiochemical yield. From α-methyl substitution (FEMT), alteration in aromatic ring 
(FEAT) and change of carboxyl group to amide (FETA), a series of tyrosine derivatives 
were prepared. Via alteration in alkyl chain (i.e. elimination of oxygen atom may enhance 
the hydrophobic interaction with LAT1), we developed a series of phenylalanine 
derivatives (FEP and FPP). Because LAT1 could transport D-isomers of phenylalaine, we 
also prepared the D-isomers of the phenylalanine derivatives. One of the FET analog, L-
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isomer of FEP was found to be transported predominately via LATs and demonstrated 
preference towards subtype LAT1. The selectivity for LATs does not guarantee that a 
radiotracer will be potential useful imaging agents for increased amino acid transport 
activity in tumor cells. In vivo studies such as kinetic studies and imaging studies need to 
be executed to determine whether tumors could be appropriately imaged.  
 
1.5.2 Tumor phospholipid metabolism and new ethanolamine tracers 
1.5.2.1 Tumor phospholipid metabolism 
 
 
Figure 1.10 Choline phospholipid metabolism. Metabolites are given in bold letters. CCT = 
CTP:phosphocholine cytidylyltransferase; ChoT = choline transporters; ChoK = Choline kinase; PCho = 
phosphocholine; PtdCho = phosphoatidyl choline; Arrows indicates upregulation.  
 
Phosphoglycerides are important in formation of cellular and organelle 
membranes in rapidly growing tumors. The elevation of phosphocholine (PCho) or 
phosphoethanolamine (PEtn) is one of widely established characteristics of cancer cells 
[73]. Numerous in vivo and in vitro 1H and 31P MR spectroscopic studies have detected 
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high levels of PCho or PEtn, or both, in a variety of cancers such as breast, prostate, and 
different types of brain tumors, whereas low levels of these metabolites were found in 
corresponding normal tissues [74, 75]. These studies demonstrate the significance of 
phospholipid precursors and catabolites as biochemical indicators of tumor progression 
and response to therapy. Most notable mechanisms underlying the increased PCho levels 
(as in Figure 1.10) include increased expression and activity of choline kinase [76, 77], a 
higher rate of choline transport [78], and increased phospholipase (PLD) [79]. Choline 
kinase (ChoK) phosphorylates free choline to PCho in the CDP-Choline pathway (or 
kennedy pathway). ChoK is considered to be an important target for cancer because it 
regulates oncogene activation and correlates with tumor growth and prognosis [80, 81]. 
 
1.5.2.2 Clinical applications of choline and its derivatives 
N
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11C
N
OH
N
OH18F18F
N
OH18F N
OH18F
11C-Choline (CH) 18F-fluorocholine (FCH) 18F-fluoroethylcholine (FEC)
18F-fluoromethylethylcholine (FMEC)
18F-fluoropropylethylcholine (FPC)
 
Figure 1.11. Choline and its derivatives as PET imaging agents  
 
Choline ([11C]CH) and its derivatives (Figure 1.11) have been developed as 
biomarkers for aberrant choline phospholipids metabolism in tumors. In particular, 
[11C]CH and [18F]FCH-PET are valuable tools for imaging prostate cancer, breast 
carcinoma, and brain tumors [82, 83]. But [11C]CH and its derivatives have limitations 
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including high bladder uptake and high radiation dose to kidney, liver and spleen [84]. 
The most activity accumulates into the liver and kidney because choline oxidase oxidazes 
choline into betaine and causes activity to be trapped there. 
 
1.5.2.3 Rational for new 11C labeled ethanolamine and its derivatives  
N
H
H311C OH
[11C]N-methyl ethanolamine (MEA)
N
H311C OH
[11C]N, N-Dimethyl ethanolamine (DMEA)
NH211CH2CH2OH
[11C]ethanolamine (EA)  
Figure 1.12. 11C labeled ethanolamine and its derivatives 
 
Elevated PEtn concentration is found to be even higher than PCho in a variety of 
tumors [85, 86]. Ethanolamine is subject to biosynthetic pathway for 
phosphoatidylethanolamine (major phospholipid component in cell membrane) similar to 
choline [87, 88]. This might be an indication that ethanolamine, the precursor of PEtn, 
could be a potential useful and more sensitive imaging agents than choline for tumor 
phospholipids metabolism.  
We first conducted preliminary studies using 14C labeled ethanolamine and N, N’-
dimethyl ethanolamine to validate the potential of ethanolamine tracers for tumor 
detection. The results demonstrated that 14C labeled ethanolamine tracers were taken up 
significantly better (2-7 fold) than [14C]choline in a wide variety of tumor cells including 
colorectal cancer (HCT116), prostate (PC-3), melanoma (A375 and 1618), glioblastoma 
(SF767, A172), and lymphoma (DLCL2) [89]. Since 11C labeled compound would 
behave the same as their natural and 14C labeled counterpart, we hypothesize that 11C 
labeled ethanolamine and its derivatives could potentially be more sensitive biomarkers 
for tumor phospholipid metabolism than [11C]CH. We then proceeded with the synthesis 
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and biological evaluations of the series of 11C labeled ethanolamine and its derivatives 
(Figure 1.12).  
 
1.6 Scope of the thesis research 
The ultimate goal of this thesis work is to develop new PET tracers with better 
imaging properties than current clinically utilized imaging agents for certain types of 
tumors such as brain tumor and prostate cancer based on altered tumor metabolism. This 
thesis work included early radiopharmaceuticals discovery phase up to preclinical PET 
imaging studies in rats. Chapter two to four describes the development of new 18F labeled 
aromatic amino acid derivatives as potential PET imaging agents based on tumor amino 
acid metabolism. Chapter two covers the synthesis of a series of new fluoroethyl tyrosine 
derivatives and their in vitro characterization through cell uptake studies in the human 
glioma cell line. Chapter three describes the preparation of fluoroalkyl phenylalanine 
derivatives and their biological evaluations including in vitro evaluations through cell 
uptake studies and uptake mechanism characterization and in vivo characterization 
through biodistribution and small animal PET imaging studies. Chapter four describes 
comparative studies of D- and L-isomers of fluoroalkyl phenylalanine derivative via in 
vitro cell uptake and transport characterization and in vivo PET imaging studies in rats. 
Chapter five covers the development of new 11C labeled ethanolamine derivatives as 
potential PET tracers based on tumor phospholipid metabolism. Preliminary studies of 
14C ethanolamine and its derivatives, labeling of 11C ligands and in vitro studies in 
prostate cancer cell lines are described. 
 - 23 - 
1.7 Clinical significance of this work 
Metabolic imaging has a significant impact on patient management by improving 
tumor staging, treatment planning and monitoring response to therapy. There is growing 
evidence demonstrating a close link between oncogene activation and metabolic change 
in cancer cells. Altered tumor metabolism is increasingly considered to represent a group 
of promising therapeutic targets, and tumor metabolic imaging provides a way to monitor  
such targeted therapies [3]. Increased amino acid transporter activity and 
choline/ethanolamine phospholipids metabolism are observed in a wide variety of 
cancers. It is our hope that these novel metabolic tracers could provide better tools for 
imaging altered amino acid transport and phospholipid metabolism in tumors. 
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Chapter 2 
 
 
Synthesis and in vitro evaluation of 18F labeled 
tyrosine derivatives as potential PET imaging agents 
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2.1 Introduction  
A number of classes of metabolically based radiotracers such as radiolabeled 
glucose, amino acids, fatty acids and their analogs were developed for tumor imaging and 
have shown tremendous success in recent years. [18F]fluorodeoxyglucose (FDG), which 
utilizes upregulated aerobic glycolysis in tumor cells [1], is routinely used in clinics for 
detecting, staging and restaging of lymphomas [2] and many solid tumors [3]. However, 
it has certain limitations such as high uptake in the cerebral cortex and non-specific 
accumulation in inflammatory tissues [4]. In search of new imaging agents, a variety of 
radiolabeled amino acids were prepared based on increased amino acid uptake and 
protein metabolism in cancer cells. Numerous studies have demonstrated that amino acid 
based tracers show better results than FDG in detecting and delineating certain tumors, 
particularly in brain tumors [5]. 
Currently, the most commonly used labeled amino acid in PET is [11C]methionine 
(MET) [6, 7]. Despite the success, its susceptibility to multiple metabolic pathways 
complicates the pharmacokinetic analysis [8, 9] and its short half-life (20.3 min) limits its 
clinical applicability. To overcome these disadvantages, a number of 18F (half-life 109.8 
min) labeled amino acid analogs such as O-(2-[18F]fluoroethyl)-L-tyrosine (FET, [18F]1) 
[10], L-3-[18F]fluoro-α-methyl tyrosine (FMT) [11], 6-[18F]fluoro-L-dihydroxy phenyl- 
alanine (FDOPA) [12], and anti-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid 
(FACBC) [13, 14] were developed. In particular FET ([18F]1), is a successful 18F labeled 
amino acid tracer and it has been used in imaging brain tumors and head-neck carcinomas 
for diagnosis and therapy planning [15, 16]. 
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 Several close analogs of FET ([18F]1), such as O-(18F]fluoromethyl)-L-tyrosine 
[17],  O-(3-[18F]fluoropropyl)-L-tyrosine [18] and O-(3-[18F]fluoropropenyl)-L-tyrosine 
[19] have been developed and evaluated. The uptake of these structurally similar tyrosine 
derivatives in tumor cells is most likely attributed to elevated amino acid transporter 
activity, in particular system L amino acid transporters (LATs) [5, 20, 21], a Na+ 
independent transport system which mediates transport of branched and aromatic amino 
acids [22]. LAT, generally upregulated in many cancer cell lines, is a target for 
development of tumor imaging agents [23-25]. System L has broad substrate selectivity; 
substitutions on aromatic ring with fluorine, hydroxy or fluoroalkyl group as well as 
substitutions on α-hydrogen with methyl are generally tolerated, this enables developing 
a variety of structurally similar analogs as potential LATs substrates [26]. 
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Figure 2.1. FET ([18F]1) and its new analogs. 
 
To pursue aromatic amino acid derivatives with better tumor-avid properties than 
FET ([18F]1) and exploring the structure-activity relationships (SAR) of LATs, three new 
18F tyrosine derivatives were synthesized and evaluated (Figure 2.1): O-(2-
[18F]fluoroethyl)-α-methyl tyrosine (FEMT, [18F]2), O-(2-[18F]fluoroethyl)-2-L-
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azatyrosine (FEAT, [18F]3), and  O-(2-[18F]fluoroethyl)- L-tyrosineamide (FETA, [18F]4). 
FEMT ([18F]2) could be considered as fluoroalkyl derivative of well established SPECT 
tracer 3-[123I]iodo-α-methyl-L-tyrosine (IMT).[27] We reasoned that FEAT ([18F]3) 
might have specific uptake in cancer cells, because its analog 2-azatyrosine was reported 
to show antitumor activity and could reverse the ras transforming cancer cells to normal 
cell without significant effect on the growth of normal cells [28]. The amide derivative 
FETA ([18F]4) was synthesized in hope that higher lipophilicity of [18F]4 may lead to 
improved pharmacokinetics compared to FET ([18F]1), such as reduced excretion through 
urinary tract. 
2.2 Results and discussion 
2.2.1 Synthesis of precursors and authentic standards for radiotracers 
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Scheme 2.1. Initial synthetic route of FEMT 2. Reagents and conditions: a) (Boc)2O, 
dioxane/H2O, details as listed in Table 2.1; b) tert-butyl 2,2,2-trichloroacetimidate, BF3.Et2O, 
CH2Cl2/THF, 1 d, 45%; c) TsO(CH2)2OTs, K2CO3, DMF, 70 oC, 26 h, 70 oC, 13%; d) 
FCH2CH2Br, NaH, DMF,0 oC to 5 oC, 7 h, 88%; e) TFA, CH2Cl2, 30 min, 40%; f) tert-butyl 
trichlorloacetimidate, CH2Cl2/cyclohexane, BF3.Et2O, rt to 50 oC, 3 d, 21%. 
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Table 2.1: Boc protection result of 5 under various conditions: 
Base Temperature (oC ) Reaction time  Yield (%) 
NaHCO3/NaOH 25 2 d  9 
Me4NOH 25 5 d 26 
Et3N 25 7 d 21 
Et3N 50 2 d 30 
HO
COOH
H2N
HO
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HO
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F
O
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TsO
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14 132
a b
cd
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.HCl
Scheme 2.2. Improved synthesis of FEMT 2.  Reagents and conditions: a) SOCl2, MeOH, 0 oC to 
reflux, 16 h, 100% b): (Boc)2O, Et3N, MeOH, 50 oC, 3 d, 63%; c) NaH, DMF, TsOCH2CH2OTs,  
0 oC to 5 oC, 6 h, 46%; d) NaH, DMF, FCH2CH2Br, 0 oC to rt, 6 h, 81%; e) 6N HCl, reflux, 2 h, 
46%. 
 
Cold standard for FEMT 2 was initially carried out as shown in Scheme 2.1 from 
commercially available α-methyl tyrosine 5. The attempt of Boc protection of amino 
group of 5 had low yield (< 30%) and required long reaction time as shown in Table 2.1. 
This might be due to steric hindrance from the α-methyl group and limited solubility of 5 
in water or organic solvents [29]. Since this synthetic route is flawed with low yield (i.e. 
yield of tosylate precursor and standard was no more than 2% and 10% respectively) and 
long reaction time, we then developed a new strategy as demonstrated in Scheme 2.2. 
Protecting the carboxylic acid group of 5 first could solve the solubility issue so 
subsequent Boc protection could be achieve with shorter reaction time and higher yield. 
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Methylation of the carboxylic group gave α-methyl tyrosine methyl ester 11 in 
quantitative yield. The subsequent Boc protection produced protected tyrosine 12 in good 
yield. Since direct nucleophilic radiofluorination is generally a better method than 
indirect labeling [30, 31], we prepared labeling precursors as protected O-tosylalkyl 
tyrosine derivatives. Tosylate precursor 13 was obtained in a yield of 46% after treating 
12 with ethylene glycol ditosylate and NaH in DMF. Alkylation of 12 with 1-bromo-2-
fluoroethane followed by deprotection in 6 N HCl, FEMT 2 was prepared with 23% 
overall yield.  
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Scheme 2.3. Synthesis of FEAT 3. Reagenet and conditions: a) (i) Zinc dust, I2, DMF, rt, 1 h; (ii) 
2,5-dibromopyridine, Pd(PPh3)Cl2, 68 oC, 2 h, 73%; b) bis(pinacolato) diboron, Pd(dppf)Cl2, 
KOAc, 85 oC, 4 h;  c) H2O2, CH2Cl2, 0 oC to rt, 16 h, 76%; d) TsOCH2CH2OTs, K2CO3, DMF, 70 
oC, 47%; e) FCH2CH2Br, K2CO3, DMF, 70 oC, 2 h, 67%; f) 6 N HCl, reflux, 4 h, 75%. 
 
For synthesis of FEAT 3, the important intermediate is Boc-L-2-azatyrosine 
methyl ester 17, which was prepared following the same procedure reported by Germain 
et al [32] via Negishi cross coupling using 2,5-dibromopyridine as precursor and 
subsequent hydroboration-oxidation  reaction (Scheme 2.3). From this protected 
azatyrosine intermediate 17, we could obtain labeling precursor 18 and FEAT 3 through 
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alkylation reactions as described in FEMT synthesis with 26 % and 28 % overall yield, 
respectively. We were interested in comparing the 2-azatyrosine and 3-azatyrosine 
derivatives to see how the position of N atom in aromatic ring affects ligands’ activity. 
However, via Negishi coupling reaction, we could not obtain the intermediate with 
acceptable yield for synthesis of labeling precursor and standard of O-fluoroethyl 3-
azatyrosine as shown in Scheme 2.4 and Table 2.2.  
N
X OH
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Scheme 2.4. Attempted synthesis of 3-azatyrosine derivative. Reagenet and conditions: a) PPh3, 
DIAD, THF, HO(CH2)2OTHP or HO(CH2)2F, -5oC-10oC, 2 h; b) 21a or 21b, Pd-catalyst, DMF, 
detailed condition and results as listed in Table 2.2; c) 22a or 22b, Pd(PPh3)2Cl2, DMF, rt 
 
Table 2.2: Conditions and results of synthesis of 23 via Negishi Coupling 
 
X Pd Catalyst (5 mol%) Temperature Reaction time (h) Yield % 
I Pd(PPh3)2Cl2  rt to 55oC 5 6% 
I Pd(PPh3)2Cl2 rt 19 ~1% 
I Pd(dppf)Cl2 rt 28 ~1% 
Br Pd(PPh3)2Cl2 50oC to 65oC 21 No product 
Br Pd(dppf)Cl2 50oC to 55oC 21 ~1% 
Br Pd(dppf)Cl2 70oC 30 5% 
Br PEPPSI 50oC 30 5% 
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Cold standard for FETA, 4 was prepared from Boc-L-tyrosine 25 in three steps 
(Scheme 2.5) – direct alkylation on phenol, coupling reaction with 2,4,6-trimethoxy 
benzylamide (Tmob-NH2) and final deprotection reaction with trifluoroacetic acid. 
Tosylate precursor 30 was synthesized in a similar manner, except it required selectively 
protecting the ethoxyl group on phenol with TBDMS and removing the protecting group 
with TBAF after coupling reaction with Tmob-NH2. Overall yield of FETA was 34% and 
of precursor 30 was 47%. 
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Scheme 2.5. Synthesis of FETA 4. Reagents and conditions: a) NaH, FCH2CH2Br, DMF, 0 oC to 
rt,overnight, 84%; b): Tmob-NH2.HCl, HOBt,DIPEA, HBTU, DMF, 0 oC to rt, 2 h, 80%; c) TFA, 
CH2Cl2, 4 h, 50%; d) NaH, BrCH2CH2OTBDMS, DMF, 0 oC to rt,overnight, 90%;e)  Tmob-
NH2.HCl, HOBt,DIPEA, HBTU, DMF,0 oC to rt, 2 h, 77%;f) TBAF, THF, 1 h, 78%; g) TsCl, 
Et3N, CH2Cl2, overnight, 87%. 
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2.2.2 Radiolabeling of tyrosine derivatives 
X
OTsO
BocHN
COR1
R2
X
O
18F
H2N
COR3
R2a, b
[18F]1, R2 =H, R3 = OH, X= CH
[18F]2, R2 = Me, R3 = OH, X =CH
[18F]3, R2 = H, R3 = OH, X= N
[18F]4,!R2 = H, R3 =!NH2, X= CH
31, R1= OBut, R2 =H, X= CH
13, R1 = OMe, R2 = Me, X =CH
18, R1 = OMe, R2 = H, X= N
30, R1 = NHTmob, R2 = H, X =!CH  
Scheme 2.6. Radiolabeling reactions for tyrosine derivatives. Reagents and conditions: a) 
[18F]KF, K[2.2.2], K2CO3, CH3CN, 90 oC, 10 min; b) deprotection as listed in Table 2.3. 
 
Table 2.3. Deprotection reaction conditions, average decay-corrected RCY and specific 
activities at end of synthesis (EOS).  
Ligands Deprotection reaction conditions	   RCY (%)	   Specific Activity (GBq/µmol)	  
[18F]1 TFA, 60 oC, 10 min 44 ± 8 32 ± 12 
[18F]2 1) TFA, 60 oC, 5 min;  
2) 2 N NaOH, 100 oC, 10 min 
30 ± 8 13 ± 3 
[18F]3 6 M HCl, 120 oC, 10 min 37 ± 8 23 ± 12 
[18F]4 TFA, 60 oC, 10 min 5 ± 2 54 ± 12 
*Values are means of three to six experiments; standard deviation is given in parentheses. 
 
 
All of the 18F labeled ligands, FET ([18F]1), FEMT ([18F]2), FEAT ([18F]3), and 
FETA ([18F]4),  were prepared via nucleophilic substitution of tosylate with non-carrier-
added [18F]KF-K[2.2.2] complex in acetonitrile, followed by deprotection (Scheme 2.6). 
In general, fluorination reaction could reach completion within 10 min at 90 oC. 
Deprotection reaction conditions vary as shown in Table 2.3. All ligands were purified 
with semi-preparative HPLC and were prepared within 100 min in good radiochemical 
purity (RCP, > 95%) determined by both analytical HPLC and TLC.  Results of labeling 
such as decay–corrected radiochemical yield (RCY) and specific activity were 
summarized in Table 2.3. It is noteworthy to point out that two-step deprotection was 
used for FEMT, first remove Boc using TFA and then cleave methyl group via reflux in 
NaOH solution. We have tried to use one-step deprotection by refluxing in 6 M HCl, 
 - 40 - 
however, even after 20 min, fluorinated intermediate still could not be fully converted to 
final product FEMT. Another issue in preparation of these tyrosine derivatives is the low 
yield of FETA. We observed that using TFA at 60 oC for 10 min was not sufficient to 
fully remove the Tmob protecting group. But considering possible hydrolysis of FETA to 
FET, we did not increase reaction temperature or time to improve the deprotection rate.  
 
2.2.3 In vitro cell uptake studies 
 
Figure 2.2a Uptake of new tyrosine derivatives in reference to FET ([18F]1). Maximum uptake of ligands 
was normalized to FET’s highest  uptake in U138-MG. 
aExperiment performed by Brain Lieberman [33]. 
 
After successfully synthesizing 18F labeled tyrosine derivatives, we carried out 
cell uptake studies as initial biological evaluation in U-138 MG human glioblastoma 
cells. U-138 MG was used as positive control in uptake of FET and IMT [34, 35]. Since 
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FET ([18F]1),  was used as reference compound, we chose U-138 MG to establish the 
standard for amino acid tracers’ uptake. The cellular uptake of 18F labeled tyrosine 
derivatives (Figure 2.2) followed the order of FET ([18F]1) > FEAT ([18F]3) > FEMT 
([18F]2) ≈ FETA ([18F]4). 
The uptake of the tracers depends on the ligands’ binding affinity to amino acid 
transporters and their transport rate. From the uptake results, we could make some 
inference about amino acid transporters substrate recognition. The low uptake of FEMT 
([18F]2), the α-methyl substituted FET ([18F]1), indicates O-fluoroalkyl α-methyl tyrosine 
derivatives may not be good substrates for amino acid transporters. As we know, there 
are four subtypes of LATs discovered by now, designated as LAT1 to LAT4. Although 
they have significant overlap of substrate selectivity, it is suggested that some amino acid 
based tracers have preference towards specific subtypes of system L, in particular, FET 
([18F]1) probably prefer to be transported via LAT2 [16]. It is reported that α-methyl 
substitution is tolerated by LAT1 but no evidence suggest that LAT2 could accept α-
methyl substitution as well,[26] this might be the reason that FEMT ([18F]2) has 
significantly lower uptake than FET ([18F]1). FEAT ([18F]3),  has a substituted pyridine 
side chain, which reduces its lipophilicity compared to FET ([18F]1) and this potentially 
leads to its low uptake into cells. FETA ([18F]4), which substitutes carboxylic acid with 
amide, is a poor substrate. In agreement, tyramine, dopamine, as well as phenylalanine 
methyl ester, which lack the free carboxylic acid group, are not good substrates for amino 
acid transporters either.[26, 36] These results suggest that α-carboxylic acid might be 
essential amino acid transporters’ substrate recognition. 
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2.3 Conclusion 
In summary, three new potential PET imaging agents FEMT ([18F]2), FEAT 
([18F]3) and FETA ([18F]4) were synthesized, radiolabeled and evaluated via cell uptake 
studies in U-138 MG. New tracers exhibited lower uptake compared to clinically utilized 
FET ([18F]1). Although these ligands might not be useful imaging agents, they provided 
insight for amino acid transporters’ substrate recognition patterns. 
 
2.4 Experimental Section 
2.4.1 General information 
All chemicals were purchased from Aldrich Chemical (St. Louis, MO) or TCI 
America (Portland, OR). The commercially available materials were used without further 
purification unless otherwise indicated. 1H spectra and 13C NMR was recorded by a 
Bruker DPX spectrometer at 200 MHz and 50 MHz respectively and referenced to NMR 
solvents as indicated. Chemical shifts are reported in ppm (δ), coupling constant J in Hz. 
High-resolution mass spectrometry (HRMS) data were obtained with an Agilent (Santa 
Clara, CA) G3250AA LC/MSD TOF system. Thin-layer chromatography (TLC) analyses 
were performed using silica gel 60 F254 plates (Merck, Germany). Crude compounds 
generally were purified by flash column chromatography (FC) packed with silica gel 
(Aldrich). [18F]Fluoride was purchased from IBA Molecular (Somerset, NJ) as an 
[18O]enriched aqueous solution of [18F]fluoride. Solid-phase extraction (SPE) cartridges 
such as Sep-Pak QMA Light and Oasis HLB cartridges were purchased from Waters 
(Milford, MA). High performance liquid chromatography (HPLC) was performed on an 
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Agilent 1100 series system. [18F]radioactivity was measured by gamma counter (Cobra II 
auto-gamma counter D5003 spectrometer, Canberra-Packard) in the 400-1600 keV 
energy range. Specific activity (SA) was calculated by comparing UV peak intensity of 
final products with calibration curves of corresponding non-radioactive standards of 
known concentrations. Cell lines were obtained from the American Tissue Culture 
Collection (ATCC) and cultured according to ATCC recommended conditions. 
 
2.4.2 Synthesis of precursors and standards for radiolabeling  
O
H2N
COOH
F
 
O-Fluoroethyl-L-tyrosine (1): 1H-NMR (200MHz, Acetic acid-d4): δ = 7.24 (d, 
2H, J = 8.6 Hz), 6.91 (d, 2H, J = 8.6 Hz), 4.73 (dt, 2H, J1 = 47.4 Hz, J2 = 4.0 Hz), 4.40 
(dd, 1H, J1 = 7.6 Hz, J2 = 5.2 Hz), 4.22 (dt, 2H, J1 = 29.2 Hz, J2 = 4.0 Hz), 3.52-3.22 (m, 
2H); 13C NMR (50MHz, Acetic acid-d4) δ =173.1, 158.2, 130.8,126.9, 115.0, 81.9 (d, J = 
167.5 Hz), 67.2 (d, J = 20.0 Hz), 55.8, 35.1; HRMS calcd for C11H14FNO3 ([M+H]+) 
228.1036, found 228.1265.  [α]23D  -3.4o (c 0.53, 6 N HCl). 
HO
BocHN
COOH
 
2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)-2-methylpropanoic acid 
(6): 2.0 to 5.0 equivalent base was added to a suspension of α-methyl tyrosine 5 in 
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dioxane/H2O (1/1), the reaction mixture was cooled to 0°C and di-tert-butyl dicarbonate 
(1.5 equiv) was added and reaction mixture was kept under various temperature and time 
as shown in Table 1.  Upon completion, 1N KHSO4 was added to reaction mixture to 
adjust pH around 2 then extract with ethyl acetate three times. Combined organic layer 
was washed with brine and dried over Na2SO4. Solvent was removed under reduced 
pressure. Resulting crude product was purified by FC (Acetic acid/MeOH/CH2Cl2, 
0.5/4/100). 1H NMR (200MHz, MeOD-d4) δ =6.96 (d, 2H, J = 8.4 Hz), 6.67 (d, 2H, J 
=8.6 Hz), 3.17 (d, 1H, J = 13.6 Hz), 3.05 (d, 1H, J = 13.6 Hz), 1.47 (s, 9H), 1.39 (s, 3H). 
13C NMR (50MHz, CDCl3) δ =177.8, 157.4, 156.7, 132.5, 128.8, 116.0, 80.5, 61.0, 41.9, 
29.0, 23.8.  HRMS calcd for C15H21NO5 ([M+Na]+) 318.1317, found 318.1314 
HO
BocHN
COOBut
 
tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)-2-methyl 
propanoate (7): tert-butyl 2,2,2-trichloroacetimidate (473 mg, 2.16 mmol) was added to 
a solution of 6 (160 mg, 0.54 mmol) in metheylene chloride (2.0 mL) and THF (0.5 mL). 
Stirred at 40°C for 18 h. After reaction being quenched with NaHCO3 (150 mg, 2.4 
mmol), the resulting mixture was filtered and concentrated in vacuo and resulting residue 
was purified by FC (EtOAc/Hexanes, 15/85 to 25/75) to yield product as white foam. 1H 
NMR (200 MHz, CDCl3) δ =7.00 (d, 2H, J = 8.4 Hz), 6.73 (d, 2H, J =8.4 Hz), 5.20 (s, 
1H), 3.31 (d, 1H, J = 13.6 Hz), 3.09 (d, 1H, J = 13.6 Hz), 1.53 (s, 3H), 1.47 (s, 18H). 13C 
NMR (50 MHz, CDCl3) δ = 173.2, 167.9, 155.1,154.6, 132.5, 128.2, 115.1, 82.1, 79.5, 
 - 45 - 
60.5, 40.9, 28.9, 27.2, 24.9.  HRMS calcd for C19H29NO5 ([M+Na]+) 374.1943, found 
374.1942.  
O
BocHN
COOBut
TsO
 
tert-butyl 2-(tert-butoxycarbonylamino)-2-methyl-3-(4-(2(tosyloxy)ethoxy) 
phenyl)propanoate (8): 7 (207 mg, 0.67mmol) was dissolved in 1mL dry DMF and 
added to NaH (60% in mineral oil, 40mg, 1.0mmol) in 4mL DMF at 0°C and reaction 
mixture was stirred at 0°C for 1h.1, 2-bis(tosyloxy)ethane (371 mg, 1.0 mmol) in 1mL 
DMF was added and reaction continued for 5h at 0 to 5°C. After reaction, reaction 
solution was diluted with 60mL EtOAc and washed with 5mL water twice and then 5mL 
brine. Organic layer dried over Na2SO4 and solvent was removed under reduced pressure. 
Crude mixture was purified by FC (MeOH/CH2Cl2, 0.5/100). 1H-NMR (200MHz, 
CDCl3): δ = 7.82 (d, 2H, J = 8.4 Hz), 7.35 (d, 2H, J = 8.4 Hz), 7.06 (d, 2H, J = 8.6 Hz), 
6.68 (d, 2H, J = 8.6 Hz), 4.36 (dd, 2H, J1 = 6.0 Hz, J2=3.5 Hz), 4.13 (dd, 2H, J1 = 5.8 Hz, 
J2=3.8 Hz), 3.33 (d, 1H, J = 13.6 Hz), 3.09 (d, 1H, J = 13.6 Hz), 2.46 (s, 3H), 1.52 (s, 
3H), 1.47 (s, 18H). 13C NMR (50MHz, CDCl3) δ =173.3, 157.2, 154.5,145.1, 133.4, 
131.5, 130.1, 128.3, 114.4, 82.2, 79.4, 68.4, 65.8, 60.7, 40.7, 28.7, 28.2, 24.2, 21.8.  
HRMS calcd for C28H39NO8S ([M+Na]+) 570.2294, found 570.2289. 
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O
BocHN
COOH
F
 
2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)-2 methylpropan-
oic acid (9): N-Boc α-methyltyrosine (6, 127 mg, 0.43mmol) was dissolved in 1mL dry 
DMF and added to NaH (60% in mineral oil, 43mg, 1.1mmol) in 2 mL DMF at 0°C and 
reaction mixture was stirred at 0°C for 1 h.1-Bromo-2-fluoro ethane (108 mg, 0.86 
mmol) in 0.5mL DMF was added and reaction continued for 6 h at 0 to 5°C. After 
reaction, reaction solution was diluted with 60mL EtOAc and washed with 5mL water 
twice and then 5mL brine. Organic layer dried over Na2SO4 and solvent was removed 
under reduced pressure. Crude mixture was purified by FC (Acetic acid/EtOAc/Hexanes, 
0.5/25/75). 1H-NMR (200MHz, CDCl3): δ = 10.4 (s, 1H), 7.08 (d, 2H, J = 8.6 Hz), 6.84 
(d, 2H, J = 8.6 Hz), 5.11 (s, 1H), 4.75 (dt, 2H, J1 = 47.4 Hz, J2 =4.0 Hz), 4.18 (dt, 2H, J1 
= 28.0 Hz, J2 =4.0 Hz), 3.24 (s, 2H), 1.54 (s, 3H) 1.47 (s, 9H). 13C NMR (50MHz, 
CDCl3) δ =180.3, 162.1, 157.1, 155.2, 131.4, 130.1, 114.2, 82.0 (d, J = 169.5 Hz), 79.5 , 
67.1 (d, J = 20.5 Hz), 60.4,  40.6, 28.4, 24.7.HRMS calcd for C17H24FNO5 ([M+Na]+) 
364.1536, found 364.1539. 
O
BocHN
COOBut
F
 
tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)-2-
methylpropanoate (10):  To solution of 9 (60 mg, 0.19 mmol) in 2 mL 
CH2Cl2/cyclohexane (1:1) was added tert-butyl 2,2,2-trichloro acetimidate (166 mg, 0.78 
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mmol). Stirred at 50 °C for 1 d. After being quenched with NaHCO3 (70 mg, 0.8 mmol), 
the reaction was filtered and concentrated in vacuo and resulting residue was purified by 
FC (EtOAc/Hexanes, 10/9) to yield product as white solid. 1H NMR (200MHz, CDCl3) δ 
=7.07 (d, 2H, J = 8.6 Hz), 6.83 (d, 2H, J =8.6 Hz), 5.19 (s, 1H), 4.75 (dt, 2H, J1 = 47.2 
Hz, J2 =4.2 Hz), 4.20 (dt, 2H, J1 = 27.8 Hz, J2 =4.2 Hz), 3.34 (d, 1H, J = 13.6 Hz), 3.11 
(d, 1H, J = 13.6 Hz), 1.53 (s, 3H), 1.48 (s, 18H). 13C NMR (50MHz, CDCl3) δ =173.3, 
157.6, 154.6, 131.5, 129.9, 114.5, 82.2, 82.1 (d, J = 169.5 Hz), 79.4, 67.4 (d, J = 21.0 
Hz), 60.7, 40.8, 28.7, 28.2, 24.2. HRMS calcd for C21H32FNO5 ([M+Na]+) 420.2162, 
found 420.2154. 
HO
COOMe
H2N .HCl
 
Methyl 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoate (11): Thionyl 
chloride (3.7 mL, 51.2 mmol) was added to a suspension of α-methyltyrosine (5, 1.00 g, 
5.12 mmol) in 25 mL methanol at 0°C. The reaction mixture was refluxed overnight. 
After concentrated in vacuo, 1.3 g transparent oil was obtained for use in the next step, as 
product without further purification. 1H NMR (200 MHz, MeOD-d4) δ = 7.00 (d, 2H, J = 
8.6 Hz), 6.77 (d, 2H, J = 8.4 Hz), 3.83 (s, 3H), 3.19 (d, 1H, J = 14.2 Hz), 3.00 (d, 1H, J = 
14.2 Hz), 1.59 (s, 3H); 13C NMR (50 MHz, MeOD-d4) δ = 172.4, 158.7, 132.4, 124.8, 
117.0, 62.2, 54.0, 43.5, 22.5; HRMS calcd for C11H15NO3 ([M+H]+) 210.1130, found 
210.1137. 
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HO
COOMe
BocHN
 
Methyl 2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)-2-methylpropane 
-ate or N-Boc α-methyltyrosine methyl ester (12): Triethylamine was added to a 
solution of α-methyltyrosine methyl ester (11, 2.37 g, 11 mmol) in 25 mL methanol.  The 
reaction mixture was cooled to 0°C.  Di-tert-butyl dicarbonate (2.23 g, 10.2 mmol) was 
added, and stirred at 50°C for 2d. Upon completion, the combined organic layer was 
washed with brine and then dried over Na2SO4. Solvent was removed under reduced 
pressure. Resulting crude product was purified by FC (EtOAc/Hexanes, 15/85 to 25/75). 
1H NMR (200 MHz, CDCl3) δ =6.95 (d, 2H, J = 8.4 Hz), 6.73 (d, 2H, J = 8.6 Hz), 5.12 
(s, 1H), 3.76 (s, 3H), 3.28 (d, 1H, J = 13.6 Hz), 3.11 (d, 1H, J = 13.6 Hz), 1.56 (s, 3H), 
1.48 (s, 9H); 13C NMR (50 MHz, CDCl3) δ =174.9, 155.5, 154.9, 131.2, 115.4, 79.7, 
60.6, 52.6, 41.6, 28.5, 23.6; HRMS calcd for C16H23NO5 ([M+Na]+) 332.1474, found 
332.1464 
O
COOMe
BocHN
TsO
 
Methyl 2-(tert-butoxycarbonylamino)-2-methyl-3-(4-(2-(tosyloxy)ethoxy) 
phenyl) propanoate (13): N-Boc α-methyltyrosine methyl ester (12, 133 mg, 0.43 
mmol) was dissolved in 1 mL dry DMF and added to NaH (16 mg, 0.65 mmol) in 2 mL 
DMF at 0°C.   The reaction mixture was stirred at 0°C for 1h.  1, 2-bis(tosyloxy)ethane 
(240 mg, 0.65 mmol) in 0.5 mL DMF was added and the reaction continued for 5h at 0 to 
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5 °C. After the reaction, the solution was diluted with 60 mL EtOAc and washed twice 
with 5 mL water and then 5 mL brine.  The organic layer was dried over Na2SO4 and 
solvent was removed under reduced pressure. Crude mixture was purified by FC (MeOH/ 
CH2Cl2, 0.5/100). 1H-NMR (200 MHz, CDCl3): δ = 7.83 (d, 2H, J = 8.2 Hz), 7.35 (d, 2H, 
J = 8.4 Hz), 6.97 (d, 2H, J = 8.4 Hz), 6.70 (d, 2H, J = 8.2 Hz), 5.11 (s, 1H), 4.36 (dd, 2H, 
J1 = 6.0 Hz, J2=3.6 Hz), 4.13 (dd, 2H, J1 = 6.0 Hz, J2=3.8 Hz), 3.31 (d, 1H, J = 13.8 Hz), 
3.12 (d, 1H, J = 13.6 Hz), 2.46 (s, 3H), 1.56 (s, 3H), 1.47 (s, 9H); 13C NMR (50 MHz, 
CDCl3) δ =174.6, 157.3, 154.5, 145.1, 133.3, 131.2, 130.0, 129.4, 128.2, 114.6, 79.7, 
68.3, 65.7, 60.6, 53.6, 52.6, 41.2, 28.6, 23.8, 21.8; HRMS calcd for C28H39NO8S 
([M+Na]+) 572.2294, found 572.2289.  
O
COOMe
BocHN
F
 
Methyl 2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)-2-methyl 
propaneate (14): N-Boc α-methyltyrosine methyl ester (12, 274 mg, 0.89 mmol) was 
dissolved in 1 mL dry DMF and added to NaH (34 mg, 1.33 mmol) in 4 mL DMF at 0°C.  
The reaction mixture was stirred at 0°C for 1h.  1-Bromo-2- fluoroethane (223 mg, 1.77 
mmol) in 1 mL DMF was added and reaction continued for 6h at 0 to 5°C. After the 
reaction, the solution was diluted with 60 mL EtOAc and washed with 5 mL water twice 
and then 5 mL brine.  The organic layer was dried over Na2SO4 and solvent was removed 
under reduced pressure. Crude mixture was purified by FC (EtOAc/Hexanes, 15/85). 1H 
NMR (200 MHz, CDCl3) δ =7.01 (d, 2H, J = 8.6 Hz), 6.84 (d, 2H, J =8.6 Hz), 5.11 (s, 
1H), 4.75 (dt, 2H, J1 = 47.2 Hz, J2 =4.2 Hz), 4.20 (dt, 2H, J1 = 27.8 Hz, J2 =4.2 Hz), 3.76 
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(s, 3H), 3.32 (d, 1H, J = 13.8 Hz), 3.14 (d, 1H, J = 13.6 Hz), 1.56 (s, 3H), 1.48 (s, 9H); 
13C NMR (50 MHz, CDCl3) δ =174.6, 157.7, 154.6, 131.3, 129.3, 114.6, 82.1 (d, J 
=169.5 Hz), 79.7, 67.3 (d, J =20.5 Hz), 60.7, 52.6, 41.3, 28.6, 23.8; HRMS calcd for 
C18H26FNO5 ([M+Na]+) 378.1693, found 360.1693.  
O
COOH
H2N
F
 
2-amino-3-(4-(2-fluoroethoxy)phenyl)-2-methylpropanoic acid or O-
Fluoroethyl α-methyl tyrosine (2): Methyl 2-(tert-butoxycarbonylamino)-3-(4-(2-
fluoroethoxy)phenyl) -2-methyl propanoate (14, 154 mg, 0.43 mmol) was dissolve in 7 
mL 6 N HCl.  The reaction mixture was stirred at reflux for 2.5 h. After evaporated to 
dryness, the resulting solid was dissolved in 2 mL MeOH. The solution was adjusted to 
pH ~7 with 5% NH4OH resulting a white precipitate. The suspension was left in the 
refrigerator overnight and then filtered to produce O-fluoroethyl α-methyl tyrosine as a 
white solid. 1H NMR (200 MHz, TFA-D+CDCl3) δ =7.11 (d, 2H, J = 7.6 Hz), 6.93 (d, 
2H, J =7.4 Hz), 4.77 (dt, 2H, J1 = 47.2 Hz, J2 =4.0 Hz), 4.21 (dt, 2H, J1 = 28.0 Hz, J2 
=4.0 Hz), 3.41 (d, 1H, J = 14.2 Hz), 3.16 (d, 1H, J = 14.8 Hz), 1.78 (s, 3H); 13C NMR (50 
MHz, TFA-D+CDCl3) δ =175.4, 159.2, 131.4, 124.0, 116.4, 82.3 (d, J = 168.5 Hz), 67.9 
(d, J = 20.0 Hz), 62.8, 41.9, 21.9; HRMS calcd for C12H16FNO3 ([M+Na]+) 264.1012, 
found 264.0922. 
 
 - 51 - 
BocHN COOMe
N
O OTs
 
(S)-methyl 2-(tert-butoxycarbonylamino)-3-(5-(2-(tosyloxy)ethoxy)pyridin-2-
yl) propaneate (18): Boc-L-azatyrosine methylester  (17, 60 mg, 0.2 mmol) was 
dissolved in 2 mL DMF. K2CO3 (84 mg, 0.6 mmol) and 1,2-bis(tosyloxy)ethane (112 mg, 
0.3 mmol) was added sequentially. The mixture was stirred at 70 oC for 3h. After the 
reaction, the mixture was diluted with 30 mL Et2O and washed with 5 mL water twice 
and then 5 mL brine.   The organic layer was dried over Na2SO4 and solvent was removed 
under reduced pressure.  Crude mixture was purified by FC (MeOH/CH2Cl2, 2:100) to 
yield light yellow foam. 1H-NMR (200 MHz, CDCl3): δ = 8.10-8.08 (m, 1H), 7.82 (d, 
2H, J = 7.8 Hz), 7.36 (d, 2H, J = 8.2 Hz), 7.05-7.03 (m, 2H), 5.76 (d, 1H, J = 8.0 Hz), 
4.67-4.62 (m, 1H), 4.40-4.36 (m, 2H), 4.20-4.15 (m, 2H), 3.70 (s, 3H), 3.22-3.19 (m, 
2H), 2.46 (s, 3H), 1.43 (s, 9H); 13C NMR (50 MHz, CDCl3) δ = 172.4, 155.4, 153.1, 
149.9, 145.1, 137.2, 132.9, 129.9, 128.0, 123.8, 122.1, 79.7, 67.8, 66.0, 53.4, 52.2, 38.5, 
28.3, 21.6; HRMS calcd for C23H30N2O8S ([M+H]+) 495.1801, found 495.1787; [α]24D 
+13.2o (c 0.67, CHCl3). 
BocHN COOMe
N
O F
 
 (S)-methyl 2-(tert-butoxycarbonylamino)-3-(5-(2-fluoroethoxy)pyridin-2-
yl)propanoate (19): Boc-L-azatyrosine methylester (17, 45 mg, 0.15 mmol) was 
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dissolved in 1 mL DMF. K2CO3 (62 mg, 0.45 mmol) and 1-bromo-2-fluoroethane (38 
mg, 0.3 mmol) were added sequentially. The mixture was stirred at 70oC for 2h. After the 
reaction, the mixture was diluted with 30 mL Et2O and washed with 5 mL water twice 
and then 5 mL brine.  The organic layer was dried over Na2SO4 and solvent was removed 
under reduced pressure.  Crude mixture was purified by FC (MeOH/CH2Cl2, 2:100) to 
yield a light yellow viscous liquid. 1H-NMR (200 MHz, CDCl3): δ = 8.24 (d, 1H, J = 2.8 
Hz), 7.17 (dd, 1H, J1 = 8.4, J2= 2.8 Hz), 7.06 (d, 1H, J = 8.6 Hz), 5.79 (d, J = 7.8 Hz), 
4.90-4.85 (m, 1H), 4.65-4.52 (m, 2H), 4.33-4.28(m, 1H), 4.19-4.14 (m, 1H), 3.70 (s, 3H), 
3.21-3.24 (m, 2H), 1.43 (s, 9H); 13C NMR (50 MHz, CDCl3) δ = 172.6, 155.6, 153.6, 
150.0, 137.3, 124.1, 122.5, 81.8 (d, J =170.0 Hz), 79.8, 67.8 (d, J = 20.5 Hz), 53.5, 52.3, 
38.7, 28.5; HRMS calcd for C16H23FN2O5 ([M+H]+) 343.1669, found 343.1680. [α]24D 
+18.7o (c 0.93, CHCl3). 
H2N COOH
N
O F
.xHCl
 
 (S)-2-amino-3-(5-(2-fluoroethoxy)pyridin-2-yl)propanoic acid (3): 5mL 6M 
HCl was added to a 10 mL round bottom flask of (S)-methyl 2-(tert-
butoxycarbonylamino)-3-(5-(2-fluoroethoxy )pyridin-2-yl)propanoate (14, 82 mg, 0.24 
mmol) and refluxed for 4h. After the reaction, the mixture was diluted with 5 mL H2O. 
The solution was washed with 2 mL CH2Cl2 three times. Aqueous phase was then 
concentrated under reduced pressure to yield light yellow foam. 1H-NMR (200 MHz, 
MeOD-d4): δ = 8.62 (d, 1H, J = 2.6 Hz), 8.28 (dd, 1H, J1 = 8.8, J2= 2.2 Hz), 8.10 (d, 1H, 
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J = 9.0 Hz), 4.95-4.92 (m, 1H), 4.70-4.68 (m, 1H), 4.62-4.57 (m, 2H), 4.49-4.46 (m, 1H), 
3.69 (d, 2H, J = 7.2 Hz); 13C NMR (50 MHz, MeOD+D2O) δ = 170.0, 158.2, 144.8, 
133.6, 131.3, 130.3, 82.9 (d, J =168.5 Hz), 71.0 (d, J = 19.5 Hz), 53.2, 34.3; HRMS calcd 
for C10H13FN2O3 ([M+Na]+) 229.0988, found 229.0987. [α]23D +36.6o (c 0.30, 6 N HCl). 
O
BocHN
COOHF
 
 (S)-2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)propanoic 
acid (26): N-Boc L-tyrosine (25, 563 mg, 2 mmol) was dissolved in 5 mL dry DMF and 
added to NaH (95%, 127mg, 5 mmol) in 15 mL DMF at 0°C.  The reaction mixture was 
stirred at 0°C for 1h. 1-bromo-2-fluoroethane (504 mg, 4 mmol) was added and the 
reaction continued overnight from 0°C to room temperature. After the reaction, the 
solution was acidified to a pH of approximately 2 and extracted with ether (20 mL) three 
times.  The combined organic layer was washed with brine (10 mL), dried over MgSO4 
and then concentrated in vaccuo.  Crude mixture was purified by FC (AcOH/MeOH/ 
CH2Cl2, 0.5/3/100) to afford 26 as white foam. 1H-NMR (200 MHz, CDCl3): δ = 7.12 (d, 
2H, J = 8.4 Hz), 6.86 (d, 2H, J = 8.6 Hz), 4.99 (d, 1H, J = 6.6 Hz), 4.86 (t, 1H, J = 4.2 
Hz), 4.65-4.55 (m, 2H), 4.19 (dt, 2H, J1 = 27.8 Hz, J2 = 4.2 Hz), 3.19- 3.01(m, 2H), 1.42 
(s, 9H); 13C NMR (50 MHz, CDCl3) δ =176.3, 157.8, 155.6, 130.7, 128.8, 115.0, 82.1 (d, 
J = 169.5 Hz), 67.4 (d, J = 20.5 Hz), 54.6, 37.1, 28.4; HRMS calcd for C16H22FNO5 
([M+Na]+) 350.1380, found 350.1378; [α]24D -13.1o (c 1.1, MeOH). 
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 (S)-tert-butyl 3-(4-(2-fluoroethoxy)phenyl)-1-oxo-1-(2,4,6-trimethoxybenzyl 
amino)propan-2-ylcarbamate (27): Diisopropylethylamine (169 mg, 1.3 mmol) was 
added to a solution of propanoic acid (26, 130 mg, 0.4 mmol), 2,4,6-
trimethoxybenzylamine hydrochloride (102 mg, 0.44 mmol) and 1-HOBt (70 mg, 0.52 
mmol) in DMF (4 mL).  The solution was cooled to 0oC before HBTU (183 mg, 0.48 
mmol) was added in one portion. Continue at 0oC for 30 min and then room temperature 
for another 1.5 h. The reaction mixture was diluted with 15 mL EtOAc and 10 mL 10% 
citric acid.  The aqueous layer was extracted twice with 15 mL EtOAc and the combined 
organic layer was washed with 5 mL saturated NaHCO3 and 5 mL brine.  The organic 
layer was dried over MgSO4 and solvent was removed under reduced pressure. Crude 
mixture was purified by FC (EtOAc/Hexanes, 50/50), which produced 27 as a white 
solid.  1H-NMR (200MHz, CDCl3): δ = 7.06 (d, 2H, J = 8.6 Hz), 6.73 (d, 2H, J = 8.6 Hz), 
6.09 (s, 2H), 5.84 (s, 1H), 5.19 (s, 1H), 4.74 (dt, 2H, J1 = 47.4 Hz, J2= 4.2 Hz), 4.50-4.27 
(m, 2H), 4.24-4.11 (m, 2H), 4.08 (t, 1H, J = 4.2 Hz), 3.82 (s, 3H), 3.76 (s, 6H), 3.06-2.84 
(m, 2H), 1.40 (s, 9H); 13C NMR (50MHz, CDCl3) δ =170.2, 161.1, 159.4, 157.4, 155.4, 
130.6, 129.9, 114.8, 106.7, 90.8, 82.1 (d, J = 169.5 Hz), 80.0, 67.3 (d, J = 20.5 Hz), 56.4, 
55.9, 55.6, 38.6, 32.4, 28.5; HRMS calcd for C26H35FN2O7 ([M+H]+) 507.2507, found 
507.2508; [α]24D -17.1o (c 0.98, CHCl3). 
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O-fluoroethyl tyrosine amide (4): Propanylcarbamate (27, 127 mg, 0.25 mmol) 
was added to 1.5 mL trifluoroacetic acid and 50 µL dimethyl sulfide, a free radical 
scavenger.  The reaction mixture was stirred in room temperature for 4 h. Upon 
completion, the mixture was concentrated under reduced pressure to remove TFA. The 
resulting mixture was dissolved in water (5 mL) and washed with ether (5 mL).  The 
aqueous layer was neutralized to pH ~ 7 with 5% NH4OH and extracted with ethyl 
acetate (15 mL) three times. Crude mixture was purified by preparative TLC 
(Et3N/MeOH/CH2Cl2, 1/7/100), which afforded 4 as a yellowish liquid. 1H-NMR 
(200MHz, MeOD-D4): δ = 7.35 (d, 2H, J = 8.6 Hz), 7.03 (d, 2H, J = 8.6 Hz), 4.85 (dt, 
2H, J1 = 47.4 Hz, J2 = 4.0 Hz), 4.62 (t, 1H, J = 7.0 Hz), 4.33 (dt, 2H, J1 = 28.8 Hz, J2 = 
4.0 Hz), 3.43-3.18 (m, 2H); 13C NMR (50MHz, MeOD-d4) δ =178.0, 159.3, 131.7, 
130.7, 116.1, 83.3 (d, J = 167.5 Hz), 68.8 (d, J = 20.0 Hz), 57.2, 40.9; HRMS calcd for 
C11H15FN2O2 ([M+H]+) 227.1196, found 227.1213. [α]24D -14.3o (c 0.57, MeOH). 
O
BocHN
TBDMSO O
NHTmob
 
 (S)-tert-butyl 3-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)phenyl)-1-oxo-1-
(2,4,6-trimethoxybenzyl amino)propan-2-ylcarbamate (29): Diisopropylethylamine 
(1.25 g, 9.7 mmol) was added to a solution of propanoic acid (28, 1.3 g, 3 mmol), 2,4,6-
trimethoxybenzylamine hydrochloride (772 mg, 3.3 mmol) and 1-HOBt (527 mg, 3.9 
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mmol) in DMF (30 mL).  The solution was cooled to 0oC before HBTU (1.35 g, 3.6 
mmol) was added in one portion. Continue at 0 oC for 30 min and then room temperature 
for another 1.5 h. The reaction mixture was diluted with 30 mL EtOAc and 30 mL 10% 
citric acid.  The aqueous layer was extracted twice with 30 mL EtOAc and the combined 
organic layer was washed with 10 mL saturated NaHCO3 and 10 mL brine.  The organic 
layer was dried over MgSO4 and solvent was removed under reduced pressure. Crude 
mixture was purified by FC (EtOAc/Hexanes, 35/65) to produce 29 as white foam. 1H 
NMR (200 MHz, CDCl3) δ = 7.04 (d, 2H, J = 8.6 Hz), 6.73 (d, 2H, J =8.4 Hz), 6.09 (s, 
2H), 5.88 (s, 1H), 5.19(s, 1H), 4.41-4.38 (m, 2H), 4.20-4.16(m, 1H), 3.96 (s, 4H), 3.82 (s, 
3H), 3.76 (s, 6H), 3.06-2.83 (m, 2H), 1.40 (s, 9H), 0.92 (s, 9H), 0.11 (s, 6H); 13C NMR 
(50 MHz, CDCl3) δ =170.3, 161.1, 159.4, 158.0, 155.4, 130.5, 129.2, 114.7, 106.7, 90.8, 
79.9, 69.5, 62.2, 56.5, 55.9, 55.5, 38.6, 32.4, 28.5, 26.1, 18.6; HRMS calcd for 
C32H50N2O8Si ([M+H]+) 619.3415, found 619.3416. 
O
BocHN
TsO O
NHTmob
 
 (S)-2-(4-(2-(tert-butoxycarbonylamino)-3-oxo-3-(2,4,6-trimethoxybenzyl 
amino)propyl)phenoxy) ethyl 4-methylbenzenesulfonate (30): A THF solution of 
TBAF (1 M in THF) was added to a solution of  2mL propanylcarbamate (29, 390 mg, 
0.63 mmol).  The reaction continued for 1 h before diluted with 10 mL water.  The 
aqueous solution was extracted with ether (15 mL × 3).  The combined organic layer was 
washed with brine and then dried over MgSO4.  Solvent was removed under reduced 
pressure. Resulting crude product was purified by FC (EtOAc/Hexanes, 75/25). 
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Deprotection product was then dissolved in 5 mL CH2Cl2, added Et3N (200 mg, 2 mmol), 
TsCl (112 mg, 0.6 mmol) and DMAP (6 mg, 0.05 mmol), reaction continued overnight. 
Dilute reaction mixture with 40 mL CH2Cl2 and then washed with 5 mL saturated 
NaHCO3 and 5 mL brine. Organic layer dried over MgSO4 and solvent was removed 
under reduced pressure. Crude mixture was purified by FC (EtOAc/Hexanes, 60/40) to 
produce 20 as yellow foam. 1H NMR (200 MHz, CDCl3) δ = 7.82 (d, 2H, J = 8.2 Hz), 
7.35 (d, 2H, J = 8.0 Hz), 7.01 (d, 2H, J = 8.4 Hz), 6.60 (d, 2H, J = 8.4 Hz), 6.08 (s, 2H), 
5.86 (s, 1H), 5.18 (s, 1H), 4.49-4.28 (m, 4H), 4.18-4.05 (m, 3H), 3.81 (s, 3H), 3.75 (s, 
6H), 3.04-2.77 (m, 2H), 2.46 (s, 3H), 1.40 (s, 9H); 13C NMR (50 MHz, CDCl3) δ =170.2, 
161.4, 159.4, 157.0, 155.4, 145.1, 133.3, 130.6, 128.2, 114.7, 106.6, 90.8, 80.0, 68.3, 
65.7, 56.4, 55.9, 55.6, 38.6, 32.4, 28.5, 21.8; HRMS calcd for C33H42N2O10S ([M+Na]+) 
681.2458, found 681.2463; [α]24D -13.4o (c 1.05, CHCl3). 
 
2.4.3 Radiochemistry 
In general, [18F]Fluoride was passed through a Sep-Pak light QMA cartridge 
(Waters, preconditioned with 10 mL 1 N NaHCO3, 10 mL water and dried with N2). The 
18F activity was eluted with 1.1 mL Kryptofix 222 K[2.2.2] /K2CO3/CH3CN/H2O solution 
(11 mg/2 mg/ 0.93 mL/0.17 mL), azeotropically dried twice under N2 at 110oC. Then 5 
mg precursor in 1 mL anhydrous CH3CN was added into 18F. Fluorination reaction 
continued for 10 min at 90oC. Chemical, radiochemical purity and specific activity of 
radioligands were analyzed with analytical HPLC and TLC. TLC system: 
NH4OH/MeOH/ CH2Cl2, 1/6/14, FET Rf is 0.3, FEMT Rf is 0.4, FETA is 0.6. TLC 
system: NH4OH/ MeOH/ CH2Cl2, 1/10/10, FEAT Rf is 0.4. Semi-Preparative HPLC was 
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carried out on a column (Phenomenex Gemini C18 semi-preparative column, 10 × 250 
mm, 5 µm). Radiochemical purity was determined by analytical HPLC (Phenomenex 
Gemini C18 analytical column, 4.6 ×250 mm, 5 µm, UV detector set at 275 nm) and 
TLC. Three solvent systems were used in analytical HPLC: A: ethanol/0.1 % formic acid, 
10/90 (for FET and FEMT) or 2/98 (FEAT), flow rate 1mL/min; B: Gradient: 0-2 min: 
100% 10mM ammonium formate buffer (AFB); 2-5min: ACN: AFB (70:30); 5-10 min: 
100% ACN; 10-15% 100% AFB, flow rate 1mL/min; C: MeOH/0.1% NH3, 40/60, 
1mL/min. For analytic HPLC solvent system A (ethanol/ 0.1% formic acid, 10/98 for 
FET/ FEMT and 2/98 for FEAT), retention time was 5.8 min for FET, 7.2min for FEMT 
and 5.5 min for FEAT respectively. For solvent system B, retention time was 7.3 min for 
FET, 7.0 min for FEMT, 7.6 min for FEAT and 7.8 min for FETA respectively. With 
solvent system C, retention time was 5.2 min for FETA. Details regarding purification 
and deprotection reactions were described in the following paragraphs: 
FET ([18F]1): After fluorination, the reaction mixture was injected to semi-
preparative HPLC, eluent MeOH/H2O (80:20), flow rate 3 mL/min. Radioactive peak 
between 10.5 min to 12 min was collected and then diluted with 20 mL water, loaded on 
HLB oasis cartridge (preconditioned with 1 mL ethanol and 5 mL water) and then eluted 
with 1mL ethanol.   Solvent was removed under N2, and then 0.25 mL TFA was added, 
and heated at 60oC for 10 min. TFA was removed with a N2 flow, and then 1 mL water 
was added to produce the final product. 
FEMT ([18F]2): After fluorination, the reaction mixture was diluted with 10 mL 
water, loaded on an Oasis HLB cartridge (preconditioned with 1 mL ethanol and 5 mL 
water), washed twice with 2 mL water, eluted with 1mL CH2Cl2. Dry CH2Cl2 under a N2 
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flow, and 0.5 mL TFA was added to the reaction mixture.  The reaction continued at 
60oC for 5 min. TFA was blow dried, and then 0.5 mL 2N NaOH was added, and 
refluxed at 100oC for 10 min.  The reaction mixture was neutralized with 2N HCl and 
then ~0.5mL PBS buffer was added, and loaded on a semi-preparative HPLC 
(ethanol/H2O, 10/90, flow rate 3.5 mL/min). Fraction containing FEMT (between 12 to 
13 min) was collected.  
FEAT ([18F]3): After fluorination, the reaction mixture was injected into a semi-
preparative HPLC (MeOH/H2O, 65/35, flow rate 3mL/min), and a radioactive peak 
between 9.5 to 11 min was collected. Diluted with 20 mL water then loaded on an oasis 
HLB cartridge and eluted with 1mL ethanol. The solution was added to 0.5 mL 6M HCl, 
refluxed at 120oC for 10 min, neutralized with 2 N NaOH, and added to PBS buffer to 
adjust pH ~6.  
FETA ([18F]4): After fluorination, the reaction mixture was diluted with 10 mL 
water, loaded on an Oasis HLB cartridge (preconditioned with 1 mL ethanol and 5 mL 
water), washed twice with 2 mL water, and eluted with 1mL ethanol.  Ethanol was dried 
under a N2 flow, and 0.25 mL TFA was added to the reaction mixture.  The reaction 
continued at 60oC for 10 min. TFA was blow dried and then 1 mL water was added and 
loaded on a semi-preparative HPLC (methanol/0.1% NH3, 4/6, flow rate 3 mL/min). 
Fraction containing FEMT (between 11 to 13 min) was collected, diluted with 20 mL 
water, loaded on a HLB cartridge and eluted with 1mL ethanol. Ethanol was removed 
under N2 and final product was dissolved in 1 mL water. 
 
 - 60 - 
2.4.4 In vitro cell studies 
Cell culture: U-138 MG in Eagle’s Minimum Essen-tial Medium (EMEM), 
supplemented with 10% Fetal Bovine Serum (FBS) and 1% streptomycin. Cells were 
incubated at 37oC under 5% CO2 and were subcultured by trypsinization using 0.25% 
trypsin-EDTA. Cell uptake studies: cells were seeded at 2 × 105 cells/well in 12 well 
tissue culture plates. After 24 h of incubation at 37°C, cells formed monolayer and 
reached confluence. Cells were washed three times with warmed phosphate-buffered 
saline (PBS) solution and were incubated with 1 mL of PBS containing approximately 
0.5 MBq (14 µCi) of ligands. Uptake experiments were run for 5, 30, 60 and 120 min at 
37°C. After incubation, PBS was quickly removed, and the cells were washed three times 
with cold PBS (w/o Ca++ and Mg++) and then lysed with 350 µL 1 N NaOH. Transfer 
resulting solution to test tubes for radioactivity measurement. The uptake results were 
normalized to protein content and to the total activity administered. Results are expressed 
as the percentage of radioactivity accumulated per 100 µg protein. 
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Chapter 3 
 
Synthesis, uptake mechanism characterization and 
biological evaluation of 18F labeled fluoroalkyl  
L-phenylalanine analogs as potential tumor imaging 
agents for PET 
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3.1 Introduction  
Malignant tumors can be detected by imaging their increased metabolic rates for 
glucose, lipids and amino acids [1]. One interesting metabolic process as a target for 
metabolic tumor imaging is increased protein metabolism in proliferating cancer cells. 
Avid uptake of amino acids is a normal feature of rapidly proliferating cells [2]. A 
number of radiolabeled amino acids (Figure 3.1) were developed and have established 
role in clinical applications, especially in brain tumor imaging [3, 4]. Amino acid based 
tracers could overcome certain limitations of most commonly used 2-[18F]fluoro-2-
deoxy-D-glucose (FDG), namely high accumulation in inflammatory tissues and high 
uptake in normal brain tissues [4]. 
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Figure 3.1. Some clinically utilized amino acid based tracers 
 
Uncontrolled and accelerated growth of cancer cells lead to elevated rate of 
protein synthesis and increased uptake of amino acids as energy source as well as carbon 
and nitrogen source in the synthesis of nucleotides, amino sugars et al [5]. Some natural 
amino acid based tracers such as [11C]methionine (MET) and [11C]tyrosine (TYR), their 
uptake reflects transport, protein synthesis and non-protein metabolic pathways such as 
transamination and transmethylation, which makes imaging kinetic analysis difficult [6-
 - 66 - 
8]. While uptake of non-natural amino acids such as O-(2-[18F]fluoroethyl)-L-tyrosine 
(FET, [18F]1) [9], 3-[18F]fluoro-α-methyl-L-tyrosine (FMT) [10], anti-1-amino-3-
[18F]fluoro-cyclobutyl-1-carboxylic acid (FACBC)  [11], 3-[123I]-α-methyl-L-tyrosine 
(IMT) [12] represents mainly transport activity but not protein synthesis. It appears that 
their differences in protein metabolism do not translate into difference in clinical 
applicability[3]. Moreover, 18F (t1/2 = 109.8 min) and 123I (t1/2 = 13.2 h) labeled non-
natural amino acid derivatives have advantage of longer half-life than 11C (t1/2 = 20.2 
min) and are generally more stable in vivo which simplifies image analysis [3, 4, 13]. For 
these reason, non-natural amino acids have been a main focus in current development of 
amino acid tracers [3, 14, 15]. 
Amino acids are taken up into cells mainly through specific membrane associated 
carrier proteins. Increased uptake of amino acids is mediated through increased 
expression and activity of amino acid transporters. Amino acid transporters identified so 
far are solute carrier transporters (SLC), which are classified into a number of transporter 
systems based on their sodium dependence, substrate specificity, kinetics, regulatory 
properties and sensitivity to pH and specific inhibitors [16]. Most commonly existing 
amino acid transporter systems in mammalian cells responsible for transporting neutral 
amino acids are system A (alanine preferring), ASC (alanine-serine-cystine preferring) 
and system L (leucine preferring) [17]. Sodium-independent amino acid transport system 
L (LATs), which is a major route for transporting large branched and aromatic amino 
acids has attracted special interest [18]. Studies demonstrated that system L is a 
promising target for developing PET tumor imaging agents [3, 4, 19]. The broad substrate 
selectivity of LATs enables it to transport amino acid-related compounds. A number of 
 - 67 - 
substrates of LATs, such as MET, FET, FACBC, IMT, are clinically utilized for imaging 
brain cancer, head and neck cancer, lung cancer and prostate cancer et al [3, 4, 15]. 
System L is commonly upregulated in many tumors and correlated with tumor growth 
and prognosis [19-21]. There are four subtypes of LATs identified and characterized in 
molecular level, designated LAT1 to LAT4 [22]. In particular, LAT1 is most studied. 
LAT1 is primarily expressed in brain, placenta and tumors and closely correlated with 
angiogenesis [23], cell proliferation [23] and prognosis of patients with astrocytoma [24], 
non-small cell lung cancer (NSCLC) [25] and prostate cancer [26].  
Phenylalanine and tyrosine derivatives, which are primarily LATs substrate, have 
proven to be useful tumor imaging agents [3, 4]. In particular, FET ([18F]1) is one of the 
first 18F labeled amino acid tracers that could be prepared in large quantity for clinical use 
and satellite distribution similar to FDG [27]. FET is useful for detecting brain tumors 
and head and neck squamous carcinoma, but its applications in peripheral tumors are 
somewhat limited [28, 29]. Another clinically utilized system L substrate p-[123I]iodo-L-
phenylalanine (IPA) demonstrated potential for imaging brain tumor as well [30]. This 
led us to develop its fluoroalkyl derivatives, which are also structural analogs of FET. 
Our goal is to develop new amino acid tracers with improved in vivo pharmacokinetics 
than FET, which could lead to a higher tumor uptake and/or lower urinary excretion that 
may be beneficial for imaging tumors in urinary tract such as prostate cancer, urinary 
bladder carcinomas and cervical cancer [31, 32]. Eliminating oxygen to form direct 
linkage of fluoroalkyl chain to phenyl ring provides a way to alter ligands’ lipophilicity 
as well as to reduce length of side chain. In this study, we describe the synthesis, 
radiolabeling and biological evaluation of two new phenylalanine derivatives, p-(2-
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[18F]fluoroethyl)-L-phenylalanine (FEP, [18F]2) and p-(3-[18F]fluoropropyl)-L-
phenylalanine (FPP, [18F]3) (Figure 3.2). Clinically utilized FET ([18F]1) was used as 
reference in biological evaluation of new ligands. 
FEP
COOH
NH218F
[18F]2
COOH
NH2
[18F]3
18F
FPP
 
Figure 3.2. Chemical structures of new phenylalanine derivatives 
 
 
3.2 Results and Discussion 
3.2.1 Synthesis of precursors and authentic standards  
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Scheme 3.1. Synthesis precursors and standards 2 and 3 for radiolabeling. Reagents and 
Conditions: a) (Boc)2O, NaHCO3, MeOH, H2O, rt, 89%; b) 2. Tf2O, pyridine, CH2Cl2, 0oC, 93%; 
c) Tributyl vinyltin or tributyl allyltin, LiCl, Pd(PPh3)2Cl2, DMF, 70oC, 92% (n = 0) or 95% (n = 
1); d)  9-BBN, THF, NaOH, H2O2, 86% (n = 1) or 88% (n = 2); e) TsCl, Et3N, CH2Cl2, 92% (n = 
1) or 75% (n = 2); f) i. NaI, acetone, reflux; ii. AgF, CH3CN, 50% (n = 1) or 58% (n = 2); g) 
TFA, CH2Cl2, 81% (n = 1) or 64% (n = 2).  
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An efficient synthesis of fluoroalkyl phenylalanine derivatives 2 and 3 was 
carried out as shown in Scheme 3.1. The tosylate precursors 9a and 9b for labeling could 
be prepared in five steps in an overall yield of 60 and 52% respectively starting from 
commercially available L-tyrosine tert-butyl ester. Standard Boc protection of amine 
group and then triflation of phenol group on protected tyrosine 5 afforded triflate 6 in 
83% yield. Triflate 6 then underwent Stille cross-coupling reaction with vinyl or allyl 
tributylstanne and Pd catalyst Pd(PPh3)2Cl2 in anhydrous DMF at 70 oC for 1 h to yield 
corresponding alkenes. Hydroboration alkenes 7a or 7b with 9-BBN and subsequent 
oxidation with sodium peroxide afforded aliphatic alcohol 8a and 8b in 86 to 88% yield. 
We chose 9-BBN as hydroboration reagent because of its high regio-selectivity in 
comparison to BH3 reagent, initial reaction with BH3⋅THF had low yield (< 20%). 
Tosylation of the alcohol compounds afforded labeling precursors in 75 to 92% yield. 
Initially we tried to use diethylaminosulfur trifluoride (DAST) to covert aliphalic alcohol 
8a directly to fluoride 10a, however under this reaction condition, it is difficult to obtain 
chemically pure product. In addition, commonly used fluorination reagent 
tetrabutylammonium fluoride (TBAF) might cause isomerization resulting fluorinated 
product in racemic form, so here we choose to adapt mild fluorination condition in the 
neutral solution. After a two-step fluorination – tosylate 9a or 9b was first convert to 
iodide by refluxing with sodium iodide in acetone and then fluorinated by reacting with 
silver fluoride, and deprotection with TFA, the standard 2 and 3 were obtained in an 
overall yield of 24% and 19% respectively. The enantiomeric purity of precursors and 
standards for radiolabeling is >95% analyzed by chiral HPLC.  
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3.2.2 Radiosynthesis of phenylalanine derivatives 
Preparation of FEP ([18F]2) and FPP ([18F]3) was carried out via a two-step 
reaction as shown in Scheme 3.2.  First step was no-carrier-added (NCA) nucleophilic 
fluorination with dried TBA18F and TBAHCO3 in acetonitrile. Intermediate [18F]10a or 
[18F]10b  was then subjected to semi-preparative HPLC purification and HLB oasis solid 
phase extraction to eliminate unreacted 18F fluoride and other by-products. Second step 
was to remove protecting groups using TFA at 60 oC. The results of labeling reactions 
were summarized in Table 3.1. Enantiomerically pure [18F]2 and [18F]3 could be prepared 
in 90 min with high radio purity (> 95% as measured by analytical HPLC and TLC), 
moderate to good radiochemical yield (11 to 37%) and high specific activity (21 to 69 
GBq/µmol) at the end of synthesis. 
TBA18F, ACN
80 oC, 5 min
TFA
60 oC, 10 min
COOBut
NHBocTsO n
COOBut
NHBoc18F n
COOH
NH218F n
n = 1, [18F]2
n = 2, [18F]3
n = 1, 9a
n = 2, 9b
n = 1, [18F]10a
n = 2, [18F]10b
 
Scheme 3.2.  Radiolabeling of FEP ([18F]2) and FPP ([18F]3) 
 
Table 3.1. Overall synthesis time, decay-corrected RCY, radiochemical purity (RCP), 
enantiomeric purity and specific activity (EOS) * 
Ligands Synthesis time 
(min) 
RCY (%) RCP (%) Enantiomeric 
Purity (%) 
Specific activity 
(GBq/ µmol) 
[18F]2 75–82 27–37 > 95 > 95 31–69 
[18F]3 78–90 11–23 > 95 > 95 21–25 
*Data obtained from two to six experiments 
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3.2.3 Cell uptake studies 
At first, we compared the time dependent uptake of new ligands FEP ([18F]2) and 
FPP ([18F]3) to clinically utilized FET ([18F]1) in 9L gliosarcoma cells (Figure 3.3). 
Uptake of tracers was measured at selected time points up to 2 h. Three ligands 
demonstrated very similar kinetics, reaching maximum uptake within 60 min and then 
washed out.  The uptake follows order FEP ([18F]2)> FET ([18F]1) ≈ FPP ([18F]3). The 
maximum uptake of FEP is about 1.4 fold of FET. In vitro uptake studies showed FEP 
had a high accumulation and good retention in 9L glioma cells. The uptake results 
indicate that shorter side chain length may be more desirable for aromatic amino acid 
tracers. This agrees with the results reported by Tsukada et al, they found the shorter 18F-
fluoroalkyl chain length L-tyrosine provided a better tumor-to-blood ratio [33]. 
 
Figure 3.3.  Time course of uptake of FET ([18F]1), FEP ([18F]2) and FPP ([18F]3) in 9L glioma cells. The 
uptake value was represented as % uptake/100 ug protein, mean ± SD (n = 3). 
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3.2.4 Uptake mechanism studies of FEP 
Uptake of amino acid based tracers depends on a group of amino acid transport 
systems, which often have substantial overlap in substrate selectivity and thus a single 
radiolabeled amino acid can be substrate for multiple amino acid transport systems. We 
are interested in characterizing the uptake mechanism of FEP ([18F]2) into tumor cells. To 
achieve this goal, we conducted competitive uptake inhibition studies using inhibitors 
specific for system A, ASC and L, given that transport of neutral amino acids into 
mammalian cells is predominantly via these systems [21]. The uptake of FEP ([18F]2) 
was measure in absence of inhibitors as well as in the presence of concentration from 0.5 
to 5 mM of N-methyl-α-aminoisobutyric acid (MeAIB), L-alanine (L-Ala), L-serine(L-
Ser), 2-amino-bicylo[2.2.1]heptane-2-carboxylic acid (BCH), D-methionine and N-Ethyl 
maleimide (NEM). The specificity and structure of the inhibitors are listed in Table 3.2.  
Table 3.2 Inhibitors and their specificity towards amino acid transport systems 
Inhibitors Structure Specificity 
MeAIB 
OH
HN
O
 
System A 
L-Ser 
NH2
COOHHO
 
System ASC, 
L-Ala 
NH2
COOH
 
ASC, A, LAT2 
BCH 
COOH
NH2  
System L, B0, B0, + 
D-Met 
NH2
COOHS
 
LAT1 
NEM 
N
O
O  
LAT2, LAT3, LAT4 
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MeAIB is selective inhibitor of system A while L-Ala and L-Ser are inhibitors of 
system ASC. BCH is primarily an inhibitor for sodium independent system L but it is 
also an inhibitor for sodium dependent system B0 and B0, + [17]. To measure the 
contribution from sodium dependent transport systems, we carried out sodium 
dependence studies comparing uptake in sodium-free buffer to uptake in PBS. To further 
explore the preference of FEP towards the subtypes of LATs, we carried out competitive 
inhibition studies using D-Met, specific inhibitor for LAT1 and N-ethylmaleimide 
(NEM), inhibitor for other subtypes LAT2 to LAT4 [22, 34].  
Figure 3.4. Summary of uptake characterization studies of FEP ([18F]2)  in 9L gliomas. Results were 
normalized to uptake of [18F]2 in PBS solution at 30 min. Data are expressed as mean ± SD (n = 3) 
 
The studies were performed with a 30 min incubation time and the results were 
normalized to uptake of FEP in phosphate buffer solution (PBS) in absence of inhibitors 
as summarized in Figure 3.4. Uptake of FEP ([18F]2) is sodium independent since 
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replacing Na+ with choline showed no difference. The effect of inhibition is 
concentration dependent. Uptake of FEP is most sensitive to inhibitor of LATs. 5 mM 
BCH can inhibit more than 98% of uptake. On the contrast, no inhibition was observed 
using MeAIB, which indicates system A has no contribution in uptake of FEP. Inhibition 
of ASC via L-Ala or L-Ser has some effect but not as significant as system L, maximum 
inhibition at 5 mM is about 90%. The results demonstrated that FEP ([18F]2) was 
selective substrate for sodium independent transporter system L. Futhermore, LAT1 
specific inhibitor D-Met has very similar effect as BCH. The impact of NEM on the 
uptake is much less compared to D-Met, the maximum inhibition at 5 mM is ~30%, this 
suggests uptake of FEP may prefer LAT1 in comparison to other subtypes of LATs. It is 
an interesting difference in comparison to previously reported FET ([18F]1), which is 
suggested to be selectively transported via LAT2. [27] There is some advantage targeting 
LAT1 because it plays a critical role in cell growth and proliferation and shows increased 
transport activity in many malignant tumors [19, 20]. LAT1 expression is rarely detected 
in nontumor areas, in contrast, LAT2 is more ubiquitously expressed and has a high level 
of expression in small intestine, kidney, placenta, as well as tissues rich in (re)absorbing 
epithelia [35]. Some cancer cells such as C6 rat glioma, HeLa cervix carcinoma cells and 
R1M rhabdomyosarcoma have high expression of LAT1 but showed no upregulation of  
LAT2. [36, 37] In such cancer cells lack of expression of LAT2, FEP ([18F]2) might have 
advantage over FET ([18F]1). Further investigations are needed to confirm the amino acid 
transport systems involved in the uptake process.  
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3.2.5 Biodistribution studies of FEP 
From in vitro studies results, FEP seemed to be a potential tracer that worth 
further investigations, so in vivo evaluations were conducted. The in vivo biodistribution 
studies were carried out in fisher rats bearing 9L tumor model, which is a well-
established animal model mimicking clinical glioblastoma multiform and a number of 
amino acid based tracers used this model for biological evaluations [11, 38]. The 
distribution of radioactivity in selective peripheral tissues and organs and the regional 
radioactivity distribution in rat brain at 30 min and 60 min after injection of FEP were 
shown in Table 3.3. 
Table 3.3a. Biodistribution of FEP in Fisher rats with 9L xenograft. After single 
intravenous injection, results reprented as % ID/g, mean ± SD (six rats per time point) 
Organs 30 min 60 min 
Blood 0.73 ± 0.08 0.65 ± 0.05 
Heart 0.70 ± 0.07 0.63 ± 0.05 
Muscle 0.58 ± 0.05 0.62 ± 0.05 
Lung 0.68 ± 0.08 0.61 ± 0.05 
Kidney 0.72 ± 0.05 0.63 ± 0.05 
Pancreas 2.66 ± 0.20 2.45 ± 0.27 
Spleen 0.75 ± 0.06 0.69 ± 0.05 
Liver 0.71 ± 0.07 0.63 ± 0.05 
Skin 0.57 ± 0.07 0.60 ± 0.09 
Brain 0.53 ± 0.03 0.52 ± 0.05 
Bone 0.41 ± 0.03 0.41 ± 0.04 
Tumorb 0.82 ± 0.06 0.90 ± 0.20 
Tumor/Brain 1.55 1.73 
Tumor/Muscle 1.41 1.45 
aExperiment carried out by Brian Lieberman [39] 
bTumor n = 5 per time point. 
 
The results showed FEP had higher accumulation in 9L tumor compared to 
surrounding organs and tissues.  The tumor to brain and tumor to muscle ratio increased 
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slightly from 30 to 60 min (from 1.55 to 1.73). Tumor to blood ratio increases from 1.12 
at 30 min to 1.38 at 60 min. The highest uptake was found in the pancreas, accumulation 
in other organs is lower than that in tumor. Bone uptake is not significant, which 
indicates that FEP ([18F]2) is metabolically stable. Similar to FET ([18F]1) [38], FEP 
([18F]2) had high uptake in pancreases. This is typical for labeled amino acid analog in 
rodents, which might due to high protein turnover in pancreas. Tumor uptake, bone 
uptake and tumor to muscle ratio is comparable to reported FET results in the same rat 
tumor model, but FEP seems to have slightly higher normal brain uptake compared with 
FET resulting lower tumor to brain ratio [38].  
3.2.6 Small animal imaging studies 
 
Figure 3.5a. Small animal PET images of FEP ([18F]2, A) and FET ([18F]1,B) in tumor bearing rats. Color-
coded PET images from summed 2 h data in transverse, coronal and sagital view from left to right followed 
injection of FEP and FET are shown. The arrowhead points to the 9L tumor. 
aExperiment carried out by Brian Lieberman [39] 
 - 77 - 
Finally, the in vivo tumor imaging in the rats bearing 9L model was examined. 
Small animal PET imaging studies in living rats were performed and time-activity curves 
were generated by drawing region of interest to assess the kinetics of FEP ([18F]2) in 
comparison to FET ([18F]1). FET and FEP exhibited very similar results as shown in 
Figure 3.5, a summed 2 h image. Tracers kinetics were similar as demonstrated in Time 
activity curve in Figure 3.6. Both tracers have higher accumulations in tumors than 
surrounding background. After 20 min of intravenous injection of FEP, radioactivity in 
heart and muscle reached a plateau (Figure 3.6a). FEP had prolonged accumulation in 9L 
tumors with a slow steadily increase in 2 h imaging period. High urinary excretion was 
observed for both tracers, which is typical for tyrosine and phenylalanine analogs. Tumor 
to muscle ratio of these two ligands is comparable, which rapidly reached a plateau 
within 20 min (as shown in Figure 3.7). Imaging results indicate FEP ([18F]2) is 
compared to FET ([18F]1), both are suitable for brain tumor imaging.  
 
Figure 3.6a: Time-activity curve after injection of FEP ([18F]2) (a) and FET ([18F]1) in the rats (b) 
aExperiment carried out by Brian Lieberman [39] 
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Figure 3.7 Comparison of FEP ([18F]2) and FET ([18F]1) tumor to muscle (T/M) ration. 
 
3.3 Materials and methods 
3.3.1. General  
In additional to what described in Chapter two, section 2.4.1, the animal 
experiments were carried out in compliance with ethics and animal welfare according to 
regulation requirements. 
3.3.2. Synthesis of precursors and authentic standards for radiotracers  
COOBut
NHBocHO
 
3.3.2.1 (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanoate (5)  
L-tyrosine tert-butyl ester (4, 949 mg, 4 mmol) was added to a round-bottom flask 
and dissolved in 40 mL MeOH/H2O (2:1). To this mixture was added NaHCO3 (1.008 g, 
12 mmol) followed by Boc2O (1.31 g, 6 mmol). The reaction mixture was allowed to stir 
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for 4 h until completion as determined by TLC analysis (MeOH/CH2Cl2, 5/100). Upon 
completion, the mixture was concentrated under reduced pressure to remove methanol 
and then resulting solution diluted with water and extracted with EtOAc. Combined 
organic layer washed with brine and dried over Na2SO4, then concentrated under reduced 
pressure and purified by FC (MeOH/CH2Cl2, 5/100) to afford the product as white foam. 
1H NMR (200 MHz, CDCl3) δ = 7.04 (d, 2H, J = 8.6 Hz), 6.75 (d, 2H, J = 8.6 Hz), 4.98 
(d, 1H, J = 8.0 Hz), 4.43-4.36 (m, 1H), 2.98 (d, 2H, J = 5.8 Hz), 1.43 (s, 18H). 13C NMR 
(50 MHz, CDCl3) δ = 171.5, 155.6, 155.4, 130.8, 128.0, 115.6, 82.4, 55.4, 37.9, 28.5, 
28.2. HRMS calcd for C18H27NO5 ([M+Na]+) 360.1997, found 360.1986. [α]24D +39.3o (c 
0.29, CHCl3). 
COOBut
NHBocTfO
 
3.3.2.2. (S)-tert-butyl2-(tert-butoxycarbonylamino)-3-(4-(trifluoromethylsulfonyloxy) 
phenyl)propanoate (6) 
5 (515 mg, 1.53 mmol) and pyridine (302 mg, 3.82 mmol) in CH2Cl2 at 0 oC was 
added Tf2O (385 µL, 2.29 mmol) dropwise. Reaction stirred for 45 min at 0 oC. Then 
dilute with CH2Cl2 (50 mL), washed with 1 N NaOH (5 mL), 10% citric acid (5 mL) and 
brine (10 mL). The organic layer was dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by FC  (EtOAC/Hexanes, 1/9) to give 5 as light yellow 
liquid. 1H NMR (200 MHz, CDCl3) δ = 7.28 (d, 2H, J = 8.8 Hz), 7.19 (d, 2H, J = 9.0 Hz), 
5.07 (d, 1H, J = 7.2 Hz), 4.53-4.37 (m, 1H), 3.07 (d, 2H, J = 6.0 Hz), 1.42 (s, 9H), 1.38 
(s, 9H). 13C NMR (50 MHz, MeOD) δ = 172.7, 157.9, 150.1, 140.0, 132.7, 122.4, 83.1, 
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80.8, 57.02, 38.4, 28.8, 28.3.  HRMS calcd for C19H26F3NO7S ([M+Na]+) 492.1280, 
found 492.1299. [α]24D +28.7o (c 1.0, CHCl3).  
3.3.2.3. Stille cross-coupling for synthesis of 7a and 7b 
Triflate 6 (1.0 equiv) in DMF was added to flamed dried flask containing LiCl 
(3.0 eqiv), Pd(PPh3)2Cl2 (0.05 equiv), tributyl(vinyl)tin or tributyl(allyl)tin (1.3 equiv) in 
DMF. Reaction mixture was degassed for 5 min and then heated at 70 oC for 90 min at 
which point TLC indicated completion of reaction. The mixture was cooled to room 
temperature, diluted with water and then extracted three times with ether, combined 
organic layer was washed with brine, dried over MgSO4, filtered and concentrated. Crude 
products were purified by FC (EtOAc/Hexanes, 5/95) to afford products as white solids. 
COOBut
NHBoc
 
3.3.2.3.1 (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-vinylphenyl)propanoate (7a) 
Yield: 92%. 1H NMR (200 MHz, CDCl3) δ = 7.34 (d, 2H, J = 8.0 Hz), 7.14 (d, 
2H, J = 8.2 Hz), 6.70 (dd, 1H, J = 17.6, 10.8 Hz), 5.73 (d, 1H, J = 17.6 Hz), 5.23 (d, 1H, 
J =10.8 Hz), 4.99 (d, 1H, J = 7.8 Hz), 4.54-4.37 (m, 1H), 3.05 (d, 2H, J = 6.0 Hz), 1.43 
(s, 18H). 13C NMR (50 MHz, CDCl3) δ = 171.1, 155.3, 136.8, 136.5, 136.3, 129.9, 126.4, 
113.7, 82.3, 79.9, 55.1, 38.5, 28.5, 28.2. HRMS calcd for C20H29NO4 ([M+Na]+) 
370.1994, found 370.2001. [α]24D +42.7o (c 1.13, CHCl3). 
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COOBut
NHBoc
 
3.3.2.3.2 (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-allylphenyl)propanoate (7b)  
Yield: 95%. 1H NMR (200 MHz, CDCl3) δ = 7.20-7.10 (m, 4H), 6.06-5.85 (m, 
1H), 5.10 (d, 1H, J = 5.8 Hz), 5.05-4.96 (m, 2H), 4.54-4.37 (m, 1H), 3.36 (d, 2H, J = 6.8 
Hz) 3.02 (d, 2H, J = 6.0 Hz), 1.43 (s, 18H). 13C NMR (50 MHz, CDCl3) δ =171.1, 155.2, 
138.7, 137.6, 134.2, 129.7, 128.7, 115.8, 82.0, 79.7, 55.1, 40.0, 38.3, 28.5, 28.1. HRMS 
calcd for C21H31NO4 ([M+Na]+) 384.2151, found 384.2133. [α]24D +33.7o (c 0.47, 
CHCl3). 
3.3.2.4. Hydroboration-oxidation reaction for synthesis of 8a and 8b 
To solution of corresponding alkene 7a or 7b in THF, 0.5 M 9-BBN in THF (3.0 
equiv) was added dropwise, stirred for 3 h at room temperature. The solution was then 
cooled to 0 oC , 3 N NaOH solution was added followed by H2O2 (30% in H2O). Reaction 
continued at room temperature for additional 3 h, the biphasic mixture was treated with 
saturated Na2S2O3 and extract three times with EtOAc, combined organic extracts were 
washed with brine, dried over MgSO4, filtered and concentrated. The crude mixtures 
were purified with FC (EtOAc/Hexanes, 3/7) to give products as clear viscous liquids. 
COOBut
NHBocHO
 
3.3.2.4.1. (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-hydroxyethyl)phenyl) 
propanoate (8a)  
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Yield: 86%. 1H NMR (200 MHz, CDCl3) δ = 7.20-7.08 (m, 4H), 4.99 (d, 1H, J = 
6.8 Hz), 4.52-4.37 (m, 1H), 3,85 (t, 2H, J = 6.6 Hz), 2.98 (d, 2H, J = 5.8 Hz), 2.85 (t, 2H, 
J = 6.6 Hz), 1.42 (s, 18H). 13C NMR (50 MHz, CDCl3) δ = 171.1, 155.2, 137.3, 134.4, 
129.7, 129.0, 82.0, 79.7, 63.6, 55.0, 38.9, 38.2, 28.3, 28.0. HRMS calcd for C20H31NO5 
([M+H]+) 366.2280, found 366.2281. [α]21D +41.4o (c  0.75, CHCl3). 
COOBut
NHBocHO
 
3.3.2.4.2. (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-hydroxypropyl)phenyl) 
propanoate (8b)  
Yield: 88%. 1H NMR (200 MHz, CDCl3) δ = 7.15-7.06 (m, 4H), 5.00 (d, 1H, J = 
7.8 Hz), 4.49-4.37 (m, 1H), 3.67 (t, 2H, J = 6.4 Hz), 3.01 (d, 2H, J = 5.8 Hz), 2.68 (t, 2H, 
J = 6.6 Hz), 1.94-1.83 (m, 2H), 1.42 (s, 18H). 13C NMR (50 MHz, CDCl3) δ = 171.2, 
155.3, 140.6, 134.0, 129.7, 128.6, 82.1, 79.9, 63.3, 55.1, 38.4, 34.4, 31.9, 28.5, 28.2. 
HRMS calcd for C21H33NO5 ([M+Na]+) 402.2256, found 402.2410. [α]24D +30.7o (c 0.93, 
CHCl3). 
3.3.2.5. Tosylation reaction for synthesis of precusors 9a and 9b 
Corresponding hydroxyl compounds 8a or 8b (1.0 equiv) in 5mL CH2Cl2 was 
added Et3N (3.0 equiv) and TsCl (1.2 equiv). Reaction continued at room temperature for 
20 h. The solution was diluted with CH2Cl2, washed with saturated NaHCO3 and brine. 
Orangic layer was dried over MgSO4, filtered and concentrated. Purify via FC 
(EtOAc/Hexanes, 2/8) to afford products as clear viscous liquid. 
 - 83 - 
COOBut
NHBocTsO
 
3.3.2.5.1.  (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-(tosyloxy)ethyl)phenyl) 
propanoate (9a) 
Yield: 92%. 1H NMR (200 MHz, CDCl3) δ = 7.72 (d, 2H, J = 8.2 Hz), 7.31 (d, 
2H, J = 8.0 Hz), 7.11-7.00 (m, 4H), 4.97 (d, 1H, J = 7.8 Hz), 4.48-4.36 (m, 1H), 4.19 (t, 
2H, J = 7.2 Hz), 3.02 (d, 2H, J = 5.6 Hz), 2.93 (t, 2H, J = 7.2 Hz), 2.45 (s, 3H), 1.43 (s, 
18H). 13C NMR (50 MHz, CDCl3) δ = 171.0, 155.2, 144.8, 135.3, 134.9, 133.4, 130.0, 
129.0, 128.0, 82.2, 79.9, 70.6, 55.0, 38.3, 35.2, 28.5, 28.1, 21.8. HRMS calcd for 
C27H37NO7S ([M+Na]+) 542.2188, found 542.2221. [α]23D +28.0o (c 1.35, CHCl3). 
COOBut
NHBocTsO
 
3.3.2.5.2. (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-(tosyloxy)propyl)phenyl) 
propanoate  (9b) 
Yield: 75%.  1H NMR (200 MHz, CDCl3) δ = 7.79 (d, 2H, J = 8.2 Hz), 7.35 (d, 
2H, J = 8.0 Hz), 7.08-6.97 (m, 4H), 4.98 (d, 1H, J = 7.6 Hz), 4.48-4.36 (m, 1H), 4.03 (t, 
2H, J = 6.2 Hz), 3.00 (d, 2H, J = 5.6 Hz), 2.61 (t, 2H, J = 7.8 Hz), 2.46 (s, 3H), 2.02 -1.85 
(m, 2H), 1.42 (s, 18H). 13C NMR (50 MHz, CDCl3) δ = 171.0, 155.2, 144.9, 139.1, 
134.5, 133.5, 130.0, 129.8, 128.6, 128.1, 82.2, 79.9, 69.8, 55.1, 38.4, 31.3, 30.7, 28.5, 
28.2, 21.8. HRMS calcd for C28H39NO7S ([M+H]+) 534.2525, found 534.2518. [α]22D 
+29.5o (c 0.40, CHCl3). 
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3.3.2.6. Fluorination for synthesis of 10a and 10b 
Corresponding tosylate 9a and 9b (1.0 equiv) in 5 mL acetone was added sodium 
iodide (5.0 equiv). The reaction mixture was refluxed for 1 h and then filtered and 
concentrated. Residue was dissolved in CH2Cl2, filtered and concentrated again to afford 
clear liquid. This intermediate product was redissolved in CH3CN, silver fluoride (4.0 
mmol) was added in the solution and reaction continued at room temperature for 1 d at 
dark. Reaction mixture was then filtered and concentrated, purified with FC to afford 
products as light yellow viscous liquids. 
COOBut
NHBocF
 
3.3.2.6.1. (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethyl)phenyl) 
propanoate (10a) 
Yield: 50%. 1H NMR (200 MHz, CDCl3) δ = 7.18-7.05 (m, 4H), 4.99 (d, 1H, J = 
7.8 Hz), 4.73 (t, 1H, 6.6 Hz), 4.53-4.35 (m, 2H), 3.10-3.00 (m, 3H), 2.93 (t, 1H, J = 6.6 
Hz), 1.42 (s, 18H). 13C NMR (50 MHz, CDCl3) δ = 171.2, 155.3, 135.9, 135.1, 130.0, 
129.2, 84.2 (d, J = 168.5 Hz), 82.2, 55.1, 38.5, 36.8 (d, J = 20.0 Hz), 28.5, 28.2. HRMS 
calcd for C20H30FNO4 ([M+Na]+) 390.2057, found 390.2063. [α]23D +38.0o (c 0.45, 
CHCl3). 
COOBut
NHBocF
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3.3.2.6.2. (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-fluoropropyl)phenyl) 
propanoate (10b)  
Yield: 58%. 1H NMR (200 MHz, CDCl3) δ = 7.20-7.07 (m, 4H), 4.98 (d, 1H, J = 
8.0 Hz), 4.57 (t, 1H, 6.0 Hz), 4.48-4.30 (m, 2H), 3.02 (d, 2H, J = 5.8 Hz ), 2.72 (t, 1H, J = 
7.6 Hz), 2.12-1.96 (m, 2H), 1.43 (s, 18H). 13C NMR (50 MHz, CDCl3) δ = 171.2, 155.3, 
139.8, 134.3, 129.9, 128.7, 83.3 (d, J = 164.0 Hz), 82.2, 79.9, 55.1, 38.4, 32.2 (d, J = 20.0 
Hz), 31.1, 28.5, 28.2. HRMS calcd for C21H32FNO4 ([M+Na]+) 404.2213, found 
404.2242. [α]24D +36.2o (c 1.4, CHCl3). 
3.3.2.7. Deprotection reaction for synthesis of 2 and 3  
Corresponding protected compound 10a and 10b (1.0 equiv) in CH2Cl2 was added  
trifluoroacetic acid (TFA), stirred for 2 h to 4h at which point TLC indicated completion 
of reaction. Reaction mixture was concentrated in vacuo and residue was then dissolved 
in 2 mL methanol, adjust pH to 6-7 with 5% NH4OH at which point white precipitate 
formed. The mixture was refrigerated overnight and then subjected to filtration, the solid 
was washed with methanol and dried in vacuo to afford products as white solids. 
COOH
NH2F
 
3.3.2.7.1. (S)-2-amino-3-(4-(2-fluoroethyl)phenyl)propanoic acid (2) 
Yield: 81%. 1H NMR (200 MHz, MeOD+TFA-D) δ = 7.17-7.05 (m, 4H), 4.58 
(dt, 2H, J = 47.2, 6.2 Hz), 4.21 (dd, 1H, J = 7.6, 5.4 Hz), 3.35-3.08 (m, 2H), 2.97 (dt, 2H, 
J = 24.6, 6.2 Hz). 13C NMR (50 MHz, D2O+DCl) δ = 171.0, 137.6, 132.1, 129.6, 85.1 (d, 
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J = 156 Hz), 54.0, 35.6 (d, J = 19.5 Hz), 35.1. HRMS calcd for C11H14FNO2 ([M+H]+) 
212.1087, found 212.1086. [α]23D -5.8o (c 0.75, 6N HCl). 
COOH
NH2F
 
 3.3.2.7.2. (S)-2-amino-3-(4-(2-fluoropropyl)phenyl)propanoic acid (3) 
Yield: 64%. 1H NMR (200 MHz, D2O+DCl) δ = 6.79-6.69 (m, 4H), 4.09 (t, 1H, J 
= 6.0 Hz), 3.90-3.80 (m, 2H), 2.73(ddd, 2H, J = 14.6, 5.8, 7.6 Hz), 2.19 (t, 2H, J = 7.6 
Hz), 1.59-1.31 (m, 2H). 13C NMR (50 MHz, D2O+DCl+MeOD) δ = 172.0, 142.5, 132.3, 
130.5,130.2, 85.7 (d, J = 156.5 Hz), 55.0, 36.1, 32.1 (d, J = 19.0 Hz), 31.2. HRMS calcd 
for C12H16FNO2 ([M+H]+) 226.1243, found 226.1256. [α]24D -5.7o (c 0.45, 6N HCl). 
 
3.3.3.Radiosynthesis  
 [18F]Fluoride trapped a Sep-Pak light QMA cartridge (pre-conditioned with 10 
mL 1 N NaHCO3, 10 mL water and dried with N2) was eluted with 0.6 mL 
tetrabutylammonium bicarbonate (TBAHCO3) solution (21.5 mg TBAHCO3 in 0.3 mL 
CH3CN and 0.3 mL H2O). The 18F activity was dried azeotropically under N2 at 110 oC. 
Precursor 9a or 9b (5 mg) in 1 mL anhydrous CH3CN was then added into dried 18F, 
fluorination reaction continued for 5 min at 80 oC. After fluorination, reaction mixture 
was injected to semi-preparative HPLC on Phenomenex Gemini C-18 column (10 × 250 
mm, 5 µm). Intermediates [18F]10a and [18F]10b  were eluted with methanol/0.1% formic 
acid in water (80/20). Radioactive peak between 11 min to 13 min was collected and then 
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diluted with 20-25 mL water, loaded on HLB oasis cartridge (preconditioned with 10 mL 
ethanol and 10 mL water), washed with 2 mL water and then eluted with 1 mL ethanol. 
Removing ethanol under N2 at 60 oC. TFA was then added, deprotection reaction 
continued at 60 oC for 10 min. After removing TFA with N2 flow, 1 mL sterile water was 
added to formulate final product. Chemical and radiochemical purity (RCP) were 
determined by analytical HPLC performed on a Phenomenex Gemini C-18 column (4.6 × 
250 mm, 5 µm) eluted by solvent system A: methanol/0.1% formic acid (20/80) at flow 
rate of 1 mL/min and TLC (NH4OH/MeOH/ CH2Cl2, 1/6/14). Retention time was 6.9 min 
for [18F]2 and 7.6 min for [18F]3. Enantiomeric purity was determined with a chirobiotic-
T (Aldrich, St. Louis, MO) chiral column (5µ, 250 × 4.6 mm) using solvent system B: 
ethanol/ H2O (50/50) at flow rate of 0.5 mL/min. Retention time was 9.7 min for [18F]2 
and 10.6 min for [18F]3. 
 
3.3.4. In vitro cell uptake studies and transport characterization studies  
Brain gliosarcoma cell line 9L was purchased from ATCC (Manassas, VA). The 
9L cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, GIBCO BRL, 
Grand Island, NY) supplemented with 10% fetal bovine serum (Hycolne, Logan, UT) and 
1% penicillin/ streptomycin. Cells were maintained in T-75 culture flask under 
humidified incubator conditions (37 oC, 5% CO2) and were routinely passaged at 
confluence. Tumor cells were plated at a concentration of 2.0 × 105 cells/well 24 h in 
culturing media prior to cell uptake and inhibition studies. On the day of experiment, the 
media was aspirated and the cells were washed three times with 1 mL of warm phosphate 
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buffered saline (PBS, containing 0.90 mM of Ca2+ and 1.05 mM of Mg2+). Each assay 
condition was performed in triplicates. 
For cell uptake studies, ligand of choice was mixed within PBS solution and was 
then added to each well (~500,000 cpm/mL/well). The cells were incubated at 37 °C for 
5, 30, 60, 120 min. At the end of the incubation period, the wells were aspirated free of 
ligand and then the residual cells were washed 3 times with 1 mL ice cold PBS without 
Ca2+ and Mg2+. After washing with ice cold PBS, 350 µL 1 M NaOH was used to lyse the 
cells. The lysed cells were collected onto filter paper and counted using a gamma counter 
(Packard Cobra). Together with the sample of initial dose. 100 µL of the cell lysate was 
used for determination of protein concentration by Lowry method. The data was 
normalized as percentage uptake of initial dose relative to 100 µg protein content (% 
ID/100 µg protein). 
In inhibition studies, [18F]2 was mixed with specific inhibitors in concentration of 
0.5 mM, 1 mM and 5 mM in PBS solution. In sodium dependence studies, PBS buffer 
was replaced with Na+ free solution (143 mM choline chloride, 2.68 mM KCl and 1.47 
mM KH2PO4). The cells were incubated at 37 °C for 30 min. The procedure following 
incubation was the same as in cell uptake studies. The data was normalized in reference 
to uptake of [18F]2 without any inhibitor in PBS solution. 
 
3.3.5. Biodistribution in Fisher rats with 9L glioma tumors 
F344 rats were purchased from Charles Rivers Laboratory (Malvern, PA).  
Xenografts using 9L cells in F344 rats were accomplished by injecting 4-5 million 
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cells/xenograft. The cells suspended in PBS solution (0.2 mL) were injected 
subcutaneously into each of shoulder flanks of the F344 rat. The growth of the tumor was 
monitored daily for two weeks.  When the volume of the tumors reached 1 cm, the rat 
tumor model was used for biodistribution or microPET imaging studies. Animals were 
fasted for 12-18 hours prior to the procedure. Saline solution containing the radioactive 
compounds in a small volume (0.2 mL) was injected into the lateral tail vein under 
isoflurane anesthesia (1-2%, 1 L/min oxygen). The animals were sacrificed at 30 and 60 
min time points post-injection by cardiac excision under anesthesia. Six rats were 
sacrificed at each time point. The organs of interest and tumors were removed and 
weighed.  The radioactivity in each tissue was measured using gamma counter together 
with sample of the initial dose. Results were expressed as the percentage of the injected 
dose per gram (%ID/g) of tissue. Each value represents the mean ± SD of six rats unless 
otherwise noted. 
 
3.3.6. Small animal imaging with a microPET 
PET imaging studies were performed on a Phillips Mosaic small animal PET 
scanner, which has an imaging field of view of 11.5 cm. Under isoflurane anesthesia (1-
2%, 1L/min oxygen) the tumor bearing F344 rats as described before were injected with 
30-37 MBq (0.8-1 mCi) of activity via an intravenous injection into the lateral tail vein.  
Data acquisition began immediately following the intravenous injection.  Dynamic scans 
were conducted over a period of 2 h (5 min/frame; image voxel size 0.5 mm3).  Rats were 
visually monitored for breathing and a heating pad was used to maintain body 
temperature throughout the entire procedure.  Images were reconstructed and region of 
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interest (ROI) analysis was performed using AMIDE software 
(http://amide.sourceforge.net/). 
 
3.4. Conclusion 
In summary, we prepared new optically pure phenylalanine derivatives FEP ([18F]2) and 
FPP ([18F]3)  in high radiochemical purity, good radiochemical yield (11-37%) and high 
specific activity (21-69 GBq/µmol). Cellular uptake in 9L glioma demonstrated that FEP 
had a higher uptake than FPP and previously reported FET ([18F]1). Uptake mechanism 
studies suggested that accumulation of FEP into 9L cells was predominantly via system 
L. In vivo biodistributon studies using rats bearing 9L glioma tumor model showed that 
FEP had higher uptake in 9L glioma than surrounding organs. Small animal PET imaging 
studies demonstrated that FEP was comparable to FET. These results indicate that FEP 
([18F]2) is a potential useful PET tumor imaging agent. 
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Chapter 4 
 
Synthesis and comparative biological evaluation of L- 
and D-isomers of 18F labeled fluoroalkyl phenylalanine 
derivatives as tumor imaging agents 
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4.1 Introduction  
Amino acids are essential for growth of cancer cells as a source for energy and 
building blocks for protein synthesis [1]. Unregulated amino acid transport and increased 
protein synthesis rate are well-known characteristics of tumor cells. A number of amino 
acids based tracers demonstrated improved imaging characteristics relative to the most 
commonly used [18F]fluoro-2-deoxy-D-glucose (FDG) for certain cancers, particularly for 
imaging of brain tumors because of their low uptake in cortical normal tissue and 
inflammatory tissues [2, 3].  
Currently, most of clinically utilized amino acid tracers for PET and SPECT are 
L-isomers. A number of L-amino acids and their derivatives have demonstrated promising 
clinical results such as 11C labeled natural amino acids [11C]L-methionine (MET) [4] and 
18F or 123I labeled non-natural amino acids, 3-[123I]Iodo-α-methyl-L-tyrosine (L-[123I]IMT) 
[5], cis-4-[18F]fluoro-L-proline [6], L-6-[18F]fluoro-DOPA [7], anti-1-amino-3-
[18F]fluoro-cyclobutyl-1-carboxylic acid (FACBC) [8], O-[18F]fluoroethyl-L-tyrosine(L-
FET, [18F]1) [9, 10]. Non-natural amino acid tracers could overcome certain 
shortcomings of natural amino acids resulting from short half-life of 11C and 
susceptibility to non-protein metabolic pathways. They generally exhibit increased uptake 
in tumor cells while show no incorporation into protein and remain metabolically stable 
in the cells [2, 11]. This suggests upregulation of amino acid transport is the dominating 
process for increased uptake of non-natural amino acid tracers and incorporation into 
protein is not necessary. Amino acid transport systems A (alanine preferring), ASC 
(alanine-serine-cysteine preferring) and L (leucine preferring) have been found to be 
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upregulated in tumor cells and they are targets of oncogene and protooncogene actions 
[12, 13].  In particular, systems L amino acid transporter system (LATs), which plays a 
critical role in angiogenesis, tumor growth and proliferation [14, 15], is a main focus for 
developing amino acid based tumor imaging agents [2, 3, 16].  
D-amino acids have been suggested to be potentially useful tumor specific 
imaging agents since 1970s. This suggestion stemmed from the observation that some 14C 
labeled D-amino acids had preferred uptake in tumor-bearing mice compared to their 
corresponding L-isomers [17]. Because D-amino acids are not commonly utilized in 
mammalian cells, they are considered to be non-natural, their increased uptake into tumor 
cells is mainly the result of over-expression of amino acid transporters [18]. It has been 
shown that LAT1 (one of four subtypes of LATs), transports certain D-amino acids such 
as D-phenylalanine (Phe), D-leucine (Leu) and D-methionine (Met) with high affinity [19-
21]. But not all subtype of LATs could tolerate D-amino acids. LAT2 for example, is 
seterospecific for L-Phe, Leu, Met et al [22]. Of all subtypes of system L, LAT1 in 
particular, is closely correlated with angiogenesis, cell proliferation [15] and prognosis of 
patients with a variety of cancers such as astrocytoma, non-small cell lung cancer 
(NSCLC) and prostate cancer [23-25]. Due to the current knowledge of transport systems, 
especially about LAT1, there has been increased interest in developing D-amino acid 
based tracers. The reported results in comparative studies of L- and D-amino acid 
compounds are somewhat controversial. On one hand, there were studies demonstrated 
low uptakes of D-amino acid tracers in tumors. D-[11C]MET was shown to have lower 
uptake in brain tumors than L-[11C]MET [26]. D-FET had negligible accumulation in 
mice brain [10] as well as in SW707 colon carcinoma cells [27] compared to that of the 
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L-isomer. On the other hand, there are a number of reports showing that some D-amino 
acid derivatives have improved tumor-imaging properties than their corresponding L-
isomers. Evaluations of O-[18F]fluoromethyl-, fluoroethyl- and fluoropropyl-tyrosine in 
tumor bearing mice demonstrated D-isomers have higher tumor-to-blood or tumor-to-
pancreas ratio [28]. Comparison of D- and L-isomer of 2-[123/125I]Iodo-tyrosine showed D-
isomer cleared faster from blood and had a lower overall body background [29]. 2-
[123I]iodo-D-phenylalanine demonstrated similar advantage over its L-isomer [30]. 
Moreover, several D-isomers showed preferential transport at the blood-brain barrier 
(BBB) compared with their L-isomers, such as cis-4-[18F]fluoro-D-proline [31, 32] and D-
FET (in porcine brain)[33].  
COOH
NH218F
COOH
NH2O
18F
 L-FET
L-[18F]1
COOH
NH2
18F
 L-FEP
L-[18F]1
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COOH
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18F
COOH
NH2
18F
COOH
NH218F
 D-FET
D-[18F]1
 D-FEP
D-[18F]2
 D-FPP
D-[18F]3  
Figure 4.1. Chemical structures of L- and D- 18F labeled tyrosine and new phenylalanine derivatives 
 
We recently reported new 18F labeled L-phenylalanine derivatives, p-(2-
[18F]fluoroethyl)-L-phenylalanine (L-FEP, L-[18F]2) and p-(3-[18F]fluoropropyl)-
phenylalanine (L-FPP, L-[18F]3) (as shown in Figure 4.1) [34]. L-FEP was shown to be 
comparable in imaging rat with 9L tumors as L-FET ([18F]1), which is a clinically utilized 
PET tracer for imaging brain tumor and head and neck squamous cell carcinomas [9]. 
The goal of this study is to evaluate the potential of D-isomer of fluoroalkyl 
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phenylalanine derivatives as tumor imaging agents in comparison with their 
corresponding L-isomers in vitro in 9L rat glioma cells and in vivo in rats bearing 9L 
tumor models. 
4.2 Results and Discussion 
4.2.1 Synthesis of labeling precursors and standards  
D-7a
a b
c d e
g
n = 1, D-2
n = 2, D-3
n = 0,
n = 1, D-7b n = 1, D-8an = 2, D-8b n = 1, D-9an = 2, D-9b
n = 1, D-10a
n = 2, D-10b
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NHBocF n
COOH
NH2F n
D-5 D-6D-4
f
 
Scheme 4.1. Synthesis of labeling precursors and standards 2 and 3. Reagents and conditions: a)  
(Boc)2O, NaHCO3, MeOH, H2O, rt , 4h, 75%; b) Tf2O, pyridine, CH2Cl2, 0oC, 81%; c) Tributyl 
vinyltin or tributyl allyltin, LiCl, Pd(PPh3)2Cl2, DMF, 70oC, 90% (n = 0) or 94% (n = 1); d)  9-
BBN, THF, NaOH, H2O2, 67% (n = 1) or 70% (n = 2); e) TsCl, Et3N, CH2Cl2, 77% (n = 1) or 
84% (n = 2); f) i. NaI, acetone, reflux; ii. AgF, CH3CN, 45% (n = 1) or 79% (n = 2); g) TFA, 
CH2Cl2, 52% (n = 1) or 71% (n = 2). 
 
b
COOBut
NHBocHO
c
a
D-11
D-1
COOBut
NHBocOTsO
D-12
COOBut
NHBocOF
COOH
NH2OF
D-5
 
Scheme 4.2. Synthesis of precursor and standard 1. Reagents and conditions: a) TsO(CH2)2OTs, 
K2CO3, DMF, 70oC, 4h, 61%; b) FCH2CH2Br, DMF, K2CO3, 70oC  2h, 76%; c) TFA, CH2Cl2, 
56%. 
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Here we showed the synthesis of D-isomers, preparation of corresponding L-
isomers was carried out in the same manner except the starting materials were in L-
isomeric form. Preparation of D-isomer of tosylate precursor and standard for labeling 
FEP ([18F]2) and FPP ([18F]3) was shown in Scheme 4.1 which followed the synthesis of 
its corresponding L-isomer as described in details in Chapter 3 [34]. D-2 and D-3 was 7% 
and 19%. Although L-FET is well established, synthesis of cold standard for D-FET has 
rarely been reported. So here we briefly described as in Scheme 4.2. It is modified from 
reported procedure for L-FET by Hamacher, K. [35]. Precursor and standard for labeling 
D-FET were readily prepared via direct alkylation on phenol group of D-5 with overall 
yields of 46% and 32% respectively. The optical rotation of all compounds was measured 
to monitor their enantiomeric purity. The enantiomeric purity of the tosylate precursors 
and standards for radiosynthesis was >95%, measured by chiral HPLC. 
 
4.2.2 Radiolabeling of L- and D-FET, FEP and FPP 
a, bCOOBut
NHBocXTsO
n
COOH
NH2X18F
n
n = 2, X = O, D-[18F]1
n = 1, X = C, D-[18F]2
n = 2, X = C, D-[18F]3
n = 2, X = O, D-11
n = 1, X = C, D-9a
n = 2, X = C, D-9b  
Scheme 4.3. Radiolabeling of D-FET ([18F]1), FEP ([18F]2) and FPP ([18F]3). Reagent and 
conditions: a) TBA18F, TBAHCO3, CH3CN, 80 oC, 5 min; b) TFA, 60 oC, 10 min. 
 
Table 4.1. Synthesis time, decay-corrected radiochemical yields (RCY), radiochemical 
purity (RCP), enantiomeric purity and specific activity (EOS). *  
Ligands Synthesis 
time (min) 
RCY (%) RCP (%)  Enantiomeric 
Purity (%) 
Specific activity 
(GBq /µmol) 
L- and D-[18F]1 79-85 21-45 > 95 > 95 26-44 
L- and D-[18F]2 75-82 23-37 > 95 > 95 31-75 
L- and D-[18F]3 78-90 11-23 > 95 > 95 21-25 
*Data were obtained from two to six experiments 
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Radiosynthesis of 18F-fluoroalkyl tyrosine and phenylalanine derivatives was 
carried out via a two-step reaction as shown in Scheme 4.3 – non-carried-added (NCA) 
nucleophilic fluorination with TBA18F and TBAHCO3 in CH3CN followed by acid 
hydrolysis in TFA. This is an efficient process suitable for potential clinical applications 
in the future. Intermediates were purified by semi-preparative HPLC to separate from 
non-reacted 18F fluoride, remaining precursors and by-products. After removing TFA, 
final products were redissolved in water, in which pH was ~ 6. In order to achieve valid 
comparative evaluation of L- and D-isomers of amino acid analogues as tumor-detecting 
agents, the quality control of enantiomeric purity was a critical factor because the uptake 
and kinetics of D-isomers in organs was demonstrated to be significantly different from 
those of the corresponding L-isomers [28]. We determined the enantiomeric purity via 
HPLC on chiral column and the configuration of both isomers was confirmed by 
comparison with those standard “cold” compounds. In additional, radiochemical purity 
was analyzed via HPLC on C-18 column and TLC. The results of radiosythesis 
(summarized in Table 4.1) demonstrated optically and chemically pure tracers (purity 
was > 95%) were efficiently prepared with moderate to good radiochemical yield (11-
45%) and high specific activity (21-75 GBq/µmol). 
It is noteworthy to point out that our initial attempts to carry out nucleophilic 
fluorination reaction using Kryptofix K[2.2.2]18F and K2CO3 in acetonitrile at 90 oC led 
to significant racemization. There were 28-35% of the final products in the epimerized 
form. To investigate the source of racemization, we examined the ratio of L- and D-
isomer after fluorination reaction as well as in final products measured by chiral HPLC 
(Figure 4.2). The HPLC profiles showed that racemization occurred in the first step – 
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fluorination reaction, the intermediates were mixtures of L- and D- isomers. Moreover, 
the ratio of L- and D-isomer was the same for the fluorinated intermediates and the final 
products, which suggest no further racemization occurred during acid deprotection. In 
nucleophilic fluorination, the pH of K[2.2.2]18F/K2CO3 solution is ~ 10, thus the 
racemization reaction is likely a base-catalyzed reaction. It was reported that factors such 
as pH and temperature of the reaction solution affect the rate of racemization [36]. Higher 
pH and temperature lead to faster racemization. In order to obtain the optically pure 
ligands, we then carried out fluorination reaction using TBA18F/TBAHCO3 in CH3CN at 
80 oC, pH of this reaction solution is ~ 8, much lower than that of K[2.2.2]18F/K2CO3 
solution. Under this condition, the enantiomerically purity of ligands was improved to 
>95%, which could be considered to be optically pure, as shown in Figure 4.3. 
 
Figure 4.2. HPLC profile of fluorination intermediate [18F]10a (a) and final products FEP ([18F]2) (b) 
under condition using K[2.2.2]/K18F at 90 oC for radiofluorination. Blue or red colored line is the result 
from radioactive detector and black line is the result from UV trace of coinjection with standard 
compounds. 
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Figure 4.3. HPLC profile with L-isomer (a) and D-isomer (b) of FEP ([18F]2). Blue or red colored line is 
the result from radioactive detector and black line is the result from UV trace of coinjection with “cold” 
standards. 
 
4.2.3 Cell uptake studies 
We evaluated L- and D- isomers of new phenylalanine derivatives FEP ([18F]2) 
and FPP ([18F]3) by examining their time dependent uptake of in 9L glioma cells. Their 
uptake was compared with L- and D-FET ([18F]1), for which comparative uptake studies 
have been reported before [27, 33]. Uptake of tracers was measured at selective time 
points up to 2 h and the results were summarized in Figure 4.4. L-isomers showed a fast 
initial uptake, quickly reached maximum uptake within 60 min and then washed out. In 
contrast, D-isomers had slow linear uptake over 2 h period. Uptake of L-isomer was 
significantly higher (4.3 to 16.0 fold) than that of the corresponding D-isomers, which is 
consistent with other reported in vitro studies comparison L and D-isomers of tyrosine 
derivatives [27, 37]. These results suggested that the cellular uptake of amino acid tracers 
was mediated via highly stereo-specific amino acid transport systems.  
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Figure 4.4. Comparative cellular uptake of L- and D-FET ([18F]1) (a), L- and D-FEP ([18F]2)  (b) and L- and 
D-FPP ([18F]3)  (c) in 9L glioma cells. The uptake value was represented as %uptake/100 ug protein, mean 
± SD. 
 
Uptake of L and D-FPP ([18F]3) was comparable to that of corresponding isomer 
of FET ([18F]1), while uptake of [18F]FEP ([18F]2) was notably higher. Maximum uptake 
of L-FEP was 1.4 fold of L-FET and D-FEP was 5.2 fold of D-FET. The difference 
between L- and D- isomers is the smallest in FEP. The major differences among these 
tracers are lipophilicity and fluoroalkyl chain length. Tracers’ lipophilicity follows the 
order of FPP (Log D = -0.73) > FEP (Log D = -1.00)>FET (Log D = -1.51) [10] while 
alkyl chain length follows the order of FEP <FET ≈ FPP. From the uptake result, it 
appears that a shorter fluoroalkyl chain length might be more desirable for aromatic 
amino acid tracers. These results suggested both isomers of FEP ([18F]2) may worth 
further investigations. 
 
4.2.4 Transport characterization studies  
Amino acid transport systems play an essential role in uptake of amino acid 
ligands in tumor cells. An amino acid tracer could be substrate for a number of amino 
acid transport systems with overlapping substrate selectivity. To examine and compare 
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the amino acid transport systems involved in uptake of L- and D-FEP ([18F]2), we 
conducted a series of inhibition studies and sodium dependence studies in 9L glioma. The 
uptake of FEP was measure in absence as well as in the presence of 0.5 to 5 mM of 
specific inhibitor (as shown in Figure 4.5.). We focus on system A, ASC and L because 
the transport of neutral amino acids in mammalian cells is predominantly through these 
systems and they are most commonly upregulated amino acid transport systems in cancer 
cells [12, 14]. 
 
Figure 4.5. Transport characterization studies of L- and D-FEP ([18F]2) in 9L glioma cells. Results were 
normalized to uptake of each isomer’s uptake in PBS solution at 30 min. Data was expressed as mean ± SD 
(n = 3). 
 
The uptake of L- and D-FEP ([18F]2) was not affected by presence of N-methyl-α-
aminoisobutyric acid (MeAIB), which is a specific inhibitor for system A. The uptake of 
both isomers exhibited similar concentration dependent inhibition by system ASC 
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inhibitors L-serine (Ser) and L-alanine (Ala). However, L-FEP was more affected by the 
presence of inhibitors in comparison with D-FEP, for example, 5 mM of L-Ser could 
inhibit 90% of uptake of L-FEP while it can only reduce 67% uptake of D-isomer. Both 
isomers uptake was strongly inhibited by 2-amino-bicylo[2.2.1]heptane-2-carboxylic acid 
(BCH),  a selective inhibitor of LATs. 5 mM of BCH could inhibit 98% and 94% uptake 
of L- and D-FEP respectively. Since BCH is not only an inhibitor for sodium independent 
system L but also an inhibitor for sodium dependent system B0 and B0,+ [38], we then 
conducted sodium dependence studies to examine the contribution from sodium 
dependent transport systems. Uptake of both isomers remained unchanged when 
replacing PBS solution with Na+-free buffer (NaCl was replaced with choline chloride as 
reported [22]. These results suggest that L- and D-FEP are selective substrates for LATs.  
There are four subtypes of system L amino acid transport systems isolated and 
characterized, with differences in topology, substrate selectivity and tissue distribution, 
designated LAT1 to LAT4 [39]. LAT1 has attracted special interests because its 
expression is rarely detected in non-tumor areas and is closely correlated with 
angiogenesis, cell proliferating and prognosis of certain cancers [24, 25]. We were 
especially interested in LAT1 since it is known that LAT1 could transport D-isomers of 
phenylalanine, in contrast, the other subtype LAT2 could not. D-Met [40], a specific 
inhibitor for LAT1, had very similar impact on uptake of L-FEP as BCH. It was not as 
potent as BCH towards D-isomer, 5 mM of D-Met could inhibit 86% of the uptake. 
Inhibition using N-ethylmaleimide (NEM), an inhibitor for LAT2 to LAT4 but not LAT1 
[39], had dramatically different effect on uptake of L- and D-FEP. While uptake of D-
isomer was strongly inhibited by NEM with maximum inhibition of 92% at 5 mM 
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concentration, uptake of L-isomer could only reduced up to 30%. These results indicated 
that L-FEP preferred system L subtype LAT1 but D-FEP did not exhibit the same 
preference. D-FEP appears to have different transport characteristics from D-Phe since it 
has been reported that LAT2, LAT3 and LAT4 could not transport D-Phe [39, 41]. Of 
four subtypes, LAT3 is the most sensitive to NEM inhibition (80% inhibition in 
comparison to 40% for LAT2 and LAT4 or 20% for LAT1 at 5 mM concentration) [39]. 
This might indicate LAT3 is involved in the transport of D-FEP in addition to LAT1. 
 
4.2.5. Small animal PET imaging studies 
 
Figure 4.6a. Small animal PET images of L-FEP (A) and D-FEP (B) in tumor bearing rats. Color-coded 
PET images from summed 2 hour data in transverse, coronal and sagittal view from left to right followed 
injection of L- and D-FEP ([18F]2) are shown. The arrowhead points to the 9L xerographs.  
aExperiment carried out by Brian Lieberman [42] 
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From in vitro studies results, L- and D-FEP ([18F]2) seemed to have potential as 
promising tumor-imaging agents, so we continued to carried out in vivo small animal 
PET imaging studies to compare these isomers’ imaging properties. Fisher rats bearing 
9L tumor model was used because it is a well-established animal model mimicking 
clinical glioblastoma multiform. Imaging studies could provide in vivo distribution data 
consistent with tissue dissection method. From this PET imaging study, we could assess 
and compare the accumulation of L- and D-FEP in 9L tumor and their in vivo kinetics.  
 
Figure 4.7. Time activity curves of L-FEP (a) and D-FEP (b) in the rat bearing 9L tumors. 
aExperiment carried out by Brian Lieberman [42]. 
Data were acquired from rats administered ~37MBq (1 mCi) of L- or D-FEP 
([18F]2) via tail vein injection (Figure 4.6). Time-activity curves were generated by region 
of interest analysis to assess the kinetics (Figure 4.7). Results demonstrated 9L tumor 
could be imaged using either L- or D-FEP. Kinetics of L- and D-isomers were similar in 
that both tracers quickly reached the stable distributions within 20 min in tumor, heart 
and muscle. L-isomer showed slow increase in tumor uptake after 20 min while D-isomer 
exhibited slow increase in muscle uptake. L-FEP had higher uptake in tumor but the 
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difference was not very significant. However, D-FEP had higher uptake in muscle than 
the L-isomer, which results tumor-to-muscle ratio of D-FEP is lower in comparison to its 
L-isomer (Figure 4.8). This result is different from a number of other reports on tyrosine 
and phenylalanine derivatives that D-isomers had lower uptake in normal tissue, which 
leads to better contrast in imaging [28, 37, 43, 44]. 
 
Figure 4.8. Comparison of tumor to muscle ratio of L- and D-FEP and in the rat bearing 9L tumors. 
 
4.3. Conclusions 
 In conclusion, we prepared new enantiomerically and radiochemically pure L- 
and D-isomers of fluoroalkyl tyrosine and phenylalanine derivatives with good 
radiochemical yield and high specific activity. Cell uptake studies in 9L glioma 
demonstrated L-isomers had much faster and higher uptake in comparison with the 
gradual linear uptake of D-isomers over 2 h period. FEP ([18F]2) had significantly higher 
uptake than FET ([18F]1) in corresponding isomeric forms. Transport characterization 
studies suggested that accumulation of L- and D-FEP into 9L cells was predominantly via 
system L; L-FEP showed preferential uptake via LATs’ subtype LAT1 but its D-isomer 
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did not exhibit the same preference. Small animal PET imaging studies using rats bearing 
9L glioma tumor model demonstrated that both L- and D-FEP had higher uptake in 9L 
tumor than surrounding tissues, but D-FEP did not exhibit improved imaging 
characteristics than its corresponding L-isomer. 
 
4.4. Materials and Methods 
Details regarding General, Radiosynthesis procedure, In vitro cell uptake and 
transport characterization studies in 9L cells and Small animal PET imaging was the 
same as what described in Chapter 3, Section 3.3.  
4.4.1. Synthesis of precursors and standards for labeling 
The synthesis of L-isomers of 2 and 3 was described in Chapter 3, section 3.2.2. 
The corresponding D-isomers followed the same procedure and here we would present 
the NMR data on D-isomers. 
COOBut
NHBocHO
 
4.4.1.1 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanoate (5)  
1H NMR (200 MHz, CDCl3) δ = 7.04 (d, 2H, J = 8.6 Hz), 6.75 (d, 2H, J = 8.6 Hz), 4.98 
(d, 1H, J = 8.0 Hz), 4.43-4.36 (m, 1H), 2.98 (d, 2H, J = 5.8 Hz), 1.43 (s, 18H). [α]23D -
39.7o (c 0.39, CHCl3). 
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COOBut
NHBocTfO
 
4.4.1.2 (R)-tert-butyl2-(tert-butoxycarbonylamino)-3-(4-(trifluoromethylsulfonyloxy) 
phenyl)propanoate (6) 
1H NMR (200 MHz, CDCl3) δ = 7.28 (d, 2H, J = 8.8 Hz), 7.19 (d, 2H, J = 9.0 Hz), 5.07 
(d, 1H, J = 7.2 Hz), 4.53-4.37 (m, 1H), 3.07 (d, 2H, J = 6.0 Hz), 1.42 (s, 9H), 1.38 (s, 9H). 
[α]24D -29.0o (c 1.0, CHCl3). 
COOBut
NHBoc
 
4.4.1.3.1 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-vinylphenyl)propanoate (7a) 
1H NMR (200 MHz, CDCl3) δ = 7.34 (d, 2H, J = 8.0 Hz), 7.14 (d, 2H, J = 8.2 Hz), 6.70 
(dd, 1H, J = 17.6, 10.8 Hz), 5.73 (d, 1H, J = 17.6 Hz), 5.23 (d, 1H, J =10.8 Hz), 4.99 (d, 
1H, J = 7.8 Hz), 4.54-4.37 (m, 1H), 3.05 (d, 2H, J = 6.0 Hz), 1.43 (s, 18H). [α]24D -40.0o 
(c  1.0, CHCl3). 
COOBut
NHBoc
 
4.4.1.3.2 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-allylphenyl)propanoate (7b)  
1H NMR (200 MHz, CDCl3) δ =7.26-7.10 (m, 4H), 6.06-5.85 (m, 1H), 5.10 (d, 1H, J = 
5.8 Hz), 5.08-4.96 (m, 2H), 4.54-4.37 (m, 1H), 3.36 (d, 2H, J = 6.8 Hz) 3.03 (d, 2H, J = 
6.0 Hz), 1.43 (s, 18H). [α]24D -34.8o (c 0.50, CHCl3). 
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COOBut
NHBocHO
 
4.4.1.4.1 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-hydroxyethyl)phenyl) 
propanoate (8a)  
1H NMR (200 MHz, CDCl3) δ =7.20-7.08 (m, 4H), 4.99 (d, 1H, J = 6.8 Hz), 4.52-4.37 
(m, 1H), 3.85 (t, 2H, J = 6.6 Hz), 2.98 (d, 2H, J = 5.8 Hz), 2.85 (t, 2H, J = 6.6 Hz), 1.42 
(s, 18H). [α]21D -41.7o (c 0.75, CHCl3).  
COOBut
NHBocHO
 
4.4.1.4.2 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-hydroxypropyl)phenyl) 
propanoate (8b)  
1H NMR (200 MHz, CDCl3) δ =7.15-7.06 (m, 4H), 5.00 (d, 1H, J = 7.8 Hz), 4.49-4.37 
(m, 1H), 3.67 (t, 2H, J = 6.4 Hz), 3.02 (d, 2H, J = 6.0 Hz), 2.68 (t, 2H, J = 6.6 Hz), 1.94-
1.83 (m, 2H), 1.42 (s, 18H). [α]24D -30.4o (c  0.95, CHCl3).  
COOBut
NHBocTsO
 
4.4.1.5.1 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-(tosyloxy)ethyl)phenyl) 
propanoate (9a) 
1H NMR (200 MHz, CDCl3) δ =7.72 (d, 2H, J = 8.2 Hz), 7.31 (d, 2H, J = 8.0 Hz), 7.11-
7.00 (m, 4H), 4.97 (d, 1H, J = 7.8 Hz), 4.48-4.36 (m, 1H), 4.19 (t, 2H, J = 7.2 Hz), 3.02 
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(d, 2H, J = 5.6 Hz), 2.93 (t, 2H, J = 7.2 Hz), 2.45 (s, 3H), 1.43 (s, 18H). [α]23D -29.0o (c  
0.87, CHCl3).  
COOBut
NHBocTsO
 
4.4.1.5.2 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-(tosyloxy)propyl)phenyl) 
propanoate  (9b) 
1H NMR (200 MHz, CDCl3) δ =7.79 (d, 2H, J = 8.2 Hz), 7.35 (d, 2H, J = 8.0 Hz), 7.08-
6.97 (m, 4H), 4.97 (d, 1H, J = 7.6 Hz), 4.48-4.36 (m, 1H), 4.03 (t, 2H, J = 6.2 Hz), 3.00 
(d, 2H, J = 5.8 Hz), 2.62 (t, 2H, J = 7.6 Hz), 2.46 (s, 3H), 2.04 -1.86 (m, 2H), 1.43 (s, 
18H). [α]23D -27.7o (c  0.35, CHCl3).  
COOBut
NHBocF
 
4.4.1.6.1 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethyl)phenyl) 
propanoate (10a) 
1H NMR (200 MHz, CDCl3) δ = 7.18-7.05 (m, 4H), 4.99 (d, 1H, J = 7.8 Hz), 4.73 (t, 1H, 
6.6 Hz), 4.53-4.35 (m, 2H), 3.10-3.00 (m, 3H), 2.93 (t, 1H, J = 6.6 Hz), 1.42 (s, 18H). 
[α]23D -38.7o (c 0.47, CHCl3).  
COOBut
NHBocF
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4.4.1.6.2 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-fluoropropyl)phenyl) 
propanoate (10b)  
1H NMR (200 MHz, CDCl3) δ =7.20-7.07 (m, 4H), 4.99 (d, 1H, J = 7.2 Hz), 4.57 (t, 1H, 
6.0 Hz), 4.48-4.30 (m, 2H), 3.02 (d, 2H, J = 5.8 Hz ), 2.72 (t, 1H, J = 7.6 Hz), 2.12-1.96 
(m, 2H), 1.42 (s, 18H). [α]24D -37.0o (c 0.90, CHCl3).  
COOH
NH2F
 
4.4.1.7 (R)-2-amino-3-(4-(2-fluoroethyl)phenyl)propanoic acid (2) 
1H NMR (200 MHz, D2O+DCl) δ = 6.89-6.77 (m, 4H), 4.23 (dt, 2H, J = 47.0, 6.2 Hz), 
3.90 (t, 1H, J = 6.6 Hz), 2.81 (ddd, 2H, J = 14.6, 5.4, 7.6 Hz), 2.54 (dt, 2H, J = 27.4, 6.0 
Hz). [α]23D +5.8o (c  0.5, 6N HCl).  
COOH
NH2F
 
4.4.1.8 (R)-2-amino-3-(4-(2-fluoropropyl)phenyl)propanoic acid (3) 
1H NMR (200 MHz, D2O+DCl) δ = 7.04-6.94 (m, 4H), 4.34 (t, 1H, J = 6.0 Hz), 4.13-
4.04 (m, 2H), 2.98 (ddd, 2H, J = 14.6, 5.8, 7.6 Hz), 2.44 (t, 2H, J = 7.6 Hz), 1.84-1.57 (m, 
2H). [α]24D +6.0o (c  0.45, 6N HCl).  
COOBut
NHBocOTsO
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4.4.1.9 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-(tosyloxy)ethoxy)phenyl) 
propanoate (11)  
D-Boc-tyrosine-tert-butyl ester (5, 1.0 equiv) was dissolved in 5mL dry DMF. 
K2CO3 (3.0 equiv) and 1,2-bis(tosyloxy)ethane (2.0 equiv) was added sequentially. The 
mixture was stirred at 70 oC for 4h. After reaction, reaction solution was diluted with 60 
mL ether, washed with 10 mL water and 10 mL brine. Organic layer dried over MgSO4 
and solvent was removed under reduced pressure. Crude mixture was purified by FC 
(MeOH/CH2Cl2, 1:200) to give final product D-11 as white foam. D-11, 1H-NMR (200 
MHz, CDCl3): δ = 7.83 (d, 2H, J = 8.4 Hz), 7.35 (d, 2H, J = 8.0 Hz), 7.06 (d, 2H, J = 8.6 
Hz), 6.70 (d, 2H, J = 8.6 Hz), 4.98 (d, 1H, J = 8.2 Hz), 4.42-4.34 (m, 3H), 4.13 (t, 2H, J = 
4.8 Hz), 2.98 (d, 2H, J = 5.8 Hz), 2.46 (s, 3H), 1.43 (s, 18H). [α]21D -24.2o (c 1.05, 
CHCl3). In comparison, (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-
(tosyloxy)ethoxy)phenyl)propanoate (L-11), 1H-NMR (200 MHz, CDCl3): δ = 7.83 (d, 
2H, J = 8.4 Hz), 7.35 (d, 2H, J = 8.0 Hz), 7.06 (d, 2H, J = 8.6 Hz), 6.70 (d, 2H, J = 8.6 
Hz), 4.98 (d, 1H, J = 8.2 Hz), 4.42-4.34 (m, 3H), 4.13 (t, 2H, J = 4.8 Hz), 2.98 (d, 2H, J = 
5.8 Hz), 2.46 (s, 3H), 1.43 (s, 18H). 13C NMR (50 MHz, CDCl3) δ = 171.1, 157.2, 155.3, 
145.1, 133.2, 130.7, 130.0, 129.5, 128.2, 114.7, 82.2, 79.8, 68.3, 65.7, 55.2, 37.8, 28.5, 
28.2, 21.8. HRMS calcd for C27H37NO8S ([M+Na]+) 558.2138, found 558.2130. [α]21D 
+21.6o (c 0.75, CHCl3). 
COOBut
NHBocOF
 
4.4.1.10 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl) 
propanoate (12) 
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D-Boc-tyrosine-tert-butyl ester (5, 1.0 equiv) was dissolved in 8 mL DMF. K2CO3 
(325 mg, 3.0 equiv) and 1-bromo-2-fluoroethane (2.0 equiv) were added sequentially. 
The mixture was stirred at 70 oC for 4 h. After reaction, reaction mixture was diluted with 
60 mL ether and washed with 10 mL water and 10 mL brine. Organic layer dried over 
MgSO4 and solvent was removed under reduced pressure. Resulting product D-12 was a 
clear viscous liquid. D-12, 1H-NMR (200 MHz, CDCl3): δ = 7.10 (d, 2H, J = 8.6 Hz), 
6.86 (d, 2H, J = 8.6 Hz), 4.97 (d, 1H, J = 8.0 Hz), 4.75 (dt, 2H, J1 = 47.2 Hz, J2 =4.2 Hz), 
4.42-4.28 (m, 1H), 4.20 (dt, 2H, J1 = 27.6 Hz, J2 =4.2 Hz), 2.98 (d, 2H, J = 5.8 Hz), 1.43 
(s, 18H). [α]23D -35.0o (c 0.42, CHCl3). In comparison, (S)-tert-butyl 2-(tert-
butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)propanoate (L-12), 1H-NMR (200 
MHz, CDCl3): δ = 7.10 (d, 2H, J = 8.6 Hz), 6.86 (d, 2H, J = 8.6 Hz), 4.97 (d, 1H, J = 8.0 
Hz), 4.75 (dt, 2H, J1 = 47.2 Hz, J2 =4.2 Hz), 4.42-4.28 (m, 1H), 4.20 (dt, 2H, J1 = 27.6 
Hz, J2 =4.2 Hz), 2.98 (d, 2H, J = 5.8 Hz), 1.43 (s, 18H). 13C NMR (50 MHz, CDCl3) δ = 
171.2, 157.7, 155.3, 130.8, 129.4, 114.8, 82.2, 82.1 (d, J = 169.5 Hz), 79.9, 67.4 (d, J = 
20.5 Hz), 55.2, 37.9, 28.5, 28.2. HRMS calcd for C20H30FNO5 ([M+Na]+) 406.2006, 
found 406.2042. [α]23D +32.1o (c 0.40, CHCl3).  
COOH
NH2OF
 
4.4.1.11 (R)-2-amino-3-(4-(2-fluoroethoxy)phenyl)propanoic acid (1) 
 D-12 (1.0 equiv) was dissolved in CH2Cl2 and equal volume of trifluoroacetic 
acid was added and reaction mixture was stirred in room temperature for 4 h. Upon 
completion, reaction mixture was concentrated under reduced pressure. Resulting solid 
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was dissolved in methanol and pH of the solution was adjusted to ~7 with 5% NH4OH to 
form a white precipitate was formed. The suspension was kept overnight at 0 oC and 
filtered to afford D-1 as whit solid. D-1, 1H-NMR (D2O+DCl): δ = 6.92 (d, 2H, J = 8.8 
Hz), 6.66 (d, 2H, J = 8.8 Hz), 4.44 (dt, 2H, J1 = 47.4 Hz, J2 = 4.0 Hz), 4.05-3.98 (m, 2H), 
3.87 (t, 1H, J = 4.0 Hz), 2.89 (ddd, 2H, J = 14.6, 5.6, 7.4 Hz). [α]23D +3.2o (c 0.5, 6 N 
HCl). In comparison,  (S)-2-amino-3-(4-(2-fluoroethoxy)phenyl)propanoic acid (L-1), 1H-
NMR (Acetic acid-d4): δ = 7.24 (d, 2H, J = 8.6 Hz), 6.91 (d, 2H, J = 8.6 Hz), 4.73 (dt, 
2H, J1 = 47.4 Hz, J2 =4.0 Hz), 4.40 (dd, 1H, J1 = 7.6 Hz, J2 = 5.2 Hz), 4.22 (dt, 2H, J1 = 
29.2 Hz, J2 = 4.0 Hz), 3.52-3.22 (m, 2H). 13C NMR (50MHz, Acetic acid-d4): δ = 173.1, 
158.2, 130.8, 126.9, 115.0, 81.9 (d, J = 167.5 Hz), 67.2 (d, J = 20.0 Hz), 55.8, 35.1. 
HRMS calcd for C11H14FNO3 ([M+H]+) 228.1036, found 228.1265. [α]23D -3.4o (c 0.53, 
6 N HCl). 
 
4.4.2. Log D measurement 
Partition coefficient was measured by mixing ligand with 3 g each of 1-octanol 
and sodium phosphate buffer (0.1 M, pH 7.4) in a test tube. The test tube was vortexed 
for 3 min at room temperature, followed by centrifuge for 5 min. Two weighted samples 
from 1-octanol and buffer layers were counted in a gamma counter. The partition 
coefficient was determined by calculating the ratio of cpm/g of 1-octanol to that of buffer. 
The measurement was done in duplicates.  
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Chapter 5 
 
Radiosynthesis and in vitro evaluation of 11C labeled 
ethanolamine derivatives as potential tumor imaging 
agents for PET 
 
 
 - 123 - 
5.1 Introduction  
 
Cancer cells exhibit significantly altered phospholipids metabolism compared 
with normal counterparts [1, 2]. Proliferating tumor cells have increased demand for 
phosphoglycerides that are essential in formation of cellular membranes. The most 
abundant phosphoglycerides in higher plants and animals are phosphatidylethanolamine 
(PtdEt) and phosphatidylcholine (PtdCho), which contain ethanolamine and choline as 
polar head group respectively [3].  
Numerous 31P-Magnetic resonance spectroscopic (MRS) studies have detected 
high levels of phoshphomonoester (PME) including phosphocholine (PCho) and 
phosphoethanolamine (PEt) in cancer cells [1, 2]. PCho, the product of choline kinase, is 
the first intermediate in the incorporation of choline into PtdCho through Kennedy 
pathway [4]. The increased concentration of PCho in cancer cells is largely due to 
upregulation and increased enzyme activity of choline kinase [5-7] and choline 
transporters [8]. Based on this aberrant tumor phospholipid metabolism, radiolabeled 
[11C]choline (CH) [9] and its 18F labeled derivatives fluoromethyl choline (FCho) and 
fluoroethyl choline (FEC) [10] (Figure 5.1) have been developed and successfully used 
for detection and staging various tumors including brain tumors and prostate cancers, 
which could improve on tumor detectability of most widely used FDG-PET [11, 12].  
N
H311C OH
[11C]Choline (CH)
N OH18F
[18F]fluoromethyl choline (FCH)
N OH
18F
[18F]fluoroethyl choline (FEC)
Cl Cl Cl
 
Figure 5.1. Radiolabeled choline and its derivatives 
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Recent development of proton-decoupled 31P-MRS method enabled the resolution 
of PEt and PCho peaks in vivo that were previously overlapped under the broad PME 
peak [13, 14]. This advance led to the discovery that PEt level in a number of cancers is 
significantly higher than PCho. For example, in human non-Hodgkin’s lymphoma (NHL) 
the PEt/PCho ratio of 2.9 has been reported (Figure 5.2) [15]. Prevailing contribution 
from PEt in elevated PME signal has also been observed in various breast cancers [16, 
17] and pediatric brain tumors [18]. This observation of higher concentration of PEt in 
tumor cells might indicate that ethanolamine, the precursor for PEt, could potentially 
more sensitive than choline as a probe for phospholipids metabolism.  
 
 
In order to validate the potential of radiolabeled ethanolamine for cancer 
detection, we initially carried out in vitro studies using 14C label compound. We 
compared uptake of [14C]ethanolamine (EA),  [14C] N, N’-dimethyl ethanolamine 
(DMEA)  and [14C]choline (CH) in a wide variety of cancer cell lines including colorectal 
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cancer (HCT116), prostate (PC-3), melanoma (A375 and 1618), glioblastoma (SF767, 
A172), and lymphoma (DLCL2). Our results showed that [14C]EA and [14C]DMEA had 
significantly higher uptake than choline and their uptake depends on the proliferating 
status of the cells [19]. These preliminary results encouraged us to develop the 
corresponding 11C labeled PET imaging agents (Figure 5.3). As consideration for ease of 
radiosynthesis, in this work we prepared [11C]N-methylethanolamine (MEA) and 
[11C]DMEA and carried out biological studies in vitro. In vivo biodistribution studies and 
imaging studies are in progress.  
 
5.2 Results and Discussion 
5.2.1 Comparison of 14C labeled choline and ethanolamine as probe for 
cancer detection 
 
 Table 5.1. Cell type and their origins 
Cell lines Cell Type Cell Origin 
SF767 Glioblastoma Multiforme Human Brain 
A172 Glioblastoma Multiforme Human Brain 
1618 Melanoma Human Skin 
A375 Melanoma Human Skin 
PC3 Androgen Independent Prostate Carcinoma Human Prostate 
LnCap Androgen Dependent Prostate Carcinoma Human Prostate 
DLCL2 Diffuse Large B-cell Lymphoma Human Lymph Node 
HCT116 Colorectal Adenocarcinoma Human Colon 
 
In vitro uptake studies were carried out with [14C]EA, [14C]DMEA and [14C]CH 
in a diversity of human tumor cell lines, including two glioblastoma lines, an androgen 
dependent and an androgen independent prostate adenocarcinoma, two melanoma cell 
lines, a colorectal cancer cell line and a diffuse large B-cell lymphoma cell line (as shown 
in Table 5.1). Uptake of [14C]MEA was compared to that of [14C]CH in two prostate 
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cancer cell lines as well. Results showed that in all tumor cell lines tested, [14C]EA and 
its derivatives had significant higher uptake (1.4 to 7.4) than [14C]CH (Figure 5.4).  
 
Figure 5.4a. Normalized uptake of [14C]EA, [14C]DMEA and [14C]MEA relative to [14C]CH in tumor cell 
lines. 
aUptake studies of [14C]EA, [14C]DMEA and  [14C]CH were carried out by Akiva Mintz [19]. 
Figure 5.5a. Cellular uptake studies of [14C]CH and [14C]EA in A172 cells. Time course studies (A) and 
after 60 min, replacing tracer-containing media with regular media (B). 
aExperiment carried out by Akiva Mintz [19]. 
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We performed time course studies of [14C]EA and [14C]CH in A172 cells, which 
demonstrated continuous linear uptake of [14C]EA after 4 hours of tracer exposure 
(Figure 5.5A). However, if the radiotracer was removed after 60 minutes, and replaced 
with non-tracer containing media, the radioactive counts in the cells were not 
significantly different after 180 minutes compared to immediately after 60 minutes of 
tracer incubation (Figure 5.5B). These results suggested the irreversible trapping of 
ethanolamine in tumor cells. 
The preliminary results using 14C labeled ligands demonstrate for the first time 
that ethanolamine and its derivatives could be potential useful oncologic imaging tracers 
for a number of cancers including brain and prostate cancer. Based on these findings, we 
then continued with preparation of 11C labeled ethanolamine tracers that could potentially 
be utilized as PET imaging agents. 
 
 
5.2.2 Radiolabeling of [11C]EA, [11C]MEA and [11C]DMEA 
Na11CN, EtOH
80 oC, 5 min
O
O Cl
O
O 11CN
LiAlH4, THF
rt, 6 min
NH211CH2CH2OH
[11C]EA
H11CN11CO2 11CH4
H2
Ni, 400 oC
NH3
Pd, 1000 oC
NaOH Na11CN
 
Scheme 5.1a. Radiolabeling of [11C]EA.  
aSynthesis carried out by Datta Ponde 
 
Radiosynthesis of [11C] EA, [11C]MEA and [11C]DMEA was carried out as shown 
in Scheme 5.1 and Scheme 5.2. [11C]EA was recently synthesized by Dr. Datta Ponde 
employing procedure reported by Thorell et al with modifications [20]. 
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H2N
OH
11CH3I, CH3CN
60 oC, 5 min
N
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OHH311C
N
H
OH 11CH3I, CH3CN
45 oC, 5 min
N OHH3
11C
[11C]MEA
[11C]DMEA
11CO2 11CH4 11CH3I
H2
Ni, 400 oC
I2
720 °C
 
Scheme 5.2. Radiolabeling of [11C]MEA and [11C]DMEA
 
 [11C]MEA and [11C]DMEA were labeled through methylation of ethanolamine 
and N-methylethanolamine respectively with [11C]CH3I prepared from [11C]CO2 using 
GE MeI box. Although these molecules have simple structure, the short half-life of 11C 
posts strict limit on reaction time – within 20 min (one half-life period) is preferable. In 
additional, [11C]CO2 produced in a cyclotron target is not suitable labeling precursor for 
the synthesis of these ligands and need to be converted into [11C]NaCN or [11C]CH3I for 
radiosynthesis. We were able to prepare radiochemically pure (>95%) [11C]MEA and 
[11C]DMEA within 20 min from end of bombardment (EOB) with good specific activity 
(~52 GBq/µmol or 1300 Ci/mmol) and high radiochemical yield (average 45 to 52%, 
decay corrected). Radiolabeled ligands were purified with silica cartridge. Radiochemical 
purity was analyzed by HPLC and TLC. The labeling procedure was carried out in 
automated synthetic module and is suitable for potential clinical applications. Several 
problems associated with purification and detection of these compounds made this 
seemly straightforward radiosynthesis an interesting challenge. We conducted a series of 
experiment to optimize their reaction condition, purification process and quality control.  
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5.2.2.1 Reaction condition studies  
Table 5.2: Effect of temperature on radiolabeling of [11C]MEA and [11C]DMEA 
Product Temp (°C) Radiochemical purity (%) Experiments 
[11C] MEA 25 No reaction 1 
[11C] MEA 60 >95 >3 
[11C] DMEA 25 No reaction 1 
[11C] DMEA 45 >95 2 
[11C] DMEA 50 >95 >3 
[11C] DMEA 55 93±3 2 
[11C] DMEA 60 60±5 2 
[11C] DMEA 65 19±3 2 
 
Temperature was a key factor in this labeling reaction (Table 5.2). No reaction 
was observed at room temperature in presence of base (NaOH or KOH) or without base. 
After careful increase of temperature it was observed that for the synthesis of [11C] MEA, 
reaction can be carried out at 60°C.  However, in the case of [11C]DMEA, reaction should 
best be set between 45 to 55°C. At higher temperature (> 60°C), we have detected the 
formation of [11C]CH (HPLC result Figure 5.6 as example) (50% to 80% in the final 
product as seen from analytical HPLC).  
 
Figure 5.6. Formation of [11C]CH in radiosynthesis of [11C]DMEA at high temperature. 
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No base is required for this methylation reaction. A number of bases such as 
sodium hydroxide, potassium hydroxide and sodium hydride were tried initially, but no 
advantage was found, moreover, sodium hydride can produce the O-methylation side 
products. We also tried different solvents such as DMF, DMSO and CH3CN, reaction 
time and yields were similar in these solvents. Since it is often more difficult to remove 
DMF and DMSO, we choose CH3CN as reaction solvent.    
 
5.2.2.2 Purification of  [11C]MEA and [11C]DMEA 
Table 5.3. Experimented purification methods and results 
Purification methods Results and comments 
Sep-Pak C18 (light or plus) cartridges could not appropriately trap products 
Weak cation exchange cartridges could not appropriately trap products 
Strong cation exchange cartridge could not be eluted with appropriate solvent 
Semi-prep HPLC with cyano column could not elute the products using water 
Silica cartridges retained products and then eluted with saline 
 
For the purification of [11C]MEA and [11C]DMEA, we tried a number of 
cartridges such as Sep-Pak C18 (light or plus) and cation exchange cartridges (weak or 
strong) without success. In the case of the Sep-Pak C18 or weak cation exchange 
cartridge, most of the radioactivity could not be trapped on the cartridges and went into 
the waste. For strong cation exchange cartridge, although activity was retained in the 
cartridge, the products could only be eluted only with strong basic buffer solution such as 
3 N ammonia hydroxide, which is not a pharmaceutically appropriate formula for further 
biological evaluations. Semi-prep HPLC with reverse phase cyano column [21] failed to 
elute the products using water at 1 mL/min. Finally silica cartridges were successfully 
implemented. The reaction mixture, which was diluted with water, was passed through 
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the silica cartridge followed by washing with ethanol, to remove excess of precursor, and 
then with 10 mL of water, to remove the residual ethanol. Final products were eluted with 
saline. 5 mL of saline was required to elute 925 to 1110 Mbq (25 to 30 mCi) of product. 
We measured the distribution of radioactivity after purification and found that ~70% of 
activity was eluted to final product while 20% of activity went to waste, 5% stayed on 
cartridge and 5% remained in the reaction vessel. The purification results were 
summarized in Table 5.3. 
5.2.2.3 Quality control of  [11C]MEA and [11C]DMEA 
It is difficult to detect N-methyl ethanolamine and N, N-dimethyl ethanolamine 
using standard UV detector in HPLC system since they are not UV active. We choose to 
use refractometer, which has adequate sensitivity for detection of cold standard. To 
achieve the best separation between ethanolamine, N-methyl ethanolamine and N, N-
dimethyl ethanolamine, we tried various HPLC conditions, such as 5 mM HCl solution, 
0.25 M NaH2PO4/CH3CN mixture in different ratios and found that isocratic 0.25 M 
NaH2PO4 was able to achieve best separation. The column used was strong cation 
exchange column (SCX).  In each case, retention time difference between the precursor 
and product was more than 1 min, which made them easy to identify.  
 
5.2.2.4 Automated synthetic module 
Radiosynthesis of [11C]MEA and [11C]DMEA was carried out in an automated 
synthetic module as depicted in Figure 5.7. The components in this synthetic module 
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include a helium supply, ten three-way solenoid controlled flow valves, a T-shaped 
reaction vessel, two collection vials (one for the waste and one for the product) and a 
charcoal trap for volatile radioactivity. This automatic synthetic module requires little 
manual control and could potentially be used in clinical settings.  
Figure 5.7. Schematic diagram of the automated system for the production of [11C]MEA and [11C]DMEA. 
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5.2.3 In vitro cell uptake studies 
Figure 5.8. Cell uptake studies in PC-3 (A) and LnCap (B) prostate cancer cell lines. 
 
After successful labeling [11C]MEA and [11C]DMEA, we first conducted the 
time-dependent cell uptake studies comparing these two 11C labeled ethanolamine 
derivatives with clinically utilized [11C]CH in androgen independent PC-3 and androgen 
dependent LnCap prostate cancer cell lines (Figure 5.8). The reason we chose PC-3 and 
LnCap for in vitro studies is that [11C]CH is most established for imaging prostate 
cancers and androgen dependence of prostate cancer cells has clinical significance for 
cancer therapeutic plan and monitoring [22, 23]. Because cell uptake studies of these 
tracers were done in different days on different batch of cells, most widely used PET 
tracer [18F]FDG was used as a reference ligand as well. All ligands demonstrated similar 
linear incremental cellular uptake in 1h time period. [11C]MEA had 1.3 (in PC-3) to 3.1 
(in LnCap) fold higher uptake in comparison to [11C]CH at 60 min time point. Uptake of 
[11C]DMEA in PC-3 was comparable to that of  [11C]CH and 2.2 fold higher in LnCap. 
All tracers had higher uptake in LnCap than in PC-3, the difference in uptake of 
[11C]MEA and  [11C]DMEA was much larger than [11C]CH. The uptake results suggested 
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that ethanolamine derivatives [11C]MEA and [11C]DMEA could be more sensitive tracers 
than [11C]CH and thus worth further investigation. Uptake studies of  [11C]EA will be 
conducted in the near future.  
 
5.2.4 Inhibition studies 
 
 
Figure 5.9.  Inhibition studies result in PC-3 and LnCap. 
 
We hypothesize that increased uptake of ethanolamine derivatives in cancer cells 
was result of upregulated ethanolamine/choline kinase and transport activity. We then 
carried out inhibition studies to characterize the uptake of tracer (Figure 5.9). It was of 
interest to measure the sensitivity of tracers’ uptake to Hemicholinium 3 (HC-3) and 
choline. There were studies suggesting both choline and ethanolamine were transportable 
substrates of the same carrier-mediated mechanism [24]. HC-3 blocks membrane 
transport of ethanolamine and choline and inhibits choline kinase (Ki = 0.5 mM) but not 
ethanolamine kinase [25, 26]. Choline was a potent competitive inhibitor of ethanolamine 
kinase (Ki = 0.33–0.50 mM)  [27]. PC-3 or LnCap cells were subjective to the inhibitors 
during preinhibition period of 10 min followed by incubation period for 60 min. The 
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effect of inhibition was similar in PC-3 and LnCap cell lines. Uptake of tracers showed 
concentration dependent inhibition by choline. The sensitivity to inhibitors followed the 
order [11C]EA>[11C]DMEA>[11C]MEA. From this inhibition studies we could not 
conclude uptake of ethanolamine and its derivatives depends on ethanolamine kinase 
activity. The inhibitory effect of HC-3 was less pronounced than choline (5mM of HC-3 
had similar effect as 0.5 mM choline), indicating contribution from ethanolamine kinase. 
 
5.3 Conclusions 
Based on preliminary studies with 14C labeled ethanolamine tracers showing that 
ethanolamine could be a potential oncologic imaging tracer for altered phospholipids 
metabolism, we prepared positron emitting isotope labeled [11C]EA, [11C]MEA and 
[11C]DMEA. Labeling of [11C]MEA and [11C]DMEA were carried out in the automatic 
synthetic module that was suitable for potential clinically applications. Radiochemically 
pure tracers could be obtained with good yields. In vitro cell uptake studies demonstrated 
that [11C]MEA and  [11C]DMEA had higher uptake than clinically utilized [11C]CH in 
prostate cancer cell lines. Further development such as metabolites analysis, 
biodistribution and small animal imaging studies of these 11C labeled ethanolamine 
tracers is warranted.  
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5.4 Experimental Section 
5.4.1 General 
All reagents were purchased from Sigma-Aldrich and Fisher Scientific in ACS 
grade. All solvents were of HPLC analytical grade. Cartridges (C18, Silica, cation 
exchange) were purchased from Waters. Cancer cell lines were purchased from American 
type culture collection (ATCC; Manassas, VA). All cell lines were cultured and 
maintained under a 5%CO2-humidified incubator at 37ºC according to standard cell 
culture protocol and in standard culture medium (GIBCO BRL, NY) recommended by 
the supplier. 14C labeled tracers were purchased from American Radiolabeled Chemicals, 
Inc.  (ARC, St. Louis, MO). HPLC was performed on a system (Agilent Technologies 
1200 series) with quaternary pump, refractometer (HP HEWLETT PACKARD series 
1100), variable wavelength-detector operating at 205 nm and NaI(Tl) radiation detector 
(EG&G ORTEC). The purity of all radioactive products was monitored with a strong 
cation exchange column (Agilent ZORBAX 300-SCX, 5uM, 4.6x250mm) using 100% 
0.25M NaH2PO4 as eluent with flow rate at 1 mL/min. Radiochemical purity was also 
monitored by radio-Thin-Layer Chromatography (TLC) performed on aluminum sheets 
coated with silica gel 60 F254 (0.25 mm thickness, E. Merck, Darmstadt, Germany) and 
developed with MeOH/29% Ammonia hydroxide (3:1). 
 
5.4.2 Radiochemistry 
 [11C] CO2 was produced by the 14N(p,α)11C nuclear reaction using a nitrogen gas 
(N2/0.5%O2) target pressurized to 300 psi and bombarded with 22 MeV protons (20 min, 
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10 µA) produced by the Japanese Steel Corporation (JSW) cyclotron at the Hospital of 
University of Pennsylvania. [11C] MeI was then prepared from [11C] CO2 using General 
Electric MeI microlab. When ready, [11C] MeI was transferred with a stream of helium 
(80 mL/min) into a reaction vessel containing 1 mg of ethanolamine or N-methyl 
ethanolamine in 250 µL of acetonitrile (Figure 5.6). The reaction mixture was heated at 
600C for [11C]MEA or 450C for [11C]MEA for 5 mins. At the end of 5 mins of reaction, 
the crude product was diluted with 3 mL of water and then passed through a silica 
cartridge (preconditioned with 3 mL of 5% of ethanol in water). The cartridge was 
washed with 8 mL of ethanol, 10 mL of water and then eluted with 5 mL of saline. The 
radiochemical purity of products was measured by analytical HPLC (0.25 M NaH2PO4, 1 
mL/min) and raido-TLC (NH4OH/MeOH, 1:4). The average decay-corrected 
radiochemical yield of this synthesis was 45 % (n = 4, EOB) for [11C]MEA and 52% (n = 
10, EOB) for [11C]DMEA. 
 
5.4.3 In vitro studies 
Cellular uptake studies were performed using standard protocol. Briefly, 
~200,000 cells were plated in 12-well tissue culture plates in triplicate and incubate for 
48 hrs in growth media at which time >90% confluency was reached. On the day of study 
the media was refreshed using a volume of 1 mL of media or media containing selected 
inhibitors in each well. Then 1µCi of 14C or 4µCi of 11C labeled tracer of choice was 
added to each well and incubated for specific time period (from 5 min to 1h) at 37°C and 
5% CO2. Following incubation, cells were washed three times with cold PBS and lysed 
with NaOH. In case of 14C labeled tracers, Sample (100 µL) of each radiotracer flask was 
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mixed with liquid scintillator and the radioactivity was counted by liquid scintillation. 
Experiments were performed in triplicates and the mean counts per minutes (CPM), were 
calculated together with standard deviation (SD). For 11C labeled tracers, lysed cells were 
collected into filter paper and counted using a gamma counter (Cobra II auto-gamma 
counter D5003 spectrometer, Canberra-Packard). Protein concentration was determined 
using the Lowry protein assay and uptake values was normalized by the dose 
administered to each well. 
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Chapter 6 
 
 
 
Concluding Remarks and Future Directions 
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6.1 Concluding Remarks 
Imaging of tumor cell metabolism continues to be a cornerstone of clinical and 
preclinical molecular imaging. It is not only used in tumor detection but also have 
significant impact on patient management via staging and monitoring response to 
therapy. Most widely used FDG-PET, which utilizes aberrant glucose metabolism in 
tumor cells, had several drawbacks that make it suboptimal for imaging certain cancers 
such as brain tumors and prostate cancer. A number of amino acid and choline 
derivatives have been developed based on altered tumor metabolism for amino acids and 
phospholipids respectively and demonstrated potential improvement over FDG in 
imaging brain tumors and prostate cancer. In this thesis we prepared a series of new 18F 
label tyrosine and phenylalanine derivatives (chapter 2 to chapter 4) targeting upregulated 
amino acid transport activity in cancer cells. These tracers were evaluated in comparison 
with clinically established tyrosine analog L-FET. Towards the end of this thesis work, 
we found a potentially useful imaging agent L-FEP. It could be efficiently labeled with 
good radiochemical yield and high purity. In vivo studies using rats bearing 9L tumor 
model demonstrated that L-FEP is comparable to clinically used L-FET. Transport 
characterization of L-FEP studies suggested that its uptake might reflect increased activity 
of LAT1 in tumor cells. We have also labeled a series of 11C labeled ethanolamine 
derivatives (Chapter 5) as potential PET imaging agents utilizing altered tumor 
phospholipids metabolism. Initial in vitro studies indicated ethanolamine derivatives 
might have improve sensitivity over reported [11C]CH. 
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6.2 Future Directions 
It is still not clear that whether L-FEP would have any advantage over L-FET as 
an imaging agent. To further validate the potential of L-FEP as brain imaging agents, 
orthotropic brain model in rats could be used. Uptake studies of L-FEP in peripheral 
tumor cell lines with high expression of LATs (R1M, HeLa et al) could be carried out to 
examine its potential for imaging peripheral tumors in comparison to L-FET. Additional 
studies with L-FEP can be done to confirm its selectivity for LAT1.  
In vivo studies including biodistribution and small animal PET imaging studies on 
PC-3 and/or LnCap xenagraft model is in progress for evaluating 11C labeled 
ethanolamine tracers. Metabolites analysis and phosphorylation studies could be 
conducted to examine whether uptake of these tracers correlates with upregulation of 
ethanolamine kinase and/or transport activity in Kennedy pathway. 
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Appendix A 
 
 
 
1H and 13C NMR Spectra of compounds 
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A.1 1H and 13C NMR spectra of key compounds in Chapter 2  
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A.2 1H and 13C NMR spectra of key compounds in Chapter 3 
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A.3 1H NMR spectra of D-isomers in Chapter 4 
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